Sie sind auf Seite 1von 74


A Atherton P, Ames MM, Erlichman C. Comparative

Pharmacokinetic Study of Continuous Venous In-
fusion Fluorouracil and Oral Fluorouracil With
Aamdal S, see Sundstrøm S Eniluracil in Patients With Advanced Solid Tu-
Aapro MS, see Bernhard J mors, 1683
see Repetto L Adler H, see Datta RV
Aaronson NK, see Detmar SB Áfra D, see Pignatti F
Aasebø U, see Sundstrøm S Agarwala SS, see Kirkwood JM
Abbruzzese JL, see Herbst RS Agarwala SS, Glaspy J, O’Day SJ, Mitchell M, Gutheil J,
see Pentz RD Whitman E, Gonzalez R, Hersh E, Feun L, Belt R,
see Pisters PWT Meyskens F, Hellstrand K, Wood D, Kirkwood JM,
Abdel-Rahman S, see Wendtner C-M Gehlsen KR, Naredi P. Results From a Random
Abdel-Wanis ME, see Tsuchiya H Phase III Study Comparing Combined Treatment
Abdi EA, see Denman JP With Histamine Dihydrochloride Plus Interleukin-2
Abdolell M, see Kiss TL Versus Interleukin-2 Alone in Patients With Meta-
Abdulkadyrov K, see Österborg A
static Melanoma, 125
Abe S, see Tsuchiya H
Agarwala SS, Hellstrand K, Naredi P. Interleukin-2 and
Abel U, see Kaiser U
Histamine Dihydrochloride in Metastatic Mela-
Abrams J, see Harlan LC
noma (correspondence), 3558
see Sateren WB
Agelaki S, see Souglakos J
Abrams R, see Shaw E
Aghajanian C, see Barakat RR
Abramson N, Aster RH. Retrospective Assessment of Hyper-
see Dizon DS
coagulability in Breast Cancer Prevention Trial
see Hensley ML
(correspondence), 4133
Aglietta M, see Fagioli F
Abramson N, Stokes PK, Luke M, Marks AR, Harris JM.
Agrawal M, Emanuel EJ. Attending to Psychologic Symp-
Ovarian and Papillary-Serous Peritoneal Carcino-
toms and Palliative Care (editorial), 624
ma: Pilot Study With Thalidomide (correspon-
Agteresch HJ, Rietveld T, Kerkhofs LGM, van den Berg
dence), 1147
JWO, Wilson JHP, Dagnelie PC. Beneficial Effects
Abuja PM, see Wölfler A
Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. of Adenosine Triphosphate on Nutritional Status in
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: Advanced Lung Cancer Patients: A Randomized
A Distinct Clinicopathologic Entity, 1269 Clinical Trial, 371
Acute Leukemia Working Party of the European Blood and Ah-See AK, see Smith IC
Marrow Transplant Registry, see Rocha V A’Hern R, see Harper-Wynne CL
Acute Myeloid Leukemia Study Group Ulm, see Fröhling S A’Hern RP, see Kolomainen DF
Adachi I, see Morita T Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA,
Adak S, see Kemeny MM Skalla K, Whedon MB, Bivens S, Mitchell T,
Adamo V, see Scagliotti GV Greenberg ER, Silberfarb PM. Neuropsychologic
Adams DJ, see Bass AJ Impact of Standard-Dose Systemic Chemotherapy
see Rizzieri DA in Long-Term Survivors of Breast Cancer and
Adams J, see Orlowski RZ Lymphoma, 485
see Pearson ML Ahmad SA, Patel SR, Ballo MT, Baker TP, Yasko AW,
Adams N, see DiPaola RS Wang X, Feig BW, Hunt KK, Lin PP, Weber KL,
Adelstein DJ, Saxton JP, Lavertu P, Rybicki LA, Esclamado Chen LL, Zagars GK, Pollock RE, Benjamin RS,
RM, Wood BG, Strome M, Carroll MA. Maximiz- Pisters PWT. Extraosseous Osteosarcoma: Re-
ing Local Control and Organ Preservation in Stage sponse to Treatment and Long-Term Outcome, 521
IV Squamous Cell Head and Neck Cancer With Ahmed T, see Seiter K
Hyperfractionated Radiation and Concurrent Che- Ahn J-H, see Lee Jung-Hee
motherapy, 1405 Ahn S-D, see Lee Jung-Hee
Adenis A, see Curé H Aiello E, see Chlebowski RT
Ades L, see Bergeron A Aish LS, see Oo TH
Adjei AA, see Dy GK Aisner J, see Berry DA
Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin Akabani G, see Reardon DA
J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Akçali Z, see Saglam S

4728 Journal
Downloaded from on June 28, 2008 of Clinical
. For Oncology,
personal Vol No
use only. 20,other
No 24 (December
uses 15), 2002: pp 4728 – 4801
without permission.
Copyright © 2002 by the American Society of Clinical Oncology. All rights reserved.

Akechi T, see Morita T Involvement in Non-Hodgkin’s Lymphoma; Case

Albain KS, Crowley JJ, Turrisi AT III, Gandara DR, Farrar 2. Isolated Meningeal Anaplastic Large-Cell Lym-
WB, Clark JI, Beasley KR, Livingston RB. Con- phoma, 4395
current Cisplatin, Etoposide, and Chest Radiother- Alquati P, see Berruti A
apy in Pathologic Stage IIIB Non-Small-Cell Lung Altavilla G, see Scagliotti GV
Cancer: A Southwest Oncology Group Phase II Alvord WG, see Urba WJ
Study, SWOG 9019, 3454 Amadori D, see Ravaioli A
Albanell J, see Baselga J Amato R, see Bukowski R
Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro Amdur RJ, see Mendenhall WM
JM, Herbst R, LoRusso P, Rischin D, Sauleda S, American Society of Clinical Oncology Bisphosphonates
Gee J, Nicholson RI, Baselga J. Pharmacodynamic Expert Panel, see Berenson JR
Studies of the Epidermal Growth Factor Receptor American Society of Clinical Oncology Breast Cancer Tech-
Inhibitor ZD1839 in Skin From Cancer Patients: nology Assessment Working Group, see Chle-
Histopathologic and Molecular Consequences of bowski RT
Receptor Inhibition, 110 American Society of Clinical Oncology Chemotherapy and
Albano JQ, see Howell A Radiotherapy Expert Panel, see Schuchter LM
Alberts DS, Markman M, Armstrong D, Rothenberg ML, Ames MM, see Adjei AA
Muggia F, Howell SB. Intraperitoneal Therapy for Amodio A, see Vici P
Stage III Ovarian Cancer: A Therapy Whose Time Amoroso M, see Benedetti-Panici P
Has Come! (editorial), 3944 Amsterdam A, see Vuky J
Alberts SR, see Adjei AA Amunni G, see Benedetti-Panici P
Alektiar KM. In Reply (correspondence), 3930 Anagnostopoulos N, see Dimopoulos MA
Alektiar KM, Leung D, Zelefsky MJ, Brennan MF. Adjuvant Anaissie E, see Badros A
Radiation for Stage II-B Soft Tissue Sarcoma of the
Andermann A, Thiffault I, Wong N, Gordon P, MacNamara
Extremity, 1643
E, Chong G, Foulkes W. Multimodal Molecular
Alexander C, see Samnick S
Screening Is Required to Improve the Sensitivity of
Alexopoulou A, see Dourakis SP
MLH1 and MSH2 Mutation Analysis (correspon-
Ali SM, see Lipton A
dence), 1705
Allal AS, Dulguerov P, Allaoua M, Haenggeli C-A, El Ghazi
Anderson D, see Seymour LW
EA, Lehmann W, Slosman DO. Standardized Up-
Anderson H, see Ross P
take Value of 2-关18F兴 Fluoro-2-Deoxy-D-Glucose
Anderson JK, see Orlowski RZ
in Predicting Outcome in Head and Neck Carcino-
Anderson JR, see Baker KS
mas Treated by Radiotherapy With or Without
Anderson K, see Berenson JR
Chemotherapy, 1398
Anderson PM, Wiseman GA, Dispenzieri A, Arndt CAS,
Allaoua M, see Allal AS
Hartmann LC, Smithson WA, Mullan BP, Bruland
Allard J, see Lipton A
Allegra C. Thymidylate Synthase Levels: Prognostic, Predic- OS. High-Dose Samarium-153 Ethylene Diamine
tive, or Both? (editorial), 1711 Tetramethylene Phosphonate: Low Toxicity of
Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Skeletal Irradiation in Patients With Osteosarcoma
Johnston P, Klein P, Behan K, O’Connell MJ, and Bone Metastases, 189
Levitt R, Kugler JW, Tirona MT, Goldberg RM. Anderson PR, see Freedman GM
Investigation of the Prognostic and Predictive Anderson TJ, see Lakhani SR
Value of Thymidylate Synthase, p53, and Ki-67 in Andersson M, see Dores GM
Patients With Locally Advanced Colon Cancer, Andre A, see Carducci MA
1735 André T, see Louvet C
Allegrini G, see Falcone A Andreeff M, see Giles FJ
Allen P, see Stojadinovic A Andreola G, see Belli F
Allgayer H, see Heiss MM Androutakis N, see Souglakos J
Allgood V, see Herbst RS Angelopoulou MK, see Rassidakis GZ
Alloisio M, see Bertuzzi A Anker G, see Geisler J
Allouache N, see Joly F Annino L, see Federico M
Allred C, see Singletary SE Ansari RH, see Schilsky RL
Allred DC, see Love RR Ansell SM, Jelinek DF, Wettstein PJ, Witzig TE. In Reply
Almadori G, see Piantelli M (correspondence), 2905
Almahmeed T, see Rabbani F Ansell SM, Ristow KM, Habermann TM, Wiseman GA,
Alonzo TA, see Woods from
Downloaded Witzig
WG on June 28, 2008 . For personal use TE.other
only. No Subsequent Chemotherapy
uses without permission. Regimens
Aloulou S, Bosq J, Vanel Copyright © 2002
D, Ribrag V.byUnusual
the American
of of Clinical Oncology.
Are Well All rights reserved.
Tolerated After Radioimmunotherapy

With Yttrium-90 Ibritumomab Tiuxetan for Non- Ashby M, see Seidman A

Hodgkin’s Lymphoma, 3885 Ashley D, see Gururangan S
Anselmo AP, see Sieber M Ashley P, see Singletary SE
Antin JH, see Cutler C Ashley S, see Powles T
see Loberiza FR Jr see Waters JS
Antman K, see Berry DA Asmar L, see Loesch D
Antolini A, see Scartozzi M Asselain B, see Rouzier R
Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Asselin B, see LeClerc JM
Economou I, Karageorgis P, Throuvalas N. Phase Asselin BL, see Lipshultz SE
II Randomized Trial of Temozolomide and Con- Assouline D, see Page E
current Radiotherapy in Patients With Brain Me- Aster JC, see Kutok JL
tastases, 3644 Aster RH, see Abramson N
Aoyama H, Shirato H, Ikeda J, Fujieda K, Miyasaka K, Atala J, see Prieto JM
Sawamura Y. Induction Chemotherapy Followed Athale UH, Stewart C, Kuttesch JF, Moghrabi A, Meyer W,
by Low-Dose Involved-Field Radiotherapy for In- Pratt C, Gajjar A, Heideman RL. Phase I Study of
tracranial Germ Cell Tumors, 857 Combination Topotecan and Carboplatin in Pediat-
Aoyama H, Shirato H, Kashiwamura M, Ikeda J, Sawamura ric Solid Tumors, 88
Y. In Reply (correspondence), 2911 Athanasiadis I, see Stathopoulos GP
Aozasa K, see Nakatsuka S Athanasiadis N, see Souglakos J
Apostolaki S, see Stathopoulou A Atherton P, see Adjei AA
Appelbaum FR, see also Morrison VA Atkins D, see Kuball J
Appelbaum FR, Sandmaier B. Sensitivity of Renal Cell Atkins MA, see Kilbridge KL
Cancer to Nonmyeloablative Allogeneic Hemato- Atula S, see Powles T
poietic Cell Transplantations: Unusual or Unusu- Au WY, see Hon C
ally Important? (editorial), 1965 Au WY, Ooi CGC, Li KH, Shek TW, Liang R. Challenges in
Arbuck SG, see Tan AR Oncology; Case 1. Oncology Emergencies: A My-
Arcese W, see Ringdén O eloma Patient With Stridor, 866
see Rocha V Audisio RA, see Repetto L
Ardizzoni A, Tjan-Heijnen VCG, Postmus PE, Buchholz E, Austenfeld JL, see Stanton AL
Biesma B, Karnicka-Mlodkowska H, Dziadziuszko Austrian Breast and Colorectal Cancer Study Group, see
R, Burghouts J, van Meerbeeck JP, Gans S, Leg- Jakesz R
rand C, Debruyne C, Giaccone G, Manegold C. Auvinen A, see Mäkinen T
Standard Versus Intensified Chemotherapy With Auvinen MI, Sihvo EIT, Ruohtula T, Salminen JT, Koivis-
Granulocyte Colony-Stimulating Factor Support in toinen A, Siivola P, Rönnholm R, Rämö JO,
Small-Cell Lung Cancer: A Prospective European Bergman M, Salo JA. Incipient Angiogenesis in
Organization for Research and Treatment of Can- Barrett’s Epithelium and Lymphangiogenesis in
cer-Lung Cancer Group Phase III Trial-08923, Barrett’s Adenocarcinoma, 2971
3947 Auvrignon A, see Perel Y
Averbuch S, see Albanell J
Arienti F, see Belli F
see Ranson M
Armand JP, see Raymond E
Averbuch SD, see Baselga J
see van Kesteren Ch
see Herbst RS
Armitage JO, see Vose JM
Aviles VM, see Machtay M
see Weekes CD
Ayers GD, see Pentz RD
Armstrong D, see Alberts DS
Ayoub J-P, see O’Shaughnessy J
Armstrong DK, see Bristow RE
Ayres M, see Gandhi V
Armstrong KA, see Shih HA
Azzabi A, see Hughes A
Arndt CAS, see Anderson PM
Aro J, see Mäkinen T
Aronson D, see Czauderna P
Arroyo CD, see Van Poznak C B
Arthur DC, see Woods WG
Arun B, see Esteva FJ Baars JW, see de Gast GC
Arusell R, see Shaw E Baas P, see Kruijtzer CMF
Asada N, see Tsuchiya H Babic R, see Heiss MM
Asami T, see Yamamoto K Bacci G, see Fagioli F
Ascani L, seeDownloaded
Belli F from on June 28, 2008 . For personal
see Ferrari S No other uses without permission.
use only.
Aschermannova A, see Howell A © 2002 by the American Society of Clinical
Bach A, Oncology.
see ModiAllS rights reserved.

Bach PB, see Schrag D Ballard-Barbash R, see Harlan LC

Bacik J, see Motzer RJ Ballo MT, see Ahmad SA
see Vuky J Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield
Backstrand KH, see Ng AK PF, Strom EA, Bedikian AY, Kim KBS, Papado-
Bacoyiannis C, see Kosmidis P poulos NE, Prieto VG, Ross MI. Sphincter-Sparing
Bader JB, see Samnick S Local Excision and Adjuvant Radiation for Anal-
Bader-Meunier B, see Perel Y Rectal Melanoma, 4549
Badran M, see Kolomainen DF Balm AJM, see Dorresteijn LDA
Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Balogh J, see El-Sayed S
Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot Balzarotti M, see Bertuzzi A
G. Improved Outcome of Allogeneic Transplanta- Bamat MK, see Pecora AL
tion in High-Risk Multiple Myeloma Patients After Bamberg M, see Timmermann B
Nonmyeloablative Conditioning, 1295 Bani JC, see Brooks BJ
Badros A. In Reply (correspondence), 4268 Bannwarth C, see Weihrauch MR
Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Bapat B, see Lindor NM
Fountzilas G, Samantas E, Kalofonos C, Skarlos D, Barakat R, see Hensley ML
Karabelis A, Kosmidis P. Temozolomide in Com- see Scheuer L
bination With Docetaxel in Patients With Ad- Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A,
vanced Melanoma: A Phase II Study of the Hel- Venkatraman E, Aghajanian C, Hensley M, Soignet
lenic Cooperative Oncology Group, 420 S, Brown C, Soslow R, Markman M, Hoskins WJ,
Bagg A, see Tao J Spriggs D. Intraperitoneal Chemotherapy for Ovar-
Bahng H, see Lee Jung-Hee ian Carcinoma: Results of Long-Term Follow-Up,
Baier P, see Rosenberg R 694
Baile WF, Lenzi R, Parker PA, Buckman R, Cohen L. Barazzoul J, see Schwartz GK
Oncologists’ Attitudes Toward and Practices in Barbarano L, see Cesana C
Giving Bad News: An Exploratory Study, 2189 Barbui T, see Radford JA
Bains MS, see Martin J Bardo DME, see Kletzel M
Bajetta E, see Littlewood TJ Barker MA, see Lindor NM
Bajetta E, Zilembo N, Bichisao E. Endocrine Effects of Barlogie B, see Badros A
Nonsteroidal Aromatase Inhibitors and Their Clin- Barnard DR, see Woods WG
ical Impact (correspondence), 3039 Barnsteiner JH, see Womer RB
Bajorin D, see Dalbagni G Baron A, see Bremnes RM
Bajorin DF, see Vuky J Barón A, see Nieto Y
Baker C, see Herbst RS Barr FG, see Sorensen PHB
Baker KS, Anderson JR, Lobe TE, Wharam MD, Qualman Barr R, see LeClerc JM
SJ, Raney RB, Ruymann FB, Womer RB, Meyer Barr RD, see Lipshultz SE
WH, Link MP, Crist WM. Children From Ethnic Barranger E, Grahek D, Cortez A, Uzan S, Darai E. Laparo-
Minorities Have Benefited Equally as Other Chil- scopic Sentinel Node Procedure in Patients With
dren From Contemporary Therapy for Rhabdomyo- Cervical Cancer (correspondence), 2602
sarcoma: A Report From the Intergroup Rhabdo- Barresi J, see Shadbolt B
myosarcoma Study Group, 4428 Barrett AJ, see Levine JE
Baker M, see Markman M Bartelink H, see Dorresteijn LDA
Baker SD, see Bélanger K Barth TFE, see Viardot A
see de Bone JS Barthe C, see Mahon FX
see Giles FJ Bartlett NL, see Horning SJ
Baker SD, Garrett E, Giles F. In Reply (correspondence), see Witzig TE
3356 Barton DPJ, see Kolomainen DF
Baker TP, see Ahmad SA Barton JH, see Greco FA
Bakker PJM, see Koedoot CG Baruchel A, see Patte C
Bakri K, see Socinski MA see Perel Y
Baldelli AM, see Cascinu S Baruchel S, see Furman WL
Baldi A, see Santini D Baselga J, see Albanell J
Baldwin AS, see Orlowski RZ see Herbst RS
Baldwin RL, see Liede A Baselga J, Rischin D, Ranson M, Calvert H, Raymond E,
Baldwin Y, see Ferrari AC Kieback DG, Kaye SB, Gianni L, Harris A, Bjork
Balestrini MR, see Massimino M T, only.
Downloaded from on June 28, 2008 . For personal use Averbuch
No otherSD,
usesFeyereislova A, Swaisland H,
without permission.
Copyright © 2002
Balibrea J-L, see González-Quevedo R by the American Society of Clinical Oncology.
Rojo F, All rights reserved.
Albanell J. Phase I Safety, Pharmacoki-

netic, and Pharmacodynamic Trial of ZD1839, a Belani CP, see Ramanathan RK

Selective Oral Epidermal Growth Factor Receptor Belghiti J, see Vauthey J-N
Tyrosine Kinase Inhibitor, in Patients With Five Belkora JK, see Sepucha KR
Selected Solid Tumor Types, 4292 Bell RS, see Davis AM
Baselga J. Targeting the Epidermal Growth Factor Receptor Bell WN, see Schilsky RL
With Tyrosine Kinase Inhibitors: Small Molecules, Belldegrun AS, see Zisman A
Big Hopes (editorial), 2217 Beller U, see Chetrit A
Baskind P, see Seiter K Belli F, see Vici P
Bass AJ, see Rizzieri DA Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli
Bass AJ, Gockerman JP, Hammett E, DeCastro CM, Adams MR, Gallino G, Piris A, Cattelan A, Lazzari I,
DJ, Rosner GL, Payne N, Davis P, Foster T, Moore Carrabba M, Scita G, Santantonio C, Pilla L, Tragni
JO, Rizzieri DA. Phase I Evaluation of Prolonged- G, Lombardo C, Arienti F, Marchianó A, Queirolo
Infusion Gemcitabine With Irinotecan for Relapsed P, Bertolini F, Cova A, Lamaj E, Ascani L, Cam-
or Refractory Leukemia or Lymphoma, 2995 erini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava
Bassett LW, see Singletary SE P, Parmiani G. Vaccination of Metastatic Mela-
Bast M, see Weekes CD noma Patients With Autologous Tumor-Derived
Baudis M, see Kaiser U Heat Shock Protein gp96-Peptide Complexes: Clin-
Bauer S, see Kaiser R ical and Immunologic Findings, 4169
Bauernhofer T, see Jakesz R Belt R, see Agarwala SS
Baumann MA, see Koduri J Beltrán M, Colomer R. Does HER-2 Status Predict Only a
Baumert J, see Wendtner C-M Decreased Response to Hormone Therapy in Ad-
Baur A, see Wendtner C-M vanced Breast Cancer, or Does It Also Predict the
Bearman SI, see Nieto Y Extent of Metastatic Disease? (correspondence),
Bearzi I, see Scartozzi M 4605
Beasley KR, see Albain KS Bemis L, see Bremnes RM
Beattie-Palmer L, see Sweeney C Ben-Baruch G, see Chetrit A
Beatty P, see Levine JE Ben-Bassat I, see Raanani P
Beauchesne P. Promising Survival and Concomitant Radia- Benda J, see Bloss JD
tion Plus Temozolomide Followed by Adjuvant Bendandi M, see Federico M
Temozolomide (correspondence), 3180 Bender C, see Kirkwood JM
Beck AF, see Bepler G Benedetti-Panici P, Greggi S, Colombo A, Amoroso M,
Beck BD, see Chetrit A Smaniotto D, Giannarelli D, Amunni G, Raspa-
Beck J, see Shariat SF gliesi F, Zola P, Mangioni C, Landoni F. Neoadju-
Becton DL, see Furman WL vant Chemotherapy and Radical Surgery Versus
Bedikian AY, see Ballo MT Exclusive Radiotherapy in Locally Advanced
see Eton O Squamous Cell Cervical Cancer: Results From the
Bednar M, see Ferrari AC Italian Multicenter Randomized Study, 179
Begg CB, see Schrag D Benedetti-Panici P, Greggi S. In Reply (correspondence),
see Shike M 2909
Beham-Schmid C, see Jäger G Benito M, see González-Quevedo R
Behan K, see Allegra CJ Benjamin RS, see Ahmad SA
Behm FG, see Crews KR see Eton O
see Rubnitz JE Benk V, see Davis AM
Behrens BC, see Bloss JD Benner A, see Döhner K
Behrens S, see Hoecht S Benner SE, see Douillard J-Y
Behringer D, see Gelderblom H see Shin DM
Beijnen JH, See Crul M Bennett CL, see Rizzo JD
see Kruijtzer CMF Bennett CL, Price DK, Kim S, Liu D, Jovanovic BD, Nathan
see Malingré MM D, Johnson ME, Montgomery JS, Cude K, Brock-
see Raymond E bank JC, Sartor O, Figg WD. Racial Variation in
see van Kesteren Ch CAG Repeat Lengths Within the Androgen Recep-
Bekradda M, see Keating MJ tor Gene Among Prostate Cancer Patients of Lower
Bélanger K, Moore M, Baker SD, Dionne J, Maclean M, Socioeconomic Status, 3599
Jolivet J, Siu L, Soulières D, Wainman N, Seymour Benson AB III, see Berlin JD
L. Phase I and Pharmacokinetic Study of Novel see Kemeny MM
L-Nucleoside Analog Troxacitabine Given as a see Tepper
Downloaded from on June 28, 2008 . For personal JE No other uses without permission.
use only.
30-Minute InfusionCopyright
Every © 2002 by the2567
21 Days, American Society of Clinical
Bentz M,Oncology. All rights
see Viardot A reserved.

Bepler G, Gautam A, McIntyre LM, Beck AF, Chervinsky Berry DA, see Guidi AJ
DS, Kim Y-C, Pitterle DM, Hyland A. Prognostic Berry DA, Broadwater G, Klein JP, Antman K, Aisner J,
Significance of Molecular Genetic Aberrations on Bitran J, Costanza M, Freytes CO, Stadtmauer E,
Chromosome Segment 11p15.5 in Non-Small-Cell Gale RP, Henderson IC, Lazarus HM, McCarthy
Lung Cancer, 1353 PL Jr, Norton L, Parnes H, Pecora A, Perry MC,
Berdzik J, see Khushalani NI Rowlings P, Spitzer G, Horowitz MM. High-Dose
Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Versus Standard Chemotherapy in Metastatic
Yee GC, Biermann JS. American Society of Clin- Breast Cancer: Comparison of Cancer and Leuke-
ical Oncology Clinical Practice Guidelines: The mia Group B Trials With Data From the Autolo-
Role of Bisphosphonates in Multiple Myeloma, gous Blood and Marrow Transplant Registry, 743
3719 Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber
Beretta GD, see Cascinu S JE, Peshkin BN, Lerman C, Watson P, Lynch HT,
Berg W, see Motzer RJ Hilsenbeck SG, Rubinstein WS, Hughes KS, Par-
Berger F, see Fermé C migiani G. BRCAPRO Validation, Sensitivity of
Berger J, see Thies A Genetic Testing of BRCA1/BRCA2, and Prevalence
Berger MS, see Jennings MT of Other Breast Cancer Susceptibility Genes, 2701
Bergerat J-P, see Herbrecht R Berry DA, Parmigiani G, Rubinstein W, Watson P. In Reply
Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, (correspondence), 3936
Espérou H, Socié G, Calvo F, Gluckman E, Ribaud Berthelet E, see El-Sayed S
P, Rousselot Ph, Tazi A. Hypersensitivity Pneumo- Bertolini F, see Belli F
nitis Related to Imatinib Mesylate (correspon- Bertozzi AI, see Patte C
dence), 4271 Bertucci D, see Schilsky RL
Bergman M, see Auvinen MI Bertuzzi A, Castagna L, Nozza A, Quagliuolo V, Siracusano
Bergot E, see Bergeron A L, Balzarotti M, Compasso S, Alloisio M, Parra
Bergsland EK, Venook AP. Shedding Old Paradigms: Devel- HS, Santoro A. High-Dose Chemotherapy in Poor-
oping Viruses to Treat Cancer (editorial), 2220 Prognosis Adult Small Round-Cell Tumors: Clini-
Berinstein NL. Carcinoembryonic Antigen as a Target for cal and Molecular Results From a Prospective
Therapeutic Anticancer Vaccines: A Review, 2197 Study, 2181
Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Bessell EM, López-Guillermo A, Villá S, Verger E, Nomd-
Benson AB III. Phase III Study of Gemcitabine in edeu B, Petit J, Byrne P, Montserrat E, Graus F.
Combination With Fluorouracil Versus Gemcitab- Importance of Radiotherapy in the Outcome of
ine Alone in Patients With Advanced Pancreatic Patients With Primary CNS Lymphoma: An Anal-
Carcinoma: Eastern Cooperative Oncology Group ysis of the CHOD/BVAM Regimen Followed by
Trial E2297, 3270 Two Different Radiotherapy Treatments, 231
Bernard-Marty C, see Khayat D Betensky RA, Louis DN, Caimcross JG. Influence of Unrec-
Bernardo MP, see Ng AK ognized Molecular Heterogeneity on Randomized
Bernath A, see Fata F Clinical Trials, 2495
Berney DM, see Oliver RTD Beyer BCM, see Heiss MM
Bernhard J, Maibach R, Thürlimann B, Sessa C, Aapro MS, Beyer J, see Bokemeyer C
Swiss Group for Clinical Cancer Research. Pa- see Kollmannsberger C
tients’ Estimation of Overall Treatment Burden: Beykirch MK, see Josting A
Why Not Ask the Obvious?, 65 Bezjak A, see Davis AM
Bernstein L, see Press MF see Shepherd FA
see Wickerham DL Bhagat R, see Orlowski RZ
Bernstein M, see Goorin AM Bhaskaran D, see Barakat RR
Bernstein ML, see Furman WL Bhatia S, Jenney MEM, Bogue MK, Rockwood TH, Feusner
Berruti A, see Sperone P JH, Friedman DL, Robison LL, Kane RL. The
Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Minneapolis-Manchester Quality of Life Instru-
Matteis A, Nuzzo F, Giardina G, Danese S, De ment: Reliability and Validity of the Adolescent
Lena M, Lorusso V, Farris A, Sarobba MG, DeFa- Form, 4692
biani E, Bonazzi G, Castiglione F, Bumma C, Moro Bianchi F, see Scartozzi M
G, Bruzzi P, Dogliotti L. Time to Progression in Biankin AV, Morey AL, Lee S-C, Kench JG, Biankin SA,
Metastatic Breast Cancer Patients Treated With Hook HC, Head DR, Hugh TB, Sutherland RL,
Epirubicin Is Not Improved by the Addition of Henshall SM. DPC4/Smad4 Expression and Out-
Either Cisplatin or Lonidamine: Final Results of a come in Pancreatic Ductal Adenocarcinoma, 4531
Phase III Study With a Factorial Design, 4150 Biankin SA, see Biankin
Downloaded from on June 28, 2008 . For personal use only. AV without permission.
No other uses
Berry D, see Singletary SE Copyright © 2002 by the American Society of Clinical
Biasin E,Oncology. All rights
see Fagioli F reserved.

Bichakjian CK, Schwartz JL, Wang TS, Hall JM, Johnson Bleiberg H, see Louvet C
TM, Biermann JS. Melanoma Information on the Bleiberg H, Di Leo A. Mortality Associated With Irinotecan
Internet: Often Incomplete—A Public Health Op- Plus Bolus Fluorouracil/Leucovorin (correspon-
portunity?, 134 dence), 1145
Bichisao E, see Bajetta E Bleiweiss IJ, see Guidi AJ
Bickert B, see Womer RB Blessing JA, see Bloss JD
Bielack SS, see Franzius C see Muggia FM
Bielack SS, Jargens H. In Reply (correspondence), 2910 Blomgren H, see Edler D
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS,
Helmke K, Kotz R, Salzer-Kuntschik M, Werner Sood AK, Markman M, Benda J. Randomized Trial
M, Winkelmann W, Zoubek A, Jürgens H, Winkler of Cisplatin and Ifosfamide With or Without Bleo-
K, Cooperative German-Austrian-Swiss Osteosar- mycin in Squamous Carcinoma of the Cervix: A
coma Study Group. Prognostic Factors in High- Gynecologic Oncology Group Study, 1832
Grade Osteosarcoma of the Extremities or Trunk: Blumenschein GR Jr, see Herbst RS
An Analysis of 1,702 Patients Treated on Neoad- Blumgart L, see Heffernan N
juvant Cooperative Osteosarcoma Study Group Boasberg PD, see Hsueh EC
Protocols, 776 Bochner B, see Graefen M
Bierman PJ, See Vose JM Bociek G, see Weekes CD
see Weekes CD Boddy AV, see Hughes A
Biermann JS, see Berenson JR Bodnar L, see Khushalani NI
see Bichakjian CK Bodurka DC, see Eifel PJ
Biesma B, see Ardizzoni A see Strasser F
Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Boerrigter L, see Crul M
Calvert AH, Gamucci T, Twelves C, Fargeot P, Boewer C, see Menssen HD
Epelbaum R, Lohrisch C, Piccart MJ. Doxorubicin Boffi R, see Galeazzi G
and Paclitaxel Versus Doxorubicin and Cyclophos- Bogue MK, see Bhatia S
phamide as First-Line Chemotherapy in Metastatic Bohlen H, see Weihrauch MR
Breast Cancer: The European Organization for Boige V, see Raymond E
Research and Treatment of Cancer 10961 Multi- Boiocchi M, see Toffoli G
center Phase III Trial, 3114 Boiron JM, see Cany L
Bigner DD, see Reardon DA see Mahon FX
Bilhou-Nabéra C, see Mahon FX Bokemeyer C, see Kersemaekers A-MF
Billett AL, see Donaldson SS see Kollmannsberger C
see LeClerc JM see Mayer F
Billups CA, see Spunt SL Bokemeyer C, Nichols CR, Droz J-P, Schmoll H-J, Horwich
Binh NC, see Love RR A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L,
Birhiray R, see Keating MJ Einhorn L, Hartmann JT. Extragonadal Germ Cell
Birkmann J, see Kaiser U Tumors of the Mediastinum and Retroperitoneum:
Birner P, Oberhuber G. Is Fluorescence In Situ Hybridization Results From an International Analysis, 1864
Really Superior to HercepTest? (correspondence), Bol CJ, see Crul M
4607 Bolla M, see Pignatti F
Bischoff HG, see Kaiser U Bomanji JB, Syed R, Brock C, Jankowska P, Dogan A, Costa
Bisogno G, see Ferrari A DC, Ell PJ, Lee SM. Challenging Cases and Diag-
Bitossi R, see Berruti A nostic Dilemmas; Case 2. Pitfalls of Positron Emis-
Bitran J, see Berry DA sion Tomography for Assessing Residual Medias-
Bivens S, see Ahles TA tinal Mass After Chemotherapy for Hodgkin’s
Bivins C, see Giles FJ Disease, 3347
Bjork T, see Baselga J Bonadonna G, see Rassidakis GZ
Black PM, see Chakravarti A Bonazzi C, see Cantù MG
Blackwood MA, see Shih HA Bonazzi G, see Berruti A
Blake PR, see Kolomainen DF Bonfante V, see Rassidakis GZ
Blamey R, see Jonat W Boni C, see Scagliotti GV
Blanch J, see Prieto JM Bonner JA. Reply 2 (correspondence), 1428
Blanchon F, see Depierre A Bonneterre J, Nabholtz J-M, Budzar A, Robertson J, Thürli-
Bland KI, see Singletary SE mann B, Steinberg M, Webster A, von Euler M. In
Blanke CD, see Heinrich MC Reply
Downloaded from on June 28, 2008 . For personal use only.(correspondence),
No other uses without 3749
Blay JY, see Viens P Copyright © 2002 by the American Society of Clinical Oncology.
Boogerd All rights reserved.
W, see Dorresteijn LDA

Bookbinder M, see Heffernan N Schey S, Chakraverty RK, Craddock C, Milligan

Boortz-Marx RL, see Smith TJ DW, Pettengell R, Marsh JCW, Linch DC, Gold-
Booser D, see Esteva FJ stone AH, Williams CD, Mackinnon S. Role of
Borbas C, see Keating NL Nonmyeloablative Allogeneic Stem-Cell Trans-
see Silliman RA plantation After Failure of Autologous Transplan-
Borgen P, see Scheuer L tation in Patients With Lymphoproliferative Malig-
Borgen PI, see Singletary SE nancies, 4022
Borner M, see Carmichael J Branstetter AD, see Stanton AL
Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Brauchli P, see Borner MM
Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Braun D, see Depierre A
Hanselmann S, Müller S, Brauchli P, Castiglione- Braun S, see Winer EP
Gertsch M, Goldhirsch A, Roth AD. Phase II Study Braun T, see Levine JE
of Capecitabine and Oxaliplatin in First- and Sec- see Yanik GA
ond-Line Treatment of Advanced or Metastatic Brawley O, see Sateren WB
Colorectal Cancer, 1759 Breast Cancer Linkage Consortium, see Lakhani SR
Bos AM, see Kehrer DFS Bréchot J-M, see Depierre A
Bos R, van der Hoeven JJM, van der Wall E, van der Groep Brecht ML, see Sarna L
P, van Diest PJ, Comans EFI, Joshi U, Semenza Bredeson CN, see Loberiza FR Jr
GL, Hoekstra OS, Lammertsma AA, Molthoff Breen N, see Sateren WB
CFM. Biologic Correlates of 18Fluorodeoxyglucose Bremnes RM, see Sundstrøm S
Uptake in Human Breast Cancer Measured by Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A,
Positron Emission Tomography, 379 Bemis L, Gemmill RM, Drabkin HA, Franklin WA.
Bosl G, see Osman I High-Throughput Tissue Microarray Analysis Used
Bosl GJ, see Vuky J to Evaluate Biology and Prognostic Significance of
Bosq J, see Aloulou S the E-Cadherin Pathway in Non-Small-Cell Lung
Bosshart H. T Helper Cell Activation in B-Cell Lymphomas Cancer, 2417
(correspondence), 2904 Brenckman WD Jr, see Rizvi NA
Bottet P, see Joly F Brennan M, see Holen KD
Bottini A, see Berruti A Brennan MF, see Alektiar KM
Bottomley A, see Efficace F see Hochwald SN
Bouchardy C, Verkooijen HM, Fioretta G, Sappino AP, see Kattan MW
Vlastos G. Increased Risk of Malignant Mullerian see Stojadinovic A
Tumor of the Uterus Among Women With Breast Brenner H, Hakulinen T. Up-to-Date Long-Term Survival
Cancer Treated by Tamoxifen (correspondence), Curves of Patients With Cancer by Period Analysis,
4403 826
Boukovinas J, see Kosmidis P Brenner H, Hakulinen T. Very-Long-Term Survival Rates of
Bouleuc C, see Louvet C Patients With Cancer (correspondence), 4405
Bourgeon A, see Etienne M-C Breslin S, see Horning SJ
Bourstyn E, see Rouzier R Breslow NE, see Green DM
Boutard P, see Patte C Breton J-L, see Depierre A
Bouvier CV, see Brett BT Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D,
Bowling MK, see Carducci MA Davidson BR, Kurzawinski TR, Watkinson AF,
Bowman LC, see Katzenstein HM Van Someren N, Pounder RE, Caplin ME. Phase II
Boyd C, see Huang J Study of Anti-Gastrin-17 Antibodies, Raised to
Boyd J, see Scheuer L G17DT, in Advanced Pancreatic Cancer, 4225
Boye N, see Sundstrøm S Brettman L, see Rai KR
Boyett JM, see Jennings MT Brey K, see Schover LR
Brach del Prever A, see Fagioli F Brezinschek R, see Jäger G
Bradley TL, see Sweet KM Briassoulis E, see Bafaloukos D
Bradof JE, see Greco FA Brice P, see Fermé C
Brady C, see Lipton A Bridge JA, see Sorensen PHB
Brainard J, see Thomas J Bridges JE, see Kolomainen DF
Bramble J, see Oscier D Brierley JD, Catton PA, O’Sullivan B, Dancey JE, Dowling
Bramwell V, see Winquist E AJ, Irish JC, McGowan TS, Sturgeon JFG, Swal-
Brandberg Y, see Österborg A low CJ, Rodrigues GB, Panzarella T. Accuracy of
Brandi M, see Vici P Recorded
Downloaded from on June 28, 2008 . For personal use only. NoTumor,
other usesNode, and
without Metastasis Stage in a
Branson K, Chopra R, Kottaridis © 2002
PD, by the American
McQuaker Society
G, Parker A, of Clinical Oncology. All rights Cancer
Comprehensive reserved.Center, 413

Brisson J, see Maunsell E Gliomas: Answering One Question in a Myriad of

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, New Questions (editorial), 2223
Montz FJ. Survival Effect of Maximal Cytoreduc- Bucana C, see Herbst RS
tive Surgery for Advanced Ovarian Carcinoma Buchbarker D, see Ramanathan RK
During the Platinum Era: A Meta-Analysis, 1248 Buchholz E, see Ardizzoni A
Broadwater G, see Berry DA Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J,
see Guidi AJ Salas J, Frye D, Strom EA, McNeese MD, Perkins
Brock C, see Bomanji JB G, Katz A, Singletary SE, Hunt KK, Buzdar AU,
Brockbank JC, see Bennett CL Hortobagyi GN. Predictors of Local-Regional Re-
Brockmöller J, see Kaiser R currence After Neoadjuvant Chemotherapy and
Broemeling L, see Ellerhorst JA Mastectomy Without Radiation, 17
see Wang XS Buchser E, see Smith TJ
Brook RH, see Malin JL Buckley JD, see Woods WG
Brooks BJ, Bani JC, Fletcher CDM, Demetri GD. Challenges Buckman R, see Baile WF
in Oncology; Case 4. Response of Metastatic Gas- Buda A, see Cantù MG
trointestinal Stromal Tumor Including CNS In- Budman DR, see Guidi AJ
volvement to Imatinib Mesylate (STI-571), 870 Budzar A, see Bonneterre J
Broome CM, see Vaughn DJ Bugat R, see Culine S
Brosteanu O, see Sieber M Buhler H, see Fuchs IB
Browman GP, see Rizzo JD Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato
see Winer EP R, Gupta SK, Tendler CL. Pegylated Interferon
Brown AE, see Timoney JP Alfa-2b Treatment for Patients With Solid Tumors:
Brown BW, see Horning SJ A Phase I/II Study, 3841
Brown C, see Barakat RR Bumma C, see Berruti A
Brown J, see Czauderna P Bundy BN, see Rose PG
Brown ML, see Warren JL Bunjes D, see Ringdén O
Bruckner H, see Lima CMSR Bunn PA Jr. Chemotherapy for Advanced Non-Small-Cell
Bruckner JD, see Rubin BP Lung Cancer: Who, What, When, Why?, 23s
Bruera E, see Ripamonti C Bunn PA Jr. Treatment of Advanced Non-Small-Cell Lung
see Strasser F Cancer With Two-Drug Combinations (editorial),
see Suarez-Almazor ME 3565
see Sweeney C Bunnell CA, Winer EP. Lumping Versus Splitting: The
Bruera E, Russell N, Sweeney C, Fisch M, Palmer JL. Place Splitters Take This Round (editorial), 3576
of Death and Its Predictors for Local Patients Burchmore M, see Osoba D
Registered at a Comprehensive Cancer Center, see Vogel CL
2127 Burgart LJ, see Lindor NM
Brugger S, see Scheithauer W Burgess C, see Damani MN
Brugger W, see Viens P Burghouts J, see Ardizzoni A
Bruggers CS, see Gururangan S Burke TW, see Levenback C
see Jennings MT Burkes RL, see Leighl NB
Brugnara S, see Ridolfi R Burkhardt JH, Litwin MS, Rose CM, Correa RJ, Sunshine
Bruland OS, see Anderson PM JH, Hogan C, Hayman JA. Comparing the Costs of
Brümmer J, see Laack E Radiation Therapy and Radical Prostatectomy for
see Thies A the Initial Treatment of Early-Stage Prostate Can-
Brun O, see Page E cer, 2869
Brundage M, see Pearcey R Burnett CB, see Liang W
Brune D, see Joly F Burns P, see El-Sayed S
Bruner JM, see Jennings MT Burris HA III, see Greco FA
Brunet R, see Louvet C Burstein HJ, see Chlebowski RT
Brunetti IM, see Falcone A see Winer EP
Bruning P, see Biganzoli L Burstein S, see Leung W
Brunner G, see Thies A Burtles S, see Seymour LW
Bruzzi P, see Berruti A Burton G, see Osborne CK
Bryant J, see Fisher B Butow PN, see Gattellari M
see Wickerham DL Buyse M, see Di Leo A
Bryce DA, see Smith TJ
Downloaded from on June 28, 2008 . ForBuzaglo
personal K,
No otherCuses without permission.
Buatti JM, Meeks SL, Ryken Copyright
2002 by the
TL.American Society of
Low-Grade ClinicalAC,
Buzaid Oncology. All rights
see Eton O reserved.

Buzdar A, see Osborne CK sponded to First-Line Platinum-Based Regimens,

Buzdar AU, see Bessell EM 1232
Buzdar AU. Superior Efficacy of Letrozole Versus Tamox- Cany L, Fitoussi O, Boiron JM, Marit G. Tumor Lysis
ifen as First-Line Therapy (correspondence), 876 Syndrome at the Beginning of Thalidomide Ther-
Byrne P, see Bessell EM apy for Multiple Myeloma (correspondence), 2212
Canzonieri V, see Pizzichetta MA
Capanna T, see DiPaola RS
Capdeville R, see Viens P
C Capelli A, see Ferrandina G
Caplin ME, see Brett BT
Cappelletti V, see Daidone MG
Cabanillas F, see Rassidakis GZ
Cardiovascular Thrombolytic to Open Occluded Lines-2
see Sarris AH
Investigators, see Deitcher SR
see Witzig TE
Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisen-
Cadoni G, see Piantelli M
berger MA, Sinibaldi V, Donehower R, Leahy TL,
Cagiannos I, see Graefen M
Carr RA, Isaacson JD, Janus TJ, Andre A, Hos-
Cagiannos I, Graefen M, Karakiewicz PI, Ohori M, Eastham
mane BS, Padley RJ. Atrasentan, an Endothelin-
JA, Rabbani F, Fair W, Wheeler TM, Hammerer
Receptor Antagonist for Refractory Adenocarcino-
PG, Haese A, Erbersdobler A, Huland H, Scardino
PT, Kattan MW. Analysis of Clinical Stage T2 mas: Safety and Pharmacokinetics, 2171
Prostate Cancer: Do Current Subclassifications Carli M, see Ferrari A
Represent an Improvement?, 2025 Carlisle TL, see Buatti JM
Cagnoni PJ, see Nieto Y Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza
Caimcross JG, see Betensky RA A, Skovsgaard T, Munier S, Martin C. Randomized
Cain AM, see Spunt SL Comparative Study of Tegafur/Uracil and Oral
Cairo MS, see Lones MA Leucovorin Versus Parenteral Fluorouracil and
Calvert AH, see Biganzoli L Leucovorin in Patients With Previously Untreated
Calvert H, see Baselga J Metastatic Colorectal Cancer, 3617
see Hughes A Carney DP, see McDermott RS
Calvert P, see Hughes A Carney W, see Lipton A
Calvo F, see Bergeron A Carpano S, see Lopez M
Calzone K, see Shih HA Carr RA, see Carducci MA
Camerini R, see Belli F Carrabba M, see Belli F
Cameron T, see Kehrer DFS Carreras E, see Prieto JM
Camidge R, Price A. Radiation Recall Dermatitis May Carson D, see Liptay MJ
Represent the Koebner Phenomenon (correspon- Carson K, see Kleinberg L
dence), 4130 Carson L, see Markman M
Camphausen K, see Coleman CN Cartwright TH, Cohn A, Varkey JA, Chen Y-M, Szatrowski
Campos F, see Herbrecht R TP, Cox JV, Schulz JJ. Phase II Study of Oral
Campos S, see Vasey PA Capecitabine in Patients With Advanced or Meta-
Cancer Research Campaign Phase I/II Clinical Trials Com- static Pancreatic Cancer, 160
mittee, see Seymour LW Casanova M, see Ferrari A
Candolfi E, see Herbrecht R see Massimino M
Canellos GP, see Graefen M see Spreafico F
Canellos GP. New Treatments for Advanced Hodgkin’s Cascinelli N, see Belli F
Disease: An Uphill Fight Beginning Close to the Cascino T, see Shaw E
Top (editorial), 607 Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P,
Cangiano T, see Graefen M Baldelli AM, Beretta GD, Ubiali E, Catalano G.
Cannistra SA. Is There a “Best” Choice of Second-Line Neuroprotective Effect of Reduced Glutathione on
Agent in the Treatment of Recurrent, Potentially Oxaliplatin-Based Chemotherapy in Advanced
Platinum-Sensitive Ovarian Cancer? (editorial), Colorectal Cancer: A Randomized, Double-Blind,
1158 Placebo-Controlled Trial, 3478
Cantor SB, see Esnaola NF Cassem NH, see Rauch PK
Cantù MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Castagna L, see Bertuzzi A
Dell’Anna T, Torri V, Colombo N. Randomized Castel T, see Mellado B
Controlled Trial of Single-Agent Paclitaxel Versus Castiglione F, see Berruti A
Cyclophosphamide, Doxorubicin, on
Downloaded from andJune
28, 2008in. ForCastiglione-Gertsch
personal use only. No M, see
other Borner
uses withoutMM
Copyright ©
Patients With Recurrent 2002 byCancer
Ovarian the American
Who Society
Re- of Clinical Oncology.
see Colleoni MAll rights reserved.

Castleberry RP, see Katzenstein HM sopharyngeal Carcinoma: Progression-Free Sur-

Castro M. Eniluracil’s Need for a Targeted Approach: A vival Analysis of a Phase III Randomized Trial,
Lesson in Drug Development (correspondence), 2038
3750 Chan DT, see Chan ATC
Castro M. The Simpleton’s Error in Drug Development Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS,
(correspondence), 4606 Junck LR, Gebarski SS, Sandler HM. Survival and
Català E, see Smith TJ Failure Patterns of High-Grade Gliomas After
Catalano G, see Cascinu S Three-Dimensional Conformal Radiotherapy, 1635
Catalano P, see Berlin JD Chan JL, Sandler HM, Fraass BA. In Reply to Drs Knisely
see Hinton S and LaCombe (correspondence), 3359
Catalano V, see Cascinu S Chan K-W, see Jennings MT
Cattelan A, see Belli F Chan S-H, see Cheng H-L
Catton CN, see Davis AM Chan WC, see Vose JM
Catton PA, see Brierley JD see Weekes CD
Cau TT, see Love RR Chang J, see Radford JA
Cavazos CM, see Gururangan S Chao DH, see Zisman A
Cazin B, see Keating MJ Chapchap P, see Czauderna P
Cecchetto G, see Ferrari A Chapman PB, see Hwu W-J
Cefalo G, see Massimino M see Wolchok JD
Cefalo GS, see Spreafico F Chapman PB. Vaccinating Patients With Autologous Tumor
Cella D, see Heffernan N (editorial), 4139
see Rizzo JD Charnsangavej C, see Herbst RS
Cellerino R, see Porfiri E see Pisters PWT
see Scartozzi M Chastang C, see Depierre A
Cellini N, see Trodella L Chau I, see Maisey N
Ceribelli A, see Scagliotti GV Chaudri-Ross HA, see Mouridsen H
Cervantes G, see O’Shaughnessy J Chazal M, see Etienne M-C
Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Cheever MA, see Disis ML
Pungolino E, Gargantini L, Granata S, Valentini M, Chemotherapy and Radiotherapy Expert Panel, American
Morra E. Prognostic Factors for Malignant Trans- Society of Clinical Oncology, see Schuchter LM
formation in Monoclonal Gammopathy of Undeter- Chen C-J, see Singer S
mined Significance and Smoldering Multiple My- Chen J-D, see Chou Y-H
eloma, 1625 Chen LL, see Ahmad SA
Cesario A, see Trodella L Chen WY, Garber JE, Higham S, Schneider KA, Davis KB,
Cha SS, see Sloan JA Deffenbaugh AM, Frank TS, Gelman RS, Li FP.
Chabannon C, see Viens P BRCA1/2 Genetic Testing in the Community Set-
Chabot P, see Davis AM ting, 4485
Chada S, see Ellerhorst JA Chen Y-M, see Cartwright TH
Chakrabarti S. Critical Factors in Optimizing Graft-Versus- Cheng H-L, Trink B, Tzai T-S, Liu H-S, Chan S-H, Ho C-L,
Leukemia Effect for Relapsed Leukemias (corre- Sidransky D, Chow N-H. Overexpression of c-met
spondence), 2756 as a Prognostic Indicator for Transitional Cell
Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein Carcinoma of the Urinary Bladder: A Comparison
DM, Dyson NJ, Loeffler JS. Quantitatively Deter- With p53 Nuclear Accumulation, 1544
mined Survivin Expression Levels Are of Prognos- Chervinsky DS, see Bepler G
tic Value in Human Gliomas, 1063 Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller
Chakraverty RK, see Branson K U, Ben-Baruch G, Fishman A, Levavi H, Lubin F,
Chalian AA, see Machtay M Menczer J, Piura B, Struewing JP, Modan B,
Chamberlain MC. Treatment of Intracranial Metastatic Es- National Israeli Study of Ovarian Cancer. Effect of
thesionneuroblastoma (correspondence), 357 BRCA Mutations on the Length of Survival in
Chambers GK, see Van Patten CL Epithelial Ovarian Tumors, 463
Chamorey E, see Etienne M-C Cheung FY, see Chan ATC
Chan ATC, Teo PML, Ngan RK, Leung TW, Lau WH, Zee Cheung YB, see Tan SB
B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu Chevalier V, see Curé H
KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Chevalier V, Curé H, Chollet P, Lévi F. In Reply (correspon-
Lai M, Kwan WH, Choi P, Johnson PJ. Concurrent dence), 3938
Chemotherapy-Radiotherapy Compared With Ra-
Downloaded from on June 28, 2008 . For personal usesee
Chevret S, Depierre
only. No otherAuses without permission.
diotherapy Alone Copyright © 2002 by theAdvanced
in Locoregionally American Society
Na- of ClinicalJ-H,
Chiang Oncology. All rights
see Chou Y-Hreserved.

Chiarion-Sileni V, see Ridolfi R Chung LP, see Chim CS

Chihara S, see Morita T Chung YFA, see Tan SB
Childhood Cancer Survivor Study, see Emmons K Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT,
Childhood Oncology Group, see Sorensen PHB Ratner L, Pluda JM, Figg WD, Krown SE, Dezube
Children’s Cancer Group, see Nachman JB BJ. Matrix Metalloproteinase Inhibitor COL-3 in
Chilosi M, see Rassidakis GZ the Treatment of AIDS-Related Kaposi’s Sarcoma:
Chim CS, Lam CCK, Nicholls JM, Ooi GC, Kwong YL. A Phase I AIDS Malignancy Consortium Study,
Unusual Hematologic Malignancies; Case 3. CNS 153
Involvement in CD56-Positive Intestinal Gamma/ Ciardella M, see DiPaola RS
Delta T-Cell Lymphoma, 3742 Cirera E, see Prieto JM
Chim CS, Wong WM, Nicholls J, Chung LP, Liang R. Cisar L, see Hudes G
Extramedullary Sites of Involvement in Hemato- Clark G, see Singletary SE
logic Malignancies; Case 3. Hemorrhagic Gastric Clark JI, see Albain KS
Plasmacytoma as the Primary Presentation in Mul- Clark JW, see Eder JP Jr
tiple Myeloma, 344 Clark MM, see Cox LS
China C, see Rajq V Clarke EA, see Dores GM
Chinchilli V, see Lipton A Classen J, Dieckmann K-P. Radiotherapy of Carcinoma-In-
Chiou H-J, see Chou Y-H Situ of the Testis (correspondence), 3559
Chiou WL, Wu TC, Ma C, Jeong HY. Enhanced Oral Clavell LA, see LeClerc JM
Bioavailability of Docetaxel by Coadministration see Lipshultz SE
of Cyclosporine: Quantitation and Role of P-Gly- Clavier J, see Depierre A
coprotein (correspondence), 1951 Clayman G, see Shin DM
Chipponi J, see Curé H Cleary KR, see Pisters PWT
Chirikos TN, see Jacobsen PB see Vauthey J-N
Chisesi T, see Federico M Cleeland CS, see Esnaola NF
Chiu KW, see Chan ATC see Wang XS
Chlebowski RT, see Winer EP Clegg L, see Harlan LC
Chlebowski RT, Aiello E, McTiernan A. Weight Loss in Clerici M, see Scagliotti GV
Breast Cancer Patient Management, 1128 Clifford JL, see Shin DM
Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings Clinton S, see Nadella P
SR, Vogel VG III, Burstein HJ, Eisen A, Lipkus I, Clipp EC, see Ingram SS
Pfister DG. American Society of Clinical Oncology Clohisy DR, see Nagarajan R
Technology Assessment of Pharmacologic Inter- Coates AS, see Colleoni M
ventions for Breast Cancer Risk Reduction Includ- see Goldhirsch A
ing Tamoxifen, Raloxifene, and Aromatase Inhibi- see Hersey P
tion, 3328 Cobau CD, see Hobday TJ
Choi P, see Chan ATC Cobleigh MA, see Vogel CL
Chollet P, see Curé H see Winer EP
see Chevalier V Codrington H, Sutedja T, Golding R, van Mourik J, Risse E,
see Zelek L Postmus PE. Unusual Pulmonary Lesions; Case 2.
Chong G, see Andermann A Endobronchial Carcinoid of the Lung, 2747
Chong N, see Vallis KA Coeffic D, see Page E
Chopra R, see Branson K Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical
Chott A, see Jäger G Radiation for Localized Prostate Cancer: Local
Chou Y-H, Chiou H-J, Tiu C-M, Chen J-D, Hung G-S, Persistence of Disease Results in a Late Wave of
Chiang J-H. Some Unusual Complications of Ma- Metastases, 3199
lignancies: Case 1. Spontaneous Rupture of Hepa- Coëtmeur D, see Depierre A
tocellular Carcinoma Demonstrated by Contrast- Coetzee G, Irvine R. Size of the Androgen Receptor CAG
Enhanced Sonography, 4108 Repeat and Prostate Cancer: Does It Matter? (edi-
Chouaki N, see Zelek L torial), 3572
Chow N-H, see Cheng H-L Cohen EEW, Vokes EE. Searching for a Standard (editorial),
Christakis J, see Dimopoulos MA 359
Christensen B, see Jatoi A Cohen GL, see Pecora AL
Christian MC, see Sateren WB Cohen HJ, see Ingram SS
Chu P, see Schwarz RE see LeClerc JM
Chun H, see Downloaded
Mikulski SM Cohen L,use
from on June 28, 2008 . For personal seeonly.
other uses without permission.
Chung JW, see Lee H-S Copyright © 2002 by the American Society of Clinical
Cohen MZ,Oncology. All rights
see Pentz RD reserved.

Cohn A, see Cartwright TH Cooperative Investigators of the Dutch Colorectal Cancer

Cohn SL, see Kletzel M Group, see Marijnen CAM
Coiffier B, see Gisselbrecht C Corbo GM, see Trodella L
Cokgor I, see Reardon DA Cordella L, see Cascinu S
Col N, see Chlebowski RT Cordon-Cardo C, see Osman I
Colan SD, see Lipshultz SE see Stojadinovic A
Coldiron B, Dinehart S. Sentinel-Node Technique Will Corle D, see Shike M
Change the Design of Clinical Trials in Malignant Corless CL, see Heinrich MC
Melanoma (correspondence), 2208 Cornetta K, see Levine JE
Cole B, see Ahles TA Cornu P, see Pignatti F
Cole BF, see Kilbridge KL Correa RJ, see Burkhardt JH
Coleman CN, Mitchell JB, Camphausen K. Tumor Hypoxia: Corry J, see Rischin D
Chicken, Egg, or a Piece of the Farm? (editorial), Corsi M, see Belli F
610 Corstens FHM, see Langenhoff BS
Coleman R, see Biganzoli L see Ruers TJM
Coleman RE, see Reardon DA Cortes JE, see Giles FJ
Coleman RL, see Levenback C Cortez A, see Barranger E
Coliarakis N, see Antonadou D Costa DC, see Bomanji JB
Colin P, see Fermé C Costa EB, see Costa L
Colleoni M, Goldhirsch A, Coates AS, Gelber RD, Gelber S, Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa
Castiglione-Gertsch M. In Reply (correspondence), EB, de Moura MC, Lipton A. Prospective Evalua-
2211 tion of the Peptide-Bound Collagen Type I Cross-
Colleoni R, see Hochwald SN
Links N-Telopeptide and C-Telopeptide in Predict-
Collini P, see Spreafico F
ing Bone Metastases Status, 850
Collins CA, see Stanton AL
Costantino J, see Wickerham DL
Collins RH Jr, see Levine JE
Costanza M, see Berry DA
Collyar DE, see Chlebowski RT
Costanzi JJ, see Mikulski SM
Colombo A, see Benedetti-Panici P
Cote K, see D’Amico AV
Colombo N, see Cantù MG
Cottler-Fox M, see Badros A
Colomer D, see Mellado B
Cottu P, see Zelek L
Colomer R, see Beltrán M
Couanet D, see Lashford LS
Colosimo C, see Massimino M
Couch FJ, see Shih HA
Colucci G, see Vici P
Coudert B, see Curé H
Colvin OM, see Quinn JA
Couëtte JE, see Joly F
Colwell B, see Rivera E
see Schilsky RL Couillaud G, see Perel Y
Comans EFI, see Bos R Court W, see Order SE
Come S, see Osborne CK Coutré S, see Keating MJ
Compasso S, see Bertuzzi A Cova A, see Belli F
Compton LD, see Lima CMSR Coventry BJ, see Hersey P
Conklin HS, see Rivera E Cowan RA, see Radford JA
Conlon K, see Holen KD Cox E, see Loesch D
see Hochwald SN Cox JV, see Cartwright TH
Connor M, see Timoney JP Cox LS, Patten CA, Ebbert JO, Drews AA, Croghan GA,
Connors JM, see Shenkier TN Clark MM, Wolter TD, Decker PA, Hurt RD.
Connors S, see Eder JP Jr Tobacco Use Outcomes Among Patients With
Conrad EU, see Rubin BP Lung Cancer Treated for Nicotine Dependence,
Conte P, see Falcone A 3461
Conti F, see Vici P Coyle LA, see Mortuza FY
Cony-Makhoul P, see Mahon FX Coyne PJ, see Smith TJ
Cooley TP, see Cianfrocca M Craddock C, see Branson K
see Evans SR Craft P, see Shadbolt B
Cooper MR, see Rai KR Cragg GM, see Schwartsmann G
Cooperative Family Registry for Colon Cancer Studies, see Cramer L, see Modi S
Lindor NM Crane CH, see Esnaola NF
Cooperative Downloaded
German-Austrian-Swiss Osteosarcoma
from 2008 . ForCrane
on June 28, Study CN,
personal usesee Pisters
only. PWT
No other uses without permission.
Group, see Bielack SS © 2002 by the American Society of Clinical
Crane EA,Oncology. All rights
see Herbst RS reserved.

Crawford ED. Intravesical Therapy for Superficial Cancer: Curé H, see Chevalier V
Need for More Options (editorial), 3185 Curé H, Chevalier V, Adenis A, Tubiana-Mathieu N, Niez-
Crawford J, see Lawrence G godzki G, Kwiatkowski F, Pezet D, Perpoint B,
see Vokes EE Coudert B, Focan C, Lévi F, Chipponi J, Chollet P.
Cremieux P, see Gabrilove JL Phase II Trial of Chronomodulated Infusion of
Cremin C, Wong N, Buzaglo K, Paradis A-J, Foulkes W. High-Dose Fluorouracil and l-Folinic Acid in Pre-
Nonovarian Pelvic Cancers in BRCA1/2 Mutation viously Untreated Patients With Metastatic Colo-
Carriers and the BRCAPRO Statistical Model (cor- rectal Cancer, 1175
respondence), 3936 Curigliano G, see De Pas T
Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Curley SA, see Esnaola NF
Behm FG, Plunkett W, Raimondi SC, Pui C-H, see Vauthey J-N
Rubnitz JE, Stewart CF, Ribeiro RC. Interim Com- Curran D, see Pignatti F
parison of a Continuous Infusion Versus a Short Curran W, see Mehta MP
Daily Infusion of Cytarabine Given in Combination see Shaw E
With Cladribine for Pediatric Acute Myeloid Leu- Curtis RE, see Dores GM
kemia, 4217 Cutler C, Antin JH. In Reply (correspondence), 604
Crinò L, see Scagliotti GV Cuzick J, see Jonat W
Cripe L, see Witzig TE Cvitkovic E, see Louvet C
Crist WM, see Baker KS Czauderna P, Mackinlay G, Perilongo G, Brown J, Shafford
see Sorensen PHB E, Aronson D, Pritchard J, Chapchap P, Keeling J,
Cristofanilli M, see Esteva FJ Plaschkes J, Otte JB for the Liver Tumors Study
Critchfield GC, see Frank TS Group of the International Society of Pediatric
Crivellari D, see Spazzapan S Oncology. Hepatocellular Carcinoma in Children:
Croghan GA, see Cox LS Results of the First Prospective Study of the Inter-
Cropp GF, see Kuenen BC national Society of Pediatric Oncology Group,
Cross C, D’Amico A. In Reply (correspondence), 4129 2798
Cross CK, Shultz D, Malkowicz SB, Huang WC, Whittington Czuczman MS, see Witzig TE
R, Tomaszewski JE, Renshaw AA, Richie JP,
D’Amico AV. Impact of Race on Prostate-Specific
Antigen Outcome After Radical Prostatectomy for D
Clinically Localized Adenocarcinoma of the Pros-
tate, 2863 Dagher R, see Schwartsmann G
Crowley JJ, see Albain KS Dagnelie PC, see Agteresch HJ
Crowther D, see Radford JA Dahle R, see Sundstrøm S
Cruciani G, see Ravaioli A Daidone MG, Veneroni S, Cappelletti V, Radice P, Pierotti
Crugnola M, see Cesana C MA, Younes M. Estrogen Receptor-Beta Expres-
Crul M, de Klerk GJ, Swart M, van’t Veer LJ, de Jong D, sion in Hereditary Breast Cancer (correspondence),
Boerrigter L, Palmer PA, Bol CJ, Tan H, de Gast 3752
GC, Beijnen JH, Schellens JHM. Phase I Clinical Dakhil S, see Loesch D
and Pharmacologic Study of Chronic Oral Admin- Dakhil SR, see Jatoi A
istration of the Farnesyl Protein Transferase Inhib- Dal Lago D, see Repetto L
itor R115777 in Advanced Cancer, 2726 Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W,
Cude K, see Bennett CL Rabbani F, Donat MS, Herr HW, Sogani P, de-
Cufer T, see Biganzoli L Palma D, Bajorin D. Phase I Trial of Intravesical
Culine S, see Tepper JE Gemcitabine in Bacillus Calmette-Guérin-Refrac-
Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, tory Transitional-Cell Carcinoma of the Bladder,
Lortholary A, Merrouche Y, Laplanche A, Fizazi 3193
K. Development and Validation of a Prognostic Daliani D, see Pagliaro LC
Model to Predict the Length of Survival in Patients see Papandreou CN
With Carcinomas of an Unknown Primary Site, Dalle J-H, see Perel Y
4679 Dalton V, see LeClerc JM
Cummings B, see Tepper JE Dalton VK, see Lipshultz SE
Cummings SR, see Chlebowski RT Damani MN, Master V, Meng MV, Burgess C, Turek P,
Cunningham D, see Maisey N Oates RD. Postchemotherapy Ejaculatory
see Ross P Azoospermia: Fatherhood With Sperm From Testis
Cunningham Downloaded
JM, see Lindor NM
from Tissue
on June 28, 2008 . For personal use only.With Intracytoplasmic
No other Sperm Injection, 930
uses without permission.
Cupini S, see Falcone A Copyright © 2002 by the American Society of Clinical Oncology.
Damasio All rights reserved.
EE, see Federico M

D’Amico AV, see Cross CK Davis MP, Dreicer R. Revisiting Truth and Consequences:
D’Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. What to Do When the Patient Doesn’t Want to
Determinants of Prostate Cancer-Specific Survival Know (correspondence), 4403
After Radiation Therapy for Patients With Clini- Davis P, see Bass AJ
cally Localized Prostate Cancer, 4567 see Rizzieri DA
D’Amico AV. Predicting Prostate-Specific Antigen Recur- Davis PC, see Nachman JB
rence Established: Now, Who Will Survive? (edi- Dawes M, see Lens MB
torial), 3188 Day A, see Davis AM
Damon L, see Linker C de Bono JS, Stephenson J Jr, Baker SD, Hidalgo M, Patnaik
Dan ME, see Vaishampayan U A, Hammond LA, Weiss G, Goetz A, Siu L,
Dancey J, see Freidlin B Simmons C, Jolivet J, Rowinsky EK. Troxacitab-
Dancey JE, see Brierley JD ine, an L-Stereoisomeric Nucleoside Analog, on a
Danese S, see Berruti A Five-Times-Daily Schedule: A Phase I and Phar-
Danesi R, see Falcone A macokinetic Study in Patients With Advanced
D’Angelillo RM, see Trodella L Solid Malignancies, 96
D’Angelo A, see Oliva EN de Braud F, see De Pas T
Daniell HW. Inhibition of Opioid Analgesia by Selective de Bruijn P, see Kehrer DFS
Serotonin Reuptake Inhibitors (correspondence), De Conno F, see Galeazzi G
2409 de Gast GC, see Crul M
Danielsen HE, see Sudbø J de Gast GC, Vyth-Dreese FA, Nooijen W, van den Bogaard
Danish RK, see Leung W CJC, Sein J, Holtkamp MMJ, Linthorst GAM,
Dann EJ, Fineman R, Rowe JM. Tumor Lysis Syndrome Baars JW, Schornagel JH, Rodenhuis S. Reinfusion
After STI571 in Philadelphia Chromosome-Posi- of Autologous Lymphocytes With Granulocyte-
tive Acute Lymphoblastic Leukemia (correspon- Macrophage Colony-Stimulating Factor Induces
dence), 354 Rapid Recovery of CD4⫹ and CD8⫹ T Cells After
Danoff-Burg S, see Stanton AL High-Dose Chemotherapy for Metastatic Breast
Darai E, see Barranger E Cancer, 58
Darrah D, see Mitchell MS de Giacomi C, see Pizzichetta MA
Daskalakis T, see Datta RV de Graeff A, see Koedoot CG
Datta RV, Daskalakis T, Adler H, Lehman H. Unusual de Gramont A, see Louvet C
Presentations of Uncommon Tumors; Case 3. Giant de Haan RJ, see Koedoot CG
Cell Plasmacytoma Presenting as an Intraperitoneal de Haes JC, see Jonat W
Mass, 2405 de Haes JCJM, see Koedoot CG
Daugaard G, see Petersen PM de Jong D, see Crul M
Daugherty CK, Steensma DP. Overcoming Obstacles to de Jonge MJA, see Kehrer DFS
Hospice Care: An Ethical Examination of Inertia see Mathiissen RHJ
and Inaction, 2752 de Jonge MJA, Punt CJA, Sparreboom A, Planting AST,
Daugherty CK. The “Cure” for Cancer: Can the Media Peters MEWJ, van de Schraaf J, Jackman A, Smith
Report the Hope Without the Hype? (editorial), R, de Mulder PHM, Verweij J. Phase I and Phar-
3761 macologic Study of Oral ZD9331, A Novel Non-
Daus H, see Trümper L polyglutamated Thymidylate Synthase Inhibitor, in
David J, see Vasey PA Adult Patients With Solid Tumors, 1923
Davidson BR, see Brett BT de Jongh F, see Sparreboom A
Davidson N, see Douillard J-Y de Jongh FE, Verweij J, Sparreboom A. In Reply (correspon-
Davidson NE, Levine M. Breast Cancer Consensus Meetings: dence), 1144
Vive la Difference? (editorial), 1719 de Juan C, see González-Quevedo R
Davis AM, O’Sullivan B, Bell RS, Turcotte R, Catton CN, de Kernion J, see Graefen M
Wunder JS, Chabot P, Hammond A, Benk V, Isler de Klerk GJ, see Crul M
M, Freeman C, Goddard K, Bezjak A, Kandel RA, de la Chapelle A. Microsatellite Instability Phenotype of
Sadura A, Day A, James K, Tu D, Pater J, Zee B. Tumors: Genotyping or Immunohistochemistry?
Function and Health Status Outcomes in a Ran- The Jury Is Still Out (editorial), 897
domized Trial Comparing Preoperative and Post- de Lemos M. Safety Issues of Soy Phytoestrogensin Breast
operative Radiotherapy in Extremity Soft Tissue Cancer Patients (correspondence), 3040
Sarcoma, 4472 De Lena M, see Berruti A
Davis D, see Disis ML De Lumley L, see Perel Y
Davis DW, see Herbst RS
Downloaded from on June 28, 2008 . ForDe Maio use
personal E, see
No otherFuses without permission.
Davis KB, see Chen WY Copyright © 2002 by the American Society of DeClinical
F, see All rights reserved.
Scagliotti GV

De Matteis A, see Berruti A Demers L, see Lipton A

de Matteis A, see Jonat W Demers LM, see Costa L
de Moura MC, see Costa L Demetri GD, see Brooks BJ
de Mulder PHM, see de Jonge MJA see Singer S
De Pas T, Pastorino U, Spaggiari L, Curigliano G, de Braud DeMets DL, see Love RR
F, Robertson C. Preoperative Chemotherapy in DeMichele A, Weber BL. Risk Management in BRCA1 and
Non-Small-Cell Lung Cancer: Nothing New in N2 BRCA2 Mutation Carriers: Lessons Learned, Chal-
Disease (correspondence), 2603 lenges Posed (editorial), 1164
De Stefano V, see Teofili L Denman JP, Gilbar PJ, Abdi EA. Hypersensitivity Reaction
de Tribolet N, see Stupp R (HSR) to Docetaxel After a Previous HSR to
de Vries EGE, see Kehrer DFS Paclitaxel (correspondence), 2760
De Wolf-Peeters C, see Achten R dePalma D, see Dalbagni G
Deakin DP, see Radford JA Depcik-Smith ND, see Orlowski RZ
Dean A, Rogers TE, Diehl J, Dowell JE. Extramedullary Sites Depee JK, see Ramanathan RK
of Involvement in Hematologic Malignancies; Case Depierre A, Milleron B, Moro-Sibilot, Chevret S, Quoix E,
1. Multifocal Intracranial Involvement With Man- Lebeau B, Braun D, Breton J-L, Lemarié E, Gouva
tle-Cell Lymphoma, 340 S, Paillot N, Bréchot J-M, Janicot H, Lebas F-X,
DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz Terrioux P, Clavier J, Foucher P, Monchâtre M,
CJ. Combination Chemotherapy and Radiotherapy Coëtmeur D, Level M-C, Leclerc P, Blanchon F,
for Primary Central Nervous System Lymphoma: Rodier J-M, Thiberville L, Villeneuve A, Westeel
Radiation Therapy Oncology Group Study 93-10, V, Chastang C, French Thoracic Cooperative
4643 Group. Preoperative Chemotherapy Followed by
Deavers M, see Levenback C Surgery Compared With Primary Surgery in Re-
Debruyne C, see Ardizzoni A sectable Stage I (except T1N0), II, and IIIa Non-
see Pignatti F Small-Cell Lung Cancer, 247
see Shepherd FA Depierre A, Westeel V, Milleron B, Moro-Sibilot D, Quoix
DeCastro C, see Kornblith AB E, Braun D, Lebeau B. In Reply (correspondence),
DeCastro CM, see Bass AJ 2605
see Rizzieri DA Depisch D, see Scheithauer W
see Silverman LR Derigs H-G, see Kollmannsberger C
Decker PA, see Cox LS DeSantis M, see Jäger G
Decker V, see Northouse LL Deschênes L, see Maunsell E
Declerck L, see LeClerc JM Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaron-
Deer T, see Smith TJ son NK. Role of Health-Related Quality of Life in
DeFabiani E, see Berruti A Palliative Chemotherapy Treatment Decisions,
Deffenbaugh AM, see Chen WY 1056
see Frank TS Detterbeck F. Unusual Pulmonary Lesions: Endobronchial
Deitcher SR, Fesen MR, Kiproff PM, Hill PA, Li X, Carcinoid of the Lung (correspondence), 4269
McCluskey ER, Semba CP, Cardiovascular Throm- Deutsch M, see Dourakis SP
bolytic to Open Occluded Lines-2 Investigators. Deutsch P, see DiPaola RS
Safety and Efficacy of Alteplase for Restoring Devergie A, see Bergeron A
Function in Occluded Central Venous Catheters: Devidas M, see Goorin AM
Results of the Cardiovascular Thrombolytic to Dezube BJ, see Cianfrocca M
Open Occluded Lines Trial, 317 Di Costanzo F, see Scagliotti GV
deKernion JB, see Zisman A Di Lauro L, see Lopez M
del Carmen Vela M, see Mellado B Di Leo A, see Bleiberg H
Del Tacca M, see Falcone A Di Leo A, Buyse M. Equivalence Between Ovarian Suppres-
Delaney S, see Quinn JA sion and Chemotherapy in the Adjuvant Treatment
Delbrel X, see Mahon FX of Endocrine-Responsive Breast Cancer (corre-
Dell’Anna T, see Cantù MG spondence), 1954
Delling G, see Bielack SS Di Leone L, see Schwartsmann G
Delmas PD, see Menssen HD Di Lorenzo G, see Perrone F
Delpassand ES, see Levenback C Di Maio M, see Perrone F
Delpero J-R, see Etienne M-C Di Mario A, see Teofili L
Delvecchio P, see El-Sayed S Di Paolo A, see Falcone A
Demakos EP,Downloaded
see Kornblith AB
from on June 28, 2008 . ForDi Roccouse
personal C, only.
see Massimino
No other usesMwithout permission.
see Silverman LR Copyright © 2002 by the American Society of
RussoOncology. All rights reserved.
A, see Galeazzi G

Diasio RB, see Adjei AA Cheever MA, Knutson KL, Schiffman K. Genera-
Diasio RB. An Evolving Role for Oral Fluoropyrimidine tion of T-Cell Immunity to the HER-2/neu Protein
Drugs (editorial), 894 After Active Immunization With HER-2/neu Pep-
Dı́az-Rubio E, see González-Quevedo R tide-Based Vaccines, 2624
Dicks-Mireaux C, see Owens CM Dispenzieri A, see Anderson PM
Dieckmann K, see Timmermann B see Rajkumar SV
Dieckmann K-P, see Classen J Distefano MG, see Ferrandina G
Diehl J, see Dean A DiTaranto S, see Womer RB
Diehl V, see Josting A Dittrich Ch, see van Kesteren Ch
see Sieber M Diviné M, see Fermé C
see Weihrauch MR Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian
Dieras V, see Zelek L C, Hummer A, Venkatraman E, Spriggs DR. Ret-
Dietemann A, see Iamandi C rospective Analysis of Carboplatin and Paclitaxel
Dietrich D, see Borner MM as Initial Second-Line Therapy for Recurrent Epi-
Dietrich P-Y, see Stupp R thelial Ovarian Carcinoma: Application Toward a
DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O’Day SJ, Dynamic Disease State Model of Ovarian Cancer,
Wanek LA, Stern SL, Morton DL. Enhanced Hu- 1238
moral Immune Response Correlates With Improved Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger
Disease-Free and Overall Survival in American M. Novel Artificial Neural Network for Early
Joint Committee on Cancer Stage II Melanoma Detection of Prostate Cancer, 921
Patients Receiving Adjuvant Polyvalent Vaccine, Djulbegovic B, see Rizzo JD
3242 Dmitrovsky E, see Freemantle SJ
DiGianni LM, Garber JE, Winer EP. Complementary and Do K-A, see Vauthey J-N
Alternative Medicine Use Among Women With Doelken G, see Sieber M
Breast Cancer, 34s see Sucker C
Dignam JJ, see Fisher B Dogan A, see Bomanji JB
Diller L, see Emmons K Dogliotti L, see Berruti A
Diller L, Nancarrow CM, Shaffer K, Matulonis U, Mauch P, see Sperone P
Neuberg D, Tarbell NJ, Litman H, Garber J. Breast Döhner H, see Döhner K
Cancer Screening in Women Previously Treated for see Viardot A
Hodgkin’s Disease: A Prospective Cohort Study, Döhner J, see Fröhling S
2085 Döhner K, see Fröhling S
Dillman RO. Radiolabeled Anti-CD20 Monoclonal Antibod- Döhner K, Tobis K, Ulrich R, Fröhling S, Benner A, Schlenk
ies for the Treatment of B-Cell Lymphoma, 3545 RF, Döhner H. Prognostic Significance of Partial
Dillon H, see Hersey P Tandem Duplications of the MLL Gene in Adult
Dimery I, see Osborne CK Patients 16 to 60 Years Old With Acute Myeloid
Dimitrov BD, see Oliva EN Leukemia and Normal Cytogenetics: A Study of
Dimopoulos M, see Kosmidis P the Acute Myeloid Leukemia Study Group Ulm,
Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou 3254
NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika Dolan ME, see Quinn JA
D, Christakis J, Anagnostopoulos N. Treatment of Domingo-Domènech JM, see Mellado B
Waldenström’s Macroglobulinemia With Ritux- Donaldson SS, see Friedmann AM
imab, 2327 Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L,
Dinapoli R, see Shaw E Billett AL, Marcus KC, Hurwitz CA, Young JA,
Dinehart S, see Coldiron B Tarbell NJ, Weinstein HJ. VAMP and Low-Dose,
Dingee C, see Kwan W Involved-Field Radiation for Children and Adoles-
Dinh NV, see Love RR cents With Favorable, Early-Stage Hodgkin’s Dis-
Dinjens WNM, see van der Sijp JRM ease: Results of a Prospective Clinical Trial, 308
Dionne J, see Bélanger K Donat MS, see Dalbagni G
DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin Donehower R, see Carducci MA
E, Capanna T, Ciardella M, Doyle-Lindrud S, Donnelly S, see Kirkwood JM
Goodwin S, Fontaine M, Adams N, Williams A, Doody D, see Harper-Wynne CL
Schwartz M, Winchell G, Wickersham K, Deutsch Doran J, see Seymour LW
P, Yao S-L. Characterization of a Novel Prostate- Dordal M, see Herbst RS
Specific Antigen-Activated Peptide-Doxorubicin Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA,
Conjugate in Patients
Downloaded With Prostate
from on Cancer,
June 28, 1874 Glimelius
2008 . For personal use only. No B,
otherStorm H, Pukkala
uses without E, van Leeuwen
Disis ML, Gooley TA, Copyright
Rinn K,© Davis
2002 byD,the American
M, of Clinical Oncology. All rights
FE, Holowaty EJ,reserved.
Andersson M, Wiklund T, Joen-

suu T, van’t Veer MB, Stovall M, Gospodarowicz Dudas M, see Stojadinovic A

M, Travis LB. Second Malignant Neoplasms Dudek A, see Lima CMSR
Among Long-Term Survivors of Hodgkin’s Dis- Dudeney S, Lieberman IH, Reinhardt M-K, Hussein M.
ease: A Population-Based Evaluation Over 25 Kyphoplasty in the Treatment of Osteolytic Verte-
Years, 3484 bral Compression Fractures as a Result of Multiple
Dorey F, see Zisman A Myeloma, 2382
Dorresteijn LDA, Kappelle AC, Boogerd W, Klokman WJ, Duehmke E, see Sieber M
Balm AJM, Keus RB, van Leeuwen FE, Bartelink Duenas-Gonzalez A, Lopez-Graniel CM, Mota A, Mohar A.
H. Increased Risk of Ischemic Stroke After Radio- Neoadjuvant Chemotherapy Followed by Surgery
therapy on the Neck in Patients Younger Than 60 in Locally Advanced Cervical Carcinoma (corre-
Years, 282 spondence), 2908
Dougherty J, see Modi S Dufour P, see Herbrecht R
Douglas PS, see Vallis KA Dugan M, see Lashford LS
Douglass EC, see Katzenstein HM see Lipton A
Douglass H, see Khushalani NI Dulguerov P, see Allal AS
Douillard JY, see Louvet C Dumez H, see van Kesteren Ch
Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson Dunleavy K, see McDermott RS
N, Harper P, Vincent MD, Lembersky BC, Thomp- Dunlop DJ, see Radford JA
son S, Maniero A, Benner SE. Multicenter Phase Dunn RL, see Wei JT
III Study of Uracil/Tegafur and Oral Leucovorin Dunst J, see Rödel C
Versus Fluorouracil and Leucovorin in Patients Dunst J, Reese T, Sutter T, Zühlke H, Hinke A, Kölling-
With Previously Untreated Metastatic Colorectal Schlebusch K, Frings S. Phase I Trial Evaluating
Cancer, 3605 the Concurrent Combination of Radiotherapy and
Dourakis SP, Sevastianos VA, Alexopoulou A, Deutsch M, Capecitabine in Rectal Cancer, 3983
Stavrianeas N. Treatment Side Effects; Case 2. Durini E, see Vici P
Toxic, Epidermal, Necrolysis-Like Reaction Asso- Dusenbery KE, see Jennings MT
ciated With Docetaxel Chemotherapy, 3030 Duvic M, see Sarris AH
Dowell JE, see Dean A Dvorak HF. Vascular Permeability Factor/Vascular Endothe-
Dowling AJ, see Brierley JD lial Growth Factor: A Critical Cytokine in Tumor
Downey RJ, see Martin J Angiogenesis and a Potential Target for Diagnosis
Downing JR, see Rubnitz JE and Therapy, 4368
Dowsett M, see Geisler J Dy GK, Adjei AA. Novel Targets for Lung Cancer Therapy:
see Harper-Wynne CL Part I, 2881
see Lønning PE Dy GK, Adjei AA. Novel Targets for Lung Cancer Therapy:
Doyle ME, see Ingram SS Part II, 3016
Doyle-Lindrud S, see DiPaola RS D’yachkova Y, see Weir L
Doz F, see Lashford LS Dyson NJ, see Chakravarti A
Drabkin HA, see Bremnes RM Dziadziuszko R, see Ardizzoni A
Dreicer R, see Davis MP
see Thomas J
Dreisbach A, see Rozans M E
Drews AA, see Cox LS
Drobyski WR, see Levine JE Eagan J, see Walshe LJ
Drolet M, see Maunsell E Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks
Drouin P, see Pearcey R JC. Impact of Referral Patterns on the Use of
Droz JP, see Bokemeyer C Chemotherapy for Lung Cancer, 1786
see van Kesteren Ch Earle J, see Shaw E
Druker BJ, see Heinrich MC Early Clinical Studies Group of the European Organization
see Mauro MJ for Research and Treatment of Cancer, see van
Du M, see Gandhi V Kesteren Ch
Du XL, Osborne C, Goodwin JS. Population-Based Assess- Eary JF, see Rubin BP
ment of Hospitalization for Toxicity From Chemo- East MJ, see Eton O
therapy in Older Women With Breast Cancer, 4636 Eastham JA, see Cagiannos I
Duc NB, see Love RR see Graefen M
Duchateau L, see Biganzoli L Easton DF, see Lakhani SR
Duck ET, seeDownloaded
Modi S from on June 28, 2008 . ForEbbert
personal JO,
usesee Cox
only. No LS
other uses without permission.
Ducreux M, see RaymondCopyright
E © 2002 by the American Society of Clinical Oncology.
Ebbinghaus S, seeAllDiPaola
rights reserved.

Eckardt J, see Lima CMSR Elias L, see Morrison VA

Economopoulos T, see Kosmidis P Ell PJ, see Bomanji JB
Economou I, see Antonadou D Elledge R, see Osborne CK
Eden L, see Schwartz GK Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L,
Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia- Yekell S, Chada S, Grimm EA. Loss of MDA-7
Carbonero R, Ryan DP, Shulman LN, Proper J, Expression With Progression of Melanoma, 1069
Kirvan M, Rattner B, Connors S, Keogan MT, Ellerton J, see Kornblith AB
Janicek MJ, Fogler WE, Schnipper L, Kinchla N, see Silverman LR
Sidor C, Phillips E, Folkman J, Kufe DW. Phase I Elliott PJ, see Orlowski RZ
Clinical Trial of Recombinant Human Endostatin Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T.
Administered as a Short Intravenous Infusion Re- Dose-Dense Anthracycline-Based Chemotherapy
peated Daily, 3772 for Node-Positive Breast Cancer, 3637
Edge SB, see Singletary SE Ellis LM, see Herbst RS
see Winer EP see Herbst RS
Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston see Vauthey J-N
PG, Magnusson I, Ragnhammar P, Blomgren H. Ellis M, see Osborne CK
Thymidylate Synthase Expression in Colorectal Ellis N, see Scheuer L
Cancer: A Prognostic and Predictive Marker of Ellis PA, see Galani E
Benefit From Adjuvant Fluorouracil-Based Chemo- see Plunkett TA
therapy, 1721 Ellman M, see Hudes G
Edler L, see Laack E Elshaikh M, see Kupelian PA
Efficace F, Bottomley A. Do Quality-of-Life Randomized Emanuel EJ, see Agrawal M
Clinical Trials Support Clinicians in Their Deci- Emmanouilides C, see Witzig TE
sion-Making? (correspondence), 4126 Emmenegger U, Spaeth PJ, Neftel KA. Intravenous Immu-
Eggermont AMM, see van der Sijp JRM noglobulin for Hemophagocytic Lymphohistiocy-
Eggert L, see Liang W tosis? (correspondence), 599
Eggleton SP, see Smith IC Emmons K, Li FP, Whitton J, Mertens AC, Hutchinson R,
Eguchi K, see Sobue T Diller L, Robison LL. Predictors of Smoking Initi-
Eiermann W, see Jonat W ation and Cessation Among Childhood Cancer
Eifel PJ, Jhingran A, Bodurka DC, Levenback C, Thames H. Survivors: A Report From the Childhood Cancer
Correlation of Smoking History and Other Patient Survivor Study, 1608
Characteristics With Major Complications of Pel- Endres S, see Schwartz GK
vic Radiation Therapy for Cervical Cancer, 3651 Eng SL, see Timoney JP
Einhorn L, see Bokemeyer C Engel J, see Kerr J
Einhorn LH, see Hinton S Enger S, see Ursin G
Einhorn LH, Levinson J, Li S, Lamar L, Kamin D, Mendel- Engert A, see Josting A
son D. American Society of Clinical Oncology see Sieber M
2001 Presidential Initiative: Impact of Regulatory Engle L, see Lipton A
Burdens on Quality Cancer Care, 4722 Engler H, see Kuball J
Eisen A, see Chlebowski RT Engstrom MC, see Wang XS
Eisen T. Thalidomide in Solid Malignancies (editorial), 2607 Enke C, see Weekes CD
Eisen TG, see Nathan PD Ennis M, see Goodwin PJ
Eisenberg P, see Douillard J-Y Epelbaum R, see Biganzoli L
Eisenberger MA, see Carducci MA Epirubicin-Lonidamine Group, see Berruti A
Eisenhauer E, see Freidlin B Epoetin Alfa Study Group, see Littlewood TJ
Ekmekcioglu S, see Ellerhorst JA Epoetin Beta Hematology Study Group, see Österborg A
El Ghazi EA, see Allal AS Epstein J, see El-Sayed S
El-Sayed S, Nabid A, Shelley W, Hay J, Balogh J, Gelinas M, Erbersdobler A, see Cagiannos I
MacKenzie R, Read N, Berthelet E, Lau H, Epstein see Graefen M
J, Delvecchio P, Ganguly PK, Wong F, Burns P, Tu Erdal S, see Nadella P
D, Pater J. Prophylaxis of Radiation-Associated Erdman W, see Levenback C
Mucositis in Conventionally Treated Patients With Eremin O, see Smith IC
Head and Neck Cancer: A Double-Blind, Phase III, Eriksson B, see Hudes G
Randomized, Controlled Trial Evaluating the Clin- Erikstein B, see Howell A
ical Efficacy of an Antimicrobial Lozenge Using a Erland JB, see Greco FA
Validated Mucositis
Downloaded Scoring System,
from 395628, 2008 . ForErlichman
on June personal useC,only.
see No
otherAAuses without permission.
Elfring GL, see Lima CMSR Copyright © 2002 by the American Society of Clinical Oncology.
Ernstoff All rights reserved.
MS, see Bukowski R

see Kirkwood JM Evans WE, see Leung W

Erwin J, see Buchholz TA Exner GU, see Bielack SS
Esmaeli B, see Esteva FJ Extra J-M, see Rouzier R
Esnaola NF, see Vauthey J-N
Esnaola NF, Cantor SB, Johnson ML, Mirza AN, Miller AR,
Curley SA, Crane CH, Cleeland CS, Janjan NA, F
Skibber JM. Pain and Quality of Life After Treat-
ment in Patients With Locally Recurrent Rectal
Fabères C, see Mahon FX
Cancer, 4361
Facon T, see Menssen HD
Esnaola NF, Lazarides SN, Mentzer SJ, Kuntz KM. Out-
Fagioli F, Aglietta M, Tienghi A, Ferrari S, Brach del Prever
comes and Cost-Effectiveness of Alternative Stag-
A, Vassallo E, Palmero A, Biasin E, Bacci G, Picci
ing Strategies for Non-Small-Cell Lung Cancer,
P, Madon E. High-Dose Chemotherapy in the
Treatment of Relapsed Osteosarcoma: An Italian
Espérou H, see Bergeron A
Sarcoma Group Study, 2150
Esseesse I, see Ferrari AC
Failla G, see Scagliotti GV
Esseltine D-L, see Orlowski RZ
Fair W, see Cagiannos I
Essennan LJ, see Sepucha KR
Fairey R, see Shenkier TN
Essner R, see DiFronzo LA
Faivre S, see Raymond E
see Hsueh EC
Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E,
Estapé J, see Mellado B
Brunetti IM, Di Paolo A, Cupini S, Del Tacca M,
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Conte P. Biweekly Chemotherapy With Oxalipla-
Pusztai L, Cristofanilli M, Arun B, Esmaeli B, tin, Irinotecan, Infusional Fluorouracil, and Leuco-
Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. vorin: A Pilot Study in Patients With Metastatic
Phase II Study of Weekly Docetaxel and Trastu- Colorectal Cancer, 4006
zumab for Patients With HER-2-Overexpressing Falcou M-C, see Rouzier R
Metastatic Breast Cancer, 1800 Falk S, see Carmichael J
Estey EH, see Gandhi V Fallowfield L, see Jenkins V
Etienne M-C, Chazal M, Laurent-Puig P, Magné N, Rosty C, Familiari U, see Sperone P
Formento J-L, Francoual M, Formento P, Renée N, Fan L, see Goh B-C
Chamorey E, Bourgeon A, Seitz J-F, Delpero J-R, Fan S-T, see Poon RT-P
Letoublon C, Pezet D, Milano G. Prognostic Value Fanale MA, Zeldenrust SR, Moynihan TJ. Some Unusual
of Tumoral Thymidylate Synthase and p53 in Complications of Malignancies: Case 2. Marantic
Metastatic Colorectal Cancer Patients Receiving Endocarditis in Advanced Cancer, 4111
Fluorouracil-Based Chemotherapy: Phenotypic and Fargeot P, see Biganzoli L
Genotypic Analyses, 2832 Farrar WB, see Albain KS
Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges Farris A, see Berruti A
C, Ring SE, Papadopoulos NE, Plager C, East MJ, Fassas A, see Badros A
Zhan F, Benjamin RS. Sequential Biochemo- Fata F, Mirza A, Bernath A. Skin Lesions in Melanoma and
therapy Versus Chemotherapy for Metastatic Mel- Kaposi’s Sarcoma; Case 3. Familial Classic Medi-
anoma: Results From a Phase III Randomized terranean Kaposi’s Sarcoma, 1415
Trial, 2045 Fay MP, see Warren JL
Ettinger LJ, see Jennings MT Fayers P, see Jordhøy MS
Eucker J, see Sezer O Federico M, Zinzani PL, Frassoldati A, Vinceti M, Modè A,
Euller-Ziegler L, see Menssen HD Annino L, Chisesi T, Pagnucco G, Invernizzi R,
European Organization for Research and Treatment of Can- Spriano M, Resegotti L, Bendandi M, Damasio EE,
cer-Lung Cancer Group, see Ardizzoni A Italian Cooperative Group for the Study of Hairy
European Organization for the Research and Treatment of Cell Leukemia. Risk of Second Cancer in Patients
Cancer Early Clinical Study Group, see Raymond With Hairy Cell Leukemia: Long-Term Follow-Up,
E 638
Evangelista L, see Sarna L Fehrenbacher L, see Vogel CL
Evans DB, see Pisters PWT Feiden W, see Samnick S
Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Feig BW, see Ahmad SA
Phase II Evaluation of Low-Dose Oral Etoposide Feld R, see Leighl NB
for the Treatment of Relapsed or Progressive Ferguson W, see Goorin AM
AIDS-Related Kaposi’s Sarcoma: An AIDS Clini- Fermé C, Mounier N, Diviné M, Brice P, Stamatoullas A,
cal Downloaded
Trials Group Clinical
from Study, 3236 Reman
on June 28, 2008 . For personal use only. O,
No Voillat L, without
other uses Jaubertpermission.
J, Lederlin P, Colin P,
Evans T, see RamanathanCopyright
RK © 2002 by the American Society of Clinical Oncology.
Berger F,AllSalles
rights G.
Intensive Salvage Therapy With

High-Dose Chemotherapy for Patients With Ad- Finkelstein DF, see Chakravarti A
vanced Hodgkin’s Disease in Relapse or Failure Finkelstein DM, see Chakravarti A
After Initial Chemotherapy: Results of the Group Finn WG, see Mirza I
d’Études des Lymphomes de l’Adulte H89 Trial, Fioretta G, see Bouchardy C
467 Fisch M, see Bruera E
Fernández C, see González-Quevedo R see Strasser F
Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi Fisher B, see DeAngelis LM
M, Legge F, Maggiano N, Mancuso S, Capelli A, see Wickerham DL
Scambia G, Ranelletti FO. Increased Cyclooxygen- Fisher B, Bryant J, Dignam JJ, Wickerham L, Mamounas EP,
ase-2 Expression Is Associated With Chemother- Fisher ER, Margolese RG, Nesbitt L, Paik S,
apy Resistance and Poor Survival in Cervical Can- Pisanksy TM, Wolmark N. Tamoxifen, Radiation
cer Patients, 973 Therapy, or Both for Prevention of Ipsilateral
Ferranti G, see Santini D Breast Tumor Recurrence After Lumpectomy in
Ferrara JLM, see Yanik GA Women With Invasive Breast Cancers of One
Ferrari A, see Massimino M Centimeter or Less, 4141
see Spreafico F Fisher C, see Kolomainen DF
Ferrari A, Bisogno G, Casanova M, Meazza C, Piva L, Fisher ER, see Fisher B
Cecchetto G, Zanetti I, Pilz T, Mattke A, Treuner J, Fisher RI. Autologous Stem-Cell Transplantation as a Com-
Carli M. Paratesticular Rhabdomyosarcoma: Re- ponent of Initial Treatment for Poor-Risk Patients
port From the Italian and German Cooperative With Aggressive Non-Hodgkin’s Lymphoma: Re-
Group, 449 solved Issues Versus Remaining Opportunity (edi-
Ferrari AC, Stone N, Stock R, Bednar M, Esseesse I, Singh torial), 4411
H, Baldwin Y, Mandeli J. 13-cis Retinoic Acid and Fishman A, see Chetrit A
Complete Androgen Blockade in Advanced Hor- Fishwick K, see Hughes A
mone-Naive Prostate Cancer Patients: Report of a Fitch TR, see Hobday TJ
Phase II Randomized Study, 538 see Jatoi A
Ferrari S, see Fagioli F Fitoussi O, see Cany L
Ferrari S, Mercuri M, Bacei G. Comment on “Prognostic Fitz CR, see Jennings MT
Factors in High-Grade Osteosarcoma of the Ex- Fizazi K, see Culine S
tremities or Trunk: An Analysis of 1,702 Patients Flaherty K, see Tao J
Treated on Neoadjuvant Cooperative Osteosarcoma Flaherty L, see Kirkwood JM
Study Group Protocols” (correspondence), 2910 Flaherty LE, see Rao UNM
Ferreira CMM, see Kashani-Sabet M see Sondak VK
Ferry D, see Ranson M see Sosman JA
Ferry DR, see Seymour LW Flamm AL, see Pentz RD
Fesen MR, see Deitcher SR Flege S, see Bielack SS
Feun L, see Agarwala SS Fleischauer AT, see Neugut AI
Feusner JH, see Bhatia S Fleisher M, see Shike M
see Katzenstein HM Fleming D, see Morkas M
Feyereislova A, see Albanell J Flesch M, see Louvet C
see Baselga J Fletcher CDM, see Brooks BJ
Fiebiger W, see Jäger G see Singer S
see Scheithauer W Fletcher JA, see Singer S
Fiere D, see Menssen HD Flinn IW, see Witzig TE
Figg WD, see Bennett CL Floeter MK, see Grem JL
see Cianfrocca M see Wilson RH
see Tan AR Flom KJ, see Press MF
Figlin RA, see Zisman A Flonn K, see Press MF
Fillet G, see Gisselbrecht C Floriani I, see Cantù MG
Fine HA. Primary Central Nervous System Lymphoma: Time Focan C, see Curé H
to Ask the Question (editorial), 4615 Fogelman I, see Jonat W
Fine R, see Mikulski SM Fogler WE, see Eder JP Jr
Finegold MJ, see Katzenstein HM Folkman J, see Eder JP Jr
Fineman R, see Dann EJ Fong Y, see Heffernan N
Fink A, see Silliman RA Fonseca R, see Rajkumar SV
Fink H, see Kröger K
Downloaded from on June 28, 2008 . ForFontaine M, only.
personal use see DiPaola RS without permission.
No other uses
Fink L, see Kaushal V Copyright © 2002 by the American Society of Clinical A,
Fontana Oncology. All rightsHD
see Menssen reserved.

Fontanillas M, see Mellado B Freezer LJ, see Toso JF

Forastiere AA, see Glisson BS Freidlin B, Dancey J, Korn EL, Zee B, Eisenhauer E.
see Shin DM Multinomial Phase II Trial Designs (correspon-
Ford J, see Mehta MP dence), 599
Ford L, see Sateren WB French Society of Pediatric Hematology and Immunology,
Formenti S, see Ursin G Group LAME, see Perel Y
Formento J-L, see Etienne M-C French Study Group on Carcinomas of Unknown Primary,
Formento P, see Etienne M-C see Culine S
Foroni L, see Mortuza FY French Thoracic Cooperative Group, see Depierre A
Foshag LJ, see DiFronzo LA Frenette G, see Glisson BS
see Hsueh EC Freschi A, see Ridolfi R
Foskett M, see McNeish IA Freter CE, see Rai KR
Fossa SD, see Bokemeyer C Freund M, see Steiner M
Fossati-Bellani F, see Massimino M Freytes CO, see Berry DA
Fossati-Bettani F, see Spreafico F Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson
Fossella FV, see Herbst RS MO. Model of Chemotherapy-Induced Myelosup-
Foster T, see Bass AJ pression With Parameter Consistency Across
see Rizzieri DA Drugs, 4713
Foucher P, see Depierre A Fric D, see Page E
Foulkes W, see Andermann A Fridrik M, see Jakesz R
see Cremin C Friebert S, Kodish E. The Right to Decide, 4115
Fountzilas G, see Bafaloukos D Friedberg J, see Ng AK
see Kosmidis P Friedman AH, see Quinn JA
Fowble BL, see Freedman GM see Reardon DA
Fraass BA, see Chan JL Friedman DL, see Bhatia S
François E, see Louvet C Friedman E, see Chetrit A
Francoual M, see Etienne M-C Friedman HS, see Gururangan S
Frank TS, see Chen WY see Quinn JA
Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, see Reardon DA
Lingenfelter B, Gumpper KL, Scholl T, Tavtigian Friedman M. Of What Value Is Uracil/Tegafur Plus Leuco-
SV, Pruss DR, Critchfield GC. Clinical Character- vorin to Colorectal Cancer Patients? (editorial),
istics of Individuals With Germline Mutations in 3574
BRCA1 and BRCA2: Analysis of 10,000 Individu- Friedmann AM, Hudson MM, Weinstein HJ, Donaldson SS,
als, 1480 Kun L, Tarbell NJ, Link MP. Treatment of Unfa-
Franke A, see Kaiser U vorable Childhood Hodgkin’s Disease With VEPA
Franklin J, see Josting A and Low-Dose, Involved-Field Radiation, 3088
see Sieber M Frings S, see Dunst J
Franklin WA, see Bremnes RM Fritsche HA, see Esteva FJ
Franzius C, Schuck A, Bielack SS. High-Dose Samarium-153 Fritsche HA Jr, see Herbst RS
Ethylene Diamine Tetramethylene Phosphonate: Fritz MA, see Kuball J
Low Toxicity of Skeletal Irradiation in Patients Fröhling S, see Döhner K
With Osteosarcoma and Bone Metastases (corre- Fröhling S, Skelin S, Liebisch C, Scholl C, Schlenk RF,
spondence), 1953 Döhner J, Döhner K for the Acute Myeloid Leuke-
Frappaz D, see Lashford LS mia Study Group Ulm. Comparison of Cytogenetic
see Patte C and Molecular Cytogenetic Detection of Chromo-
Frassoldati A, see Federico M some Abnormalities in 240 Consecutive Adult
Frassoni F, see Ringdén O Patients With Acute Myeloid Leukemia, 2480
see Rocha V Frontini L, see Scagliotti GV
Fratino L, see Repetto L Fry WA, see Liptay MJ
Freedman GM, Hanlon AL, Fowble BL, Anderson PR, Frye D, see Buchholz TA
Nicolaou N. Recursive Partitioning Identifies Pa- see Rivera E
tients at High and Low Risk for Ipsilateral Tumor Fuchs IB, Loebbecke M, Buhler H, Stoltenburg-Didinger G,
Recurrence After Breast-Conserving Surgery and Heine B, Lichtenegger W, Schaller G. HER2 in
Radiation, 4015 Brain Metastases: Issues of Concordance, Survival,
Freeman C, see Davis AM and Treatment (correspondence), 4130
Freemantle SJ, Dmitrovsky E. Clinical Link Between p53 and
Downloaded from on June 28, 2008 . For personal usesee
Fujieda K, Aoyama
only. No otherHuses without permission.
Angiogenesis inCopyright © 2002(editorial),
Lung Cancer by the American
883 Society of Clinical Oncology.
Fujiwara All rights reserved.
Y, see Schwartsmann G

Fukuda H, see Takada M Gammon G, see Hsueh EC

Fukunaga H, see Noura S Gamucci T, see Biganzoli L
Fukuoka M, see Takada M Gandara DR, see Albain KS
Fuller RA, see Schwarz RE Gandemer V, see Perel Y
Fumoleau P, see O’Shaughnessy J Gandhi V, see Crews KR
see Raymond E Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Prolonged
see van Kesteren Ch Infusion of Gemcitabine: Clinical and Pharmaco-
Furman WL, Stewart CF, Kirstein M, Kepner JL, Bernstein dynamic Studies During a Phase I Trial in Relapsed
ML, Kung F, Vietti TJ, Steuber CP, Becton DL, Acute Myelogenous Leukemia, 665
Baruchel S, Pratt C. Protracted Intermittent Sched- Gandini D, see Mortuza FY
ule of Topotecan in Children With Refractory Gandolo L, see Massimino M
Acute Leukemia: A Pediatric Oncology Group Ganguly PK, see El-Sayed S
Study, 1617 Gans S, see Ardizzoni A
Furstenberg CT, see Ahles TA Ganz PA, see Levine MN
Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, see Pearson ML
Manchul L, Hill RP. Tumor Hypoxia Has Indepen- see Silliman RA
dent Predictor Impact Only in Patients With Node- Garber J, see Diller L
Negative Cervix Cancer, 680 Garber JE, see Berry DA
see Chen WY
see DiGianni LM
G Garcia-Carbonero R, see Eder JP Jr
Garcia-Manero G, see Giles FJ
Gabarre J, see Gisselbrecht C Gargantini L, see Cesana C
Gabrielson E, see Bremnes RM Garrett E, see Baker SD
Gabrilove JL, Sarokhan B, Cremieux P. In Reply (correspon- Garrison MA, Glanton C, Rasnke M, Smith ME, Ornstein
dence), 3183 DL. Challenging Cases and Diagnostic Dilemmas;
Gabrilove JL, Sarokhan B, Cremieux P. Statistical Explana- Case 1. Tracheal Compression in Hodgkin’s Dis-
tions for a Community-Based Study of Once- ease, 3344
Weekly Epoetin Alfa Therapy in Patients Receiv- Gascón P, see Mellado B
ing Chemotherapy (correspondence), 2757 Gascoyne RD, see Mirza I
Gajewski TF, see Rini BI see Shenkier TN
Gajjar A, see Athale UH Gasparini M, see Spreafico F
Galani E, see Steer CB Gastó C, see Prieto JM
Galani E, Ellis PA, Harper PG. Small-Cell Lung Cancer, Gatineau M, see Raymond E
High Growth Rate, High Response Rate to Chemo- Gattellari M, Voigt KJ, Butow PN, Tattersall MHN. When
therapy: Ideal for High-Dose Chemotherapy? (edi- the Treatment Goal Is Not Cure: Are Cancer
torial), 3941 Patients Equipped to Make Informed Decisions?,
Galbraith SM, Rustin GJS, Lodge MA, Taylor NJ, Stirling JJ, 503
Jameson M, Thompson P, Hough D, Gumbrell L, Gatti A, see Pizzichetta MA
Padhani AR. Effects of 5,6-Dimethylxanthenone-4- see Spazzapan S
Acetic Acid on Human Tumor Microcirculation Gaulard P, see Mounier N
Assessed by Dynamic Contrast-Enhanced Mag- Gautam A, see Bepler G
netic Resonance Imaging, 3826 Gebarski SS, see Chan JL
Gale RP, see Berry DA Gebbia N, see Vici P
Galeazzi G, Di Russo A, Boffi R, De Conno F. Unusual Gebbia V, see Vici P
Presentations of Lung Cancer: Case 4. Palliative Geberth M, see Jonat W
Radiotherapy in Eyelid Non-Hodgkin’s Lym- Gebhardt MC, see Goorin AM
phoma, 4601 Gedlicka C, see Scheithauer W
Galetta D, see Trodella L Gedlicka C, Scheithauer W, Schüll B, Kornek GV. Effective
Galizia E, see Scartozzi M Treatment of Oxaliplatin-Induced Cumulative
Gallinger S, see Lindor NM Polyneuropathy With Alpha-Lipoic Acid (corre-
Gallino G, see Belli F spondence), 3359
Gallo C, see Perrone F Gee J, see Albanell J
Galvin E, see Northouse LL Gehlsen KR, see Agarwala SS
Gameiro P, see Mortuza FY Geisler J, see Lønning PE
Gamelin E, see Louvet C
Downloaded from on June 28, 2008 . ForGeisler
only. NoB, Anker
other G, Dowsett
uses without M, Lønning PE.
see Zelek L Copyright © 2002 by the American Society of Clinical Oncology.
rights reserved.and Anastrozole on Total

Body Aromatization and Plasma Estrogen Levels in Jolivet J, Kantarjian HM. Phase II Study of Trox-
Postmenopausal Breast Cancer Patients Evaluated acitabine, a Novel Dioxolane Nucleoside Analog,
in a Randomized, Cross-Over Study, 751 in Patients With Refractory Leukemia, 656
Geissler G, see Kletzel M Gill PG, see Hersey P
Gelber RD, see Colleoni M Gill VJ, see Toso JF
see Earle CC Gille J, see Spieth K
see Goldhirsch A Gillon T, see Hudes G
see LeClerc JM Ginsberg L, see Shin DM
see Lipshultz SE Ginsberg M, see Motzer RJ
Gelber S, see Colleoni M Ginsberg RJ, see Martin J
Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, see Minsky BD
van Zomeren DM, Verweij J, Sparreboom A. Com- Gioia F, see Repetto L
parative Pharmacokinetics of Unbound Paclitaxel Giordani P, see Cascinu S
During 1- and 3-Hour Infusions, 574 Giotta F, see Vici P
Gelinas M, see El-Sayed S Giovanis P, see Ravaioli A
Geller G, see Hensley ML Giralt S, see Levine JE
Gelman RS, see Chen WY Giralt SA, see Wang XS
Gelmann EP. Molecular Biology of the Androgen Receptor, Gisselbrecht C, see Mounier N
3001 Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G,
Gelmon KA, see Van Patten CL Lederlin P, Coiffier B, Tilly H, Gabarre J, Guilmin
Gemmill RM, see Bremnes RM G, Hermine O, Reyes F for the Groupe d’Etude des
Genitori L, see Massimino M Lymphomes de l’Adulte. Shortened First-Line
Georgii A, see Sieber M High-Dose Chemotherapy for Patients With Poor-
Georgoulias V, see Bafaloukos D Prognosis Aggressive Lymphoma, 2472
see Souglakos J Gitlitz BJ, see Zisman A
see Stathopoulou A Gitten R, see Socinski MA
Gerber M, see Kleinberg L Giwercman A, see Petersen PM
Gerl A, see Bokemeyer C Glanton C, see Garrison MA
see Kollmannsberger C Glantz MJ, see Mehta MP
Gershenwald JE, see Ballo MT Glaspy J, see Agarwala SS
Gerson SL. Clinical Relevance of MGMT in the Treatment of see Holmes FA
Cancer, 2388 Glatstein E, see Machtay M
Gertler SZ, see Osborne CK Glick HA, see Lee JH
Gertz MA, see Rajkumar SV Glick JH, see Goldhirsch A
Gesk S, see Viardot A see Goldhirsch A
Gessi M, see Ferrandina G Glimelius B, see Dores GM
Geyer S, see Rajkumar SV see Edler D
Gheewala P, see Narasimhan P Glisson BS, see Shin DM
Ghossein RA, see Stojadinovic A Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere
Giaccone G, see Ardizzoni A AA. Phase II Trial of Docetaxel and Cisplatin
see Kuenen B Combination Chemotherapy in Patients With Squa-
see Shepherd FA mous Cell Carcinoma of the Head and Neck, 1593
Giannarelli D, see Benedetti-Panici P Gluckman E, see Bergeron A
see Vici P see Ringdén O
Gianni AM, see Rassidakis GZ see Rocha V
Gianni L, see Baselga J Gnant M, see Jakesz R
Gianni W, see Repetto L Gockerman JP, see Bass AJ
Giantris AL, see Lipshultz SE see Rizzieri DA
Giardina G, see Berruti A Goddard K, see Davis AM
Giardini R, see Rassidakis GZ Goepfert H, see Shin DM
Gika D, see Dimopoulos MA Goessling W, McKee PH, Mayer RJ. Merkel Cell Carcinoma,
Gilbar PJ, see Denman JP 588
Gilbert FJ, see Smith IC Goetz A, see de Bono JS
Gilchrist GS, see Nachman JB Gogas H, see Bafaloukos D
Giles F, see Baker SD Goh B-C, Lee S-C, Wang L-Z, Fan L, Guo J-Y, Lamba J,
Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, Schuetz
Downloaded from on June 28, 2008 . For personal use E,other
only. No Limuses
R, Lim H-L,
without Ong A-B, Lee H-S.
O’Brien SM, Thomas © 2002
DA, by the M,
Andreeff American
C, of Clinical Oncology. All rights
Explaining reserved. Variability of Docetaxel

Pharmacokinetics and Pharmacodynamics in see Kolomainen DF

Asians Through Phenotyping and Genotyping see Nathan PD
Strategies, 3683 Gorzegno G, see Berruti A
Gold S, see Woods WG see Sperone P
Goldberg RM, see Adjei AA Gospodarowicz M, see Dores GM
see Allegra CJ see Warde P
see Hobday TJ Gospodarowicz M. Radiotherapy and Organ Preservation in
see Lindor NM Bladder Cancer: Are We Ignoring the Evidence?
see Sloan JA (editorial), 3048
Goldberg RM, Sargent DJ, Morton RF, Mahoney MR, Krook Gouva S, see Depierre A
JE, O’Connell MJ. Early Detection of Toxicity and Gouveia-Oliveira A, see Costa L
Adjustment of Ongoing Clinical Trials: The His- Grabenbauer GG, see Rödel C
tory and Performance of the North Central Cancer Grace MJ, see Kuball J
Treatment Group’s Real-Time Toxicity Monitoring Graefen M, see Cagiannons I
Program, 4591 Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian
Goldberg S, see Pecora AL PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland
Goldhirsch A, see Bomer MM RL, Stricker PD, de Kernion J, Cangiano T, Schrö-
see Colleoni M der FH, Wildhagen MF, Scardino PT, Kattan MW.
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J. In Validation Study of the Accuracy of a Postopera-
Reply (correspondence),880, 1956 tive Nomogram for Recurrence After Radical Pros-
Golding R, see Codrington H tatectomy for Localized Prostate Cancer, 951
Golding RP, see Kunst PWA Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall
Goldman JM, see Raanani P
SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein
Goldstein LJ, see Winer EP
E, Kupelian P, Skinner DG, Lieskovsky G, Boch-
Goldstone A, see Mortuza FY
ner B, Huland H, Hammerer PG, Haese A, Erber-
Goldstone AH, see Branson K
sdobler A, Eastham JA, de Kernion J, Cangiano T,
Golub TR, see Ramaswamy S
Schröder FH, Wildhagen MF, van der Kwast TH,
Gonen M, see Holen KD
Scardino PT, Kattan MW. International Validation
see Wong RJ
of a Preoperative Nomogram for Prostate Cancer
González-Quevedo R, Iniesta P, Morán A, de Juan C,
Recurrence After Radical Prostatectomy, 3206
Sánchez-Pernaute A, Fernández C, Torres A, Dı́az-
Graham M, see Rivera E
Rubio E, Balibrea J-L, Benito M. Cooperative Role
Grahek D, see Barranger E
of Telomerase Activity and p16 Expression in the
Gralow J, see Winer EP
Prognosis of Non-Small-Cell Lung Cancer, 254
Gralow JR, see Ellis GK
Gonzalez R, see Agarwala SS
Goode MJ, see Rizzo JD Granata S, see Cesana C
Goodin T, see Herbst RS Grann VR, see Hershman D
Goodwin JS, see Du XL see Neugut AI
Goodwin PJ, see Leighl NB see Sundararajan V
Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan
Madarnas Y, Hartwick W, Hoffman B, Hood N. DF, Neugut AI. Effect of Prevention Strategies on
Fasting Insulin and Outcome in Early-Stage Breast Survival and Quality-Adjusted Survival of Women
Cancer: Results of a Prospective Cohort Study, 42 With BRCA1/2 Mutations: An Updated Decision
Goodwin S, see DiPaola RS Analysis, 2520
Gooley TA, see Disis ML Granone P, see Trodella L
Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas Grasso Y, see Thomas J
M, Siegal GP, Gebhardt MC, Schwartz CL, Link Graus F, see Bessell EM
M, Grier HE. Phase II/III Trial of Etoposide and Gravenstein S, see Ramanathan RK
High-Dose Ifosfamide in Newly Diagnosed Meta- Gray B, see Kemeny MM
static Osteosarcoma: A Pediatric Oncology Group Gray JR, see Hainsworth JD
Trial, 426 Gray JR. Prostate Cancer Risk Groups and Comparisons:
Gordon LI, see Witzig TE Fruitless or Fruitful? (correspondence), 4129
Gordon MS, see Rizzo JD Greco FA, see Hainsworth JD
Gordon P, see Andermann A Greco FA, Burris HA III, Litchy S, Barton JH, Bradof JE,
Gore M, see Vasey PA Richards P, Scullin DC Jr, Erland JB, Morrissey
see Wheatley K
Downloaded LH,only.
from on June 28, 2008 . For personal use Hainsworth JD. Gemcitabine,
No other uses Carboplatin, and
without permission.
Gore ME, see Bukowski Copyright
R © 2002 by the American Society of Clinical Oncology. All rights
Paclitaxel reserved.With Carcinoma of Un-
for Patients

known Primary Site: A Minnie Pearl Cancer Re- Grütter R, see Kröger K
search Network Study, 1651 Grygiel JJ, see Graefen M
Greco W, see Khushalani NI Gu C-D, see Osaki T
Green DM, Peabody EM, Nan B, Peterson S, Kalapurakal JA, Guadagnoli E, see Keating NL
Breslow NE. Pregnancy Outcome After Treatment see Silliman RA
for Wilms Tumor: A Report From the National Gualano G, see Trodella L
Wilms Tumor Study Group, 2506 Gudbjartsson DF, see Berry DA
Green DM. Use of Chest Computed Tomography for Staging Guerciolini R, see Orlowski RZ
and Treatment of Wilms’ Tumor in Children (edi- Guerra LT, see Esteva FJ
torial), 2763 Guévin R, see Klasa RJ
Green MR, see Lima CMSR Guida M, see Ridolfi R
see Vokes EE Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss
Green S, Liu P-Y, O’Sullivan J. Factorial Design Consider- IJ, Budman DR, Henderson IC, Norton L, Hayes
ations, 3424 DF. Association of Angiogenesis and Disease Out-
Green SJ, see Ellis GK come in Node-Positive Breast Cancer Patients
Greenberg ER, see Ahles TA Treated With Adjuvant Cyclophosphamide, Doxo-
Greenberg HS, see Chan JL rubicin, and Fluorouracil: A Cancer and Leukemia
Greenberg MJ, see Machtay M Group B Correlative Science Study From Protocols
Greene FL, see Singletary SE 8541/8869, 732
Greenwald P. Cancer Prevention Clinical Trials, 14s Guilmin G, see Gisselbrecht C
Greggi S, see Benedetti-Panici P Gumbrell L, see Galbraith SM
Gregurich MA, see Loesch D Gumpper KL, see Frank TS
Greil R, see Sieber M Gunderson LL, see Tepper JE
Greiner T, see Weekes CD Gunnarsson PO, see Hudes G
Greipp PR, see Rajkumar SV Guo J-Y, see Goh B-C
Grem JL, see Leonard GD Gupta M, see Thomas J
see Wilson RH Gupta RK, see DiFronzo LA
Grem JL. In Reply (correspondence), 3562 see Radford JA
Grenier J-F, see Klasa RJ Gupta SK, see Bukowski R
Gribben JG, see Howard OM Gururangan S, see Quinn JA
Gridelli C, see Scagliotti GV Gururangan S, Cavazos CM, Ashley D, Herndon JE II,
Grier HE, see Goorin AM Bruggers CS, Moghrabi A, Scarcella DL, Watral
Griffin M, see Hughes A M, Tourt-Uhlig S, Reardon D, Friedman HS. Phase
Griffiths PD, see Lashford LS II Study of Carboplatin in Children With Progres-
Grigoraki V, see Dimopoulos MA sive Low-Grade Gliomas, 2951
Grillo-López AJ, see Witzig TE Gurwitz J, see Silliman RA
Grimm EA, see Ellerhorst JA Gutheil J, see Agarwala SS
Groeger JS, see Timoney JP Gutheil JC, see Vaughn DJ
see Vogel CL
Groen HJ, see Kehrer DFS
Gutierrez L, see Mellado B
Groene WS, see Pecora AL
Gutierrez M, Pautier P, Lhommé C. Replacement of Carbo-
Grondin SC, see Liptay MJ
platin by Oxaliplatin May Be One Solution for
Groome PA, see Huang J
Patients Treated for Ovarian Carcinoma Who Are
Gross P, see Pecora AL
Hypersensitive to Carboplatin (correspondence),
Grossbard M, see Howard OM
Grosshans E, see Iamandi C
Grossman SA, see Kleinberg L
Group LAME of the French Society of Pediatric Hematology
and Immunology, see Perel Y H
Groupe d’Etude des Lymphomes de l’Adulte, see Gisselbre-
cht C Haas JE, see Katzenstein HM
Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson Haas N, see Hudes G
P, Yung WKA, Levin VA. Phase II Trial of Habermann TM, see Ansell SM
Temozolomide Plus the Matrix Metalloproteinase Haenggeli C-A, see Allal AS
Inhibitor, Marimastat, in Recurrent and Progressive Haese A, see Cagiannos I; Graefen M
Glioblastoma Multiforme, 1383 Haglund MM, see Quinn JA
Gruetzner KU, see Heiss MM
Downloaded from on June 28, 2008 . ForHahl M, use
personal see only.
Morkas M uses without permission.
No other
Grundeis M, see Kaiser UCopyright © 2002 by the American Society of ClinicalK,
Haider Oncology. All rights
see Jakesz R reserved.

Hainsworth J, see Lima CMSR Cancer: Practice Patterns of Community Physi-

Hainsworth JD, see Greco FA cians, 1809
Hainsworth JD, Gray JR, Morrissey LH, Kalman LA, Hon Harper P, see Douillard J-Y
JK, Greco FA. Long-Term Follow-Up of Patients see Marx GM
Treated With Paclitaxel/Carboplatin-Based Che- see Ross P
motherapy for Advanced Non-Small-Cell Lung Harper PG, see Galani E
Cancer: Sequential Phase II Trials of the Minnie see Steer CB
Pearl Cancer Research Network, 2937 Harper-Wynne CL, Sacks NPM, Shenton K, MacNeill FA,
Hainsworth JD, Litchy S, Burris HA III, Scullin DC Jr, Corso Sauven P, Laidlaw IJ, Rayter Z, Miall S, Howes A,
SW, Yardley DA, Morrissey L, Greco FA. Ritux- Salter J, Hills MJ, Lowe FM, A’Hern R, Nasiri N,
imab as First-Line and Maintenance Therapy for Doody D, Iqbal J, Dowsett M. Comparison of the
Patients With Indolent Non-Hodgkin’s Lymphoma, Systemic and Intratumoral Effects of Tamoxifen
4261 and the Aromatase Inhibitor Vorozole in Postmeno-
Haioun C, see Mounier N pausal Patients With Primary Breast Cancer, 1026
Hakama M, see Mäkinen T Harrington A, see Maisey N
Hakama M. Screening for Lung Cancer (correspondence), Harris A, see Baselga J
3931 Harris JM, see Abramson N
Hakulinen T, see Brenner H Harris LN, see Vogel CL
Halabi S, see Small EJ Harris MB, see Goorin AM
Hall J, see Markman M Hars V, see Small EJ
Hall JM, see Bichakjian CK Hartley-Asp B, see Hudes G
Haller DG, see Berlin JD Hartmann JT, see Bokemeyer C
Hallström M, see Edler D Hartmann LC, see Anderson PM
Halpern S, see Mitchell MS Hartwick W, see Goodwin PJ
Haluska FG, see Kilbridge KL Harvey HA, see Lipton A
Haluska FJ, see Kirkwood JM Hasenclever D, see Sieber M
Halyard MY, see Loprinzi CL Hassoun H, see Oo TH
Hamilton A. Ethical Issues Surrounding the Conduct of Hatlevoll R, see Sundstrøm S
Off-Shore Clinical Research (correspondence), Hauger M, see Nadella P
3934 Hausmaninger H, see Jakesz R
Hamilton M, see Kehrer DFS Haut PR, see Kletzel M
Hamilton-Nelson KL, see Sofer M Havemann K, see Kaiser U
Hammel P, see Louvet C Havighurst TC, see Love RR
Hammerer PG, see Cagiannos I Hawkins MJ, see Rizvi NA
see Graefen M Haworth L, see Toso JF
Hammett E, see Bass AJ Hay J, see El-Sayed S
Hammond A, see Davis AM Hayakawa K, see Sekine I
Hammond LA, see de Bono JS Hayashi Y, see Yamamoto K
see Ranson M Hayes DF, see Guidi AJ
Hanaoka N, see Shoji T see Singletary SE
Hancock B, see Wheatley K see Stearns V
Hancock ML, see Leung W Hayman JA, see Burkhardt JH
Hanlon AL, see Freedman GM see Lee JH
Hannisdal E, see Sundstrøm S Hayman S, see Rajkumar SV
Hanselmann S, see Borner MM Haynes B, see Geisler J
Hansen SW, see Petersen PM Head DR, see Biankin AV
Hanson J, see Suarez-Almazor ME Headlee D, see Tan AR
Hanson LJ, see Adjei AA Heaney ML, see Timoney JP
Harbeck N, Kates RE, Schmitt M. Clinical Relevance of Hedenus M, see Österborg A
Invasion Factors Urokinase-Type Plasminogen Ac- Hedley D, see Fyles A
tivator and Plasminogen Activator Inhibitor Type I Heffernan N, Cella D, Webster K, Odom L, Martone M,
for Individualized Therapy Decisions in Primary Passik S, Bookbinder M, Fong Y, Jarnagin W,
Breast Cancer Is Greatest When Used in Combina- Blumgart L. Measuring Health-Related Quality of
tion, 1000 Life in Patients With Hepatobiliary Cancers: The
Harlan LC, see Potosky AL Functional Assessment of Cancer Therapy-Hepato-
Harlan LC, Downloaded
Abrams J, from
Warren JL, Clegg L, Stevens J, biliary on June 28, 2008 . For personal use only. Questionnaire, 2229permission.
No other uses without
Ballard-BarbashCopyright © 2002Therapy
R. Adjuvant by the American Society of
for Breast Clinical Oncology.
Heidecke C-D, seeAllSucker
rights reserved.

Heideman RL, see Athale UH Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr,
Heider U, see Sezer O Meyers CA, Seabrooke LF, Khuri FR, Puduvalli
Heine B, see Fuchs IB VK, Allgood V, Fritsche HA Jr, Hinton L, Newman
Heinrich MC, see Mauro MJ RA, Crane EA, Fossella FV, Dordal M, Goodin T,
Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition Hong WK. Safety and Pharmacokinetic Effects of
of KIT Tyrosine Kinase Activity: A Novel Molec- TNP-470, an Angiogenesis Inhibitor, Combined
ular Approach to the Treatment of KIT-Positive With Paclitaxel in Patients With Solid Tumors:
Malignancies, 1692 Evidence for Activity in Non-Small-Cell Lung
Heinz J, see Josting A Cancer, 4440
Heiss MM, Simon EH, Beyer BCM, Gruetzner KU, Tarabichi Herbst RS, Maddox A-M, Rothenberg ML, Small EJ, Rubin
A, Babic R, Schildberg FW, Allgayer H. Minimal EH, Baselga J, Rojo F, Hong WK, Swaisland H,
Residual Disease in Gastric Cancer: Evidence of an Averbuch SD, Ochs J, LoRusso PM. Selective Oral
Independent Prognostic Relevance of Urokinase Epidermal Growth Factor Receptor Tyrosine Ki-
Receptor Expression by Disseminated Tumor Cells nase Inhibitor ZD1839 Is Generally Well-Tolerated
in the Bone Marrow, 2005 and Has Activity in Non-Small-Cell Lung Cancer
Heisterkamp SH, see Koedoot CG and Other Solid Tumors: Results of a Phase I Trial,
Heitjan DF, see Hershman D 3815
see Grann VR Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey
see Neugut AI DJ, Charnsangavej C, O’Reilly MS, Kim H-W,
Hellenic Cooperative Oncology Group, see Kosmidis P Baker C, Roach J, Ellis LM, Rashid A, Pluda J,
Hellman R, see Shaw E Bucana C, Madden TL, Tran HT, Abbruzzese JL.
Hellstrand K, see Agarwala SS Development of Biologic Markers of Response and
Hellwig D, see Samnick S Assessment of Antiangiogenic Activity in a Clini-
Helmchen B, see Guidi AJ cal Trial of Human Recombinant Endostatin, 3804
Helmke K, see Bielack SS Herling M, see Rassidakis GZ
Henderson CI. A Rose Is No Longer a Rose (editorial), 3365 Herman T, see Kleinberg L
Henderson IC, see Berry DA Herman TS, see Vijayalaxmi
see Guidi AJ Hermine O, see Gisselbrecht C
Hennan TS, see Vijayalaxmi Herndon JE II, see Gururangan S
Henningsson A, see Friberg LE see Kornblith AB
Henry-Amar M, see Joly F see Quinn JA
Henshall SM, see Biankin AV see Reardon DA
see Graefen M see Vokes EE
Hensley M, see Barakat RR Héron JF, see Joly F
see Scheuer L Herr HW, see Dalbagni G
Hensley ML, see Dizon DS see Rabbani F
see Schuchter LM Herrmann R, see Borner MM
Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren see Sieber M
M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Herrmann Z, see Menssen HD
Spriggs DR. Gemcitabine and Docetaxel in Patients Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar
With Unresectable Leiomyosarcoma: Results of a RW, McLeod R, Gill PG, Coventry BJ, McMullen
Phase II Trial, 2824 A, Dillon H, Simes RJ. Adjuvant Immunotherapy
Hérait P, see Keating MJ of Patients With High-Risk Melanoma Using Vac-
Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, cinia Viral Lysates of Melanoma: Results of a
Campos F, Villard O, Liu K-L, Natarajan-Amé S, Randomized Trial, 4181
Lutz P, Dufour P, Bergerat J-P, Candolfi E. As- Hersh E, see Agarwala SS
pergillus Galactomannan Detection in the Diagno- Hershman D, see Grann VR
sis of Invasive Aspergillosis in Cancer Patients, see Sundararajan V
1989 Hershman D, Sundararajan V, Jacobson JS, Heitjan DF,
Herbst RS, see Albanell J Neugut AI, Grann VR. Outcomes of Tamoxifen
see Pentz RD Chemoprevention for Breast Cancer in Very High-
Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Risk Women: A Cost-Effectiveness Analysis, 9
Charnsangavej C, Madden T, Davis DW, McCon- Hershock D, see Machtay M
key DJ, O’Reilly MS, Ellis LM, Pluda J, Hong Herzog P, see Nachman JB
WK, Abbruzzese JL. Phase I Study of Recombinant Hess KR, see Groves MD
Human Endostatin
Downloaded in Patients With
from on JuneAdvanced see Herbst
28, 2008 . For personal RS No other uses without permission.
use only.
Copyright © 2002 by the American Society of
Solid Tumors, 3792 Clinical Oncology.
Hesslewood S, seeAllSeymour
rights reserved.

Heston WD, see Thomas J Pancreatic Endocrine Neoplasms: An Analysis of

Hewitt M, Rowland JH. Mental Health Service Use Among 136 Cases With a Proposal for Low-Grade and
Adult Cancer Survivors: Analyses of the National Intermediate-Grade Groups, 2633
Health Interview Survey, 4581 Hodges C, see Eton O
Heys SD, see Smith IC Hodges E, see Oscier D
Hiatt M-A, see Roche K Hoecht S, Rosenthal P, Sancar D, Behrens S, Hinkelbein W,
Hibi S, see Imashuku S Hoeller U. Implantable Cardiac Defibrillators May
Hickish T, see Maisey N Be Damaged by Radiation Therapy (correspon-
see Ross P dence), 2212
Hidalgo M, see de Bono JS Hoekman K, see Kuenen BC
Hiddemann W, see Wendtner C-M Hoekstra OS, see Bos R
Hien NN, see Love RR Hoeller U, see Hoecht S
Higashigawa M, see Yamamoto K Hoff PM, see Douillard J-Y
Higginson IJ, Costantini M. Communication in End-of-Life Hoffbrand AV, see Mortuza FY
Cancer Care: A Comparison of Team Assessments Hoffman B, see Goodwin PJ
in Three European Countries, 3674 Höfler G, see Jäger G
Higham S, see Chen WY Hogan C, see Burkhardt JH
Hill DA, see Spunt SL Högel J, see Viardot A
Hill LR, see Holmes FA Hohenberg G, see Ortmann E
Hill M, see Maisey N Hohenberger P, see Stein U
Hill PA, see Deitcher SR Holden L, see McNeish IA
Hill RP, see Fyles A Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K,
Hiller EH, see Berry DA Brennan M, Saltz LB. Clinical Characteristics and
Hillner BE, see Berenson JR Outcomes From an Institutional Series of Acinar
see Love RR Cell Carcinoma of the Pancreas and Related Tu-
Hills MJ, see Harper-Wynne CL mors, 4673
Hilsenbeck SG, see Berry DA Holland JC, see Kornblith AB
Himelstein B. In Reply (correspondence), 1953 see Silverman LR
Hinerman RW, see Mendenhall WM Holland JF, see Kornblith AB
Hines JD, see Morrison VA see Silverman LR
Hinke A, see Dunst J Hollis DR, see Tepper JE
Hinkelbein W, see Hoecht S Holmes C, see Sarna L
Hinterleitner T, see Jäger G Holmes E, see Jennings MT
Hinton L, see Herbst RS Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE,
Hinton S, Catalano P, Einhorn LH, Loehrer PJ Sr, Kuzel T, Shogan J, Savin M, Glaspy J, Moore M, Meza L,
Vaughn D, Wilding G. Phase II Study of Paclitaxel Wiznitzer I, Neumann TA, Hill LR, Liang BC.
Plus Gemcitabine in Refractory Germ Cell Tumors Blinded, Randomized, Multicenter Study to Evalu-
(E9897): A Trial of the Eastern Cooperative On- ate Single Administration Pegfilgrastim Once per
cology Group, 1859 Cycle Versus Daily Filgrastim as an Adjunct to
Hirsch FR, see Bremnes RM Chemotherapy in Patients With High-Risk Stage II
Hirsh V, see Shepherd FA or Stage III/IV Breast Cancer, 727
Hirsh-Yechezkel G, see Chetrit A Holmes HE, see Levine JE
Hislop TG, see Van Patten CL Holowaty E, see Vallis KA
Hitti IF, see Narasimhan P Holowaty EJ, see Dores GM
Ho AD, see Viardot A Holtkamp MMJ, see de Gast GC
Ho C-L, see Cheng H-L Hölzel D, see Kerr J
Hobday TJ, Kugler JW, Mahoney MR, Sargent DJ, Sloan JA, Hon C, Au WY, Ma ESK, Kwok AKH, Lie AKW, Liang
Fitch TR, Krook JE, O’Connell MJ, Mailliard JA, RHS. Unusual Sites of Involvement in Non-
Tirona MT, Tschetter LK, Cobau CD, Goldberg Hodgkin’s Lymphoma; Case 1. Isolated Orbit Re-
RM. Efficacy and Quality-of-Life Data Are Related lapse After Allogeneic Bone Marrow Transplanta-
in a Phase II Trial of Oral Chemotherapy in tion for Malignant Lymphoma, 4394
Previously Untreated Patients With Metastatic Hon JK, see Hainsworth JD
Colorectal Carcinoma, 4574 Honegger H, see Borner MM
Hobson R, see Lashford LS Hong WK, see Herbst RS
Hochhauser D, see Brett BT see Rizvi NA
Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, see Shin
Downloaded from on June 28, 2008 . For personal useDM
only. No other uses without permission.
Brennan MF, Klimstra © 2002 by the American
Prognostic Society
Factors in of Clinical
Hood N, Oncology. All rights
see Goodwin PJ reserved.

Hoogerbrugge N, see van Roosmalen MS Hubers D, see Yanik GA

Hook HC, see Biankin AV Hudes G. Boosting Bioavailability of Topotecan: What Do
Hoos A, see Rosenberg R We Gain? (editorial), 2918
see Stojadinovic A Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO,
Hoppe RT, see Horning SJ Ellman M, Nordle O, Eriksson B, Miller L, Cisar L,
Hopper J, see Lindor NM Kopreski M, Viaro D, Hartley-Asp B. Phase I
Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Clinical and Pharmacologic Trial of Intravenous
Rosenberg SA. Stanford V and Radiotherapy for Estramustine Phosphate, 1115
Locally Extensive and Advanced Hodgkin’s Dis- Hudis C, see Modi S
ease: Mature Results of a Prospective Clinical see Seidman A
Trial, 630 see Seidman AD
Horowitz M, see Levine JE see Van Poznak C
Horowitz MM, see Berry DA see Winer EP
see Loberiza FR Jr Hudson MM. Pediatric Hodgkin’s Therapy: Time for a
Hortobagyi GN, see Buchholz TA Paradigm Shift (editorial), 3755
see Esteva FJ Hudson MM, see Donaldson SS
see Rivera E see Friedmann AM
Hortobagyi GN. Can We Cure Limited Metastatic Breast see Leung W
Cancer? (editorial), 620 Hugh TB, see Biankin AV
Horwich A, see Bokemeyer C Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R,
see Warde P Rusthoven J, Griffin M, Fishwick K, Boddy AV,
Hoshida Y, see Nakatsuka S Verrill M, Calvert H. Phase I Clinical and Pharma-
Hoskins P, see Shenkier TN cokinetic Study of Pemetrexed and Carboplatin in
Hoskins WJ, see Barakat RR Patients With Malignant Pleural Mesothelioma,
Hosmane BS, see Carducci MA 3533
Hossfeld DK, see Kaiser U Hughes C, see Schwartz MD
see Laack E Hughes KS, see Berry DA
Hough D, see Galbraith SM Hughes LL, see Singletary SE
Houghton AN, see Hwu W-J Hughes P, see Rischin D
House A, see Stark D Huisman H, see Kuenen BC
Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor Huland H, see Cagiannos I
C, Janicek MJ, Shipp MA. Rituximab and CHOP see Graefen M
Induction Therapy for Newly Diagnosed Mantle- Hulick M, see Frank TS
Cell Lymphoma: Molecular Complete Responses Hummer A, see Dizon DS
Are Not Predictive of Progression-Free Survival, see Holen KD
1288 Hung G-S, see Chou Y-H
Howell A, Robertson JFR, Albano JQ, Aschermannova A, Hunt KK, see Ahmad SA
Mauriac L, Kleeberg UR, Vergote I, Erikstein B, see Buchholz TA
Webster A, Morris C. Fulvestrant, Formerly ICI Huong DT, see Love RR
182,780, Is as Effective as Anastrozole in Post- Hurt RD, see Cox LS
menopausal Women With Advanced Breast Cancer Hurwitz C, see LeClerc JM
Progressing After Prior Endocrine Treatment, 3396 Hurwitz CA, see Donaldson SS
Howell SB, see Alberts DS see Lipshultz SE
Howes A, see Harper-Wynne CL Hurwitz H, see Rizzieri DA
Hrubisko M, see Menssen HD Hussain M, see Vaishampayan U
Hsi ED, see Mirza I see Vaughn DJ
Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, Hussein M, see Dudeney S
O’Day SJ, Boasberg PD, Stern SL, Ye X, Morton Hutcheon AW, see Smith IC
DL. Prolonged Survival After Complete Resection Hutchins B, see Kuball J
of Disseminated Melanoma and Active Immuno- Hutchinson R, see Emmons K
therapy With a Therapeutic Cancer Vaccine, 4561 Hutchinson RJ, see Nachman JB
Huang J, Boyd C, Tyldesley S, Zhang-Salomons J, Groome see Yanik GA
PA, Mackillop WJ. Time Spent in Hospital in the Hutter RVP, see Singletary SE
Last Six Months of Life in Patients Who Died of Hwang Y-T, see Liang W
Cancer in Ontario, 1584 Hwu P, see Toso JF
Huang WC, see Cross CK
Downloaded from on June 28, 2008 . ForHwu W-J,
personal useKrown
only. NoSE,
otherPanageas KS,permission.
uses without Menell JH, Chapman
Huber C, see Kuball J Copyright © 2002 by the American Society of Clinical Oncology. All rights reserved.
PB, Livingston PO, Williams LJ, Quinn CJ,

Houghton AN. Temozolomide Plus Thalidomide in Isu K, see Tsuchiya H

Patients With Advanced Melanoma: Results of a Italian Cooperative Group for the Study of Hairy Cell
Dose-Finding Trial, 2610 Leukemia, see Federico M
Hyland A, see Bepler G Italian Lung Cancer Project, see Scagliotti GV
Italian Melanoma Intergroup, see Ridolfi R
Ito E, see Yamamoto K
I Iturria N, see Rajkumar SV
Itzhaki M, see Keating MJ
Iuchi K, see Nakatsuka S
Iacobelli S, see Piantelli M Iversen ES Jr, see Berry DA
Iamandi C, Dietemann A, Grosshans E, Pauli G, Quoix E. Ives N, see Wheatley K
Unusual Presentations of Lung Cancer: Case 3. Iveson T, see Maisey N
Paraneoplasic Digital Necrosis in a Patient With see Ross P
Small-Cell Lung Cancer, 4600 Ivnik R, see Shaw E
Ibrahim J, see Kirkwood JM Iwashyna TJ, Lamont EB. Effectiveness of Adjuvant Flu-
see Rao UNM orouracil in Clinical Practice: A Population-Based
Iezzi M, see Piantelli M Cohort Study of Elderly Patients With Stage III
Ikeda J, see Aoyama H Colon Cancer, 3992
see Aoyama H Izawa JI, Madsen LT, Scott SS, Tran J-P, McGuire EJ, von
Ikeda M, see Noura S Eschenbach AC, Pisters LL. Salvage Cryotherapy
Ikenaga M, see Noura S for Recurrent Prostate Cancer After Radiotherapy:
Ilson D, see Schwartz GK Variables Affecting Patient Outcome, 2664
Ilson DH. Epirubicin, Cisplatin, and Fluorouracil in Gastric
and Esophageal Cancer: A Step Ahead? (editorial),
Imashuku S, Teramura T, Ishii E, Kinugawa N, Kato M, Sako J
M, Kuriyama K, Hibi S. In Reply (correspon-
dence), 600 Jackman A, see de Jonge MJA
Imeson J, see Owens CM Jackson J, see Kwan W
Implantable Drug Delivery Systems Study Group, see Smith Jacob JH, see Louvet C
TJ Jacobs G, see Trümper L
Indelicato RA, see Portenoy RK Jacobs H, see Rizvi NA
Indelicato RA, Portenoy RK. Opioid Rotation in the Man- Jacobs SA, see Ramanathan RK
agement of Refractory Cancer Pain, 348 Jacobsen PB, Meade CD, Stein KD, Chirikos TN, Small BJ,
Ingle JN, see Winer EP Ruckdeschel JC. Efficacy and Costs of Two Forms
Ingram SS, Seo PH, Martell RE, Clipp EC, Doyle ME, of Stress Management Training for Cancer Patients
Montana GS, Cohen HJ. Comprehensive Assess- Undergoing Chemotherapy, 2851
ment of the Elderly Cancer Patient: The Feasibility Jacobson JS, see Grann VR
of Self-Report Methodology, 770 see Hershman D
Iniesta P, see González-Quevedo R see Neugut AI
International Breast Cancer Study Group, see Colleoni M see Sundararajan V
International Society of Pediatric Oncology, Liver Tumors Jacobson R, see Rizzieri DA
Study Group, see Czauderna P Jacquemier J, see Lakhani SR
Invernizzi R, see Federico M Jacques C, see Raymond E
Inwards D, see Vose JM Jaeckle KA, see Groves MD
Iosava G, see Österborg A Jäger G, Neumeister P, Brezinschek R, Hinterleitner T,
Iqbal J, see Harper-Wynne CL Fiebiger W, Penz M, Neumann HJ, Mlineritsch B,
Iriondo A, see Rocha V DeSantis M, Quehenberger F, Chott A, Beham-
Irish JC, see Brierley JD Schmid C, Höfler G, Linkesch W, Raderer M.
Ironside J, see Lashford LS Treatment of Extranodal Marginal Zone B-Cell
Irvine R, see Coetzee G Lymphoma of Mucosa-Associated Lymphoid Tis-
Isaacs C, see Schwartz MD sue Type With Cladribine: A Phase II Study, 3872
Isaacson JD, see Carducci MA Jager GJ, see Langenhoff BS
Ishii E, see Imashuku S see Ruers TJM
Ishikawa S, see Shoji T Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C,
Ishizuka N, see Sekine I Bauernhofer T, Seifert M, Haider K, Mlineritsch B,
Isler M, see Davis AM Steindorfer
Downloaded from on June 28, 2008 . For personal use P, Kwasny
only. No other W,permission.
uses without Fridrik M, Steger G,
Issels RD, see Wendtner Copyright
C-M © 2002 by the American Society of Clinical Oncology.
Wette V,AllSamonigg
rights reserved.
H. Randomized Adjuvant Trial

of Tamoxifen and Goserelin Versus Cyclophosph- tion Chemotherapy in Primary High-Risk Brain-
amide, Methotrexate, and Fluorouracil: Evidence stem Tumors: Phase II Study CCG-9941 of the
for the Superiority of Treatment With Endocrine Children’s Cancer Group, 3431
Blockade in Premenopausal Patients With Hor- Jeong HY, see Chiou WL
mone-Responsive Breast Cancer-Austrian Breast Jett JR. Screening for Lung Cancer: No Longer a Taboo
and Colorectal Cancer Study Group Trial 5, 4621 Subject (editorial), 1959
Jakob C, see Sezer O Jewell RC, see Kruijtzer CMF
Jakobsen A, see Edler D Jhingran A, see Eifel PJ
Jakowatz JG, see Sondak VK Joensuu T, see Dores GM
Jakubowski AA, see Rizzo JD Johannessen AC, see Sudbø J
Jamal N, see Kiss TL Johnson BA, see Wang XS
James K, see Davis AM Johnson DH. “The Guard Dies, It Does Not Surrender!”
James RD, see Radford JA Progress in the Management of Small-Cell Lung
Jameson M, see Galbraith SM Cancer? (editorial), 4618
Janicek MJ, see Eder JP Jr Johnson KA, see Potosky AL
see Howard OM Johnson M, see Levine JE
Janicot H, see Depierre A Johnson ME, see Bennett CL
Janjan NA, see Esnaola NF Johnson ML, see Esnaola NF
see Pisters PWT Johnson PJ, see Chan ATC
Jankowska P, see Bomanji JB Johnson R, see Hughes A
Jansson A, Sun X-F. Bax Expression Decreases Significantly Johnson TM, see Bichakjian CK
From Primary Tumor to Metastasis in Colorectal Johnston D, see Pearcey R
Cancer, 811 Johnston P, see Allegra CJ
Janus TJ, see Carducci MA Johnston PG, see Edler D
Janvier M, see Viens P Johnston S, see Vasey PA
Janzer R, see Stupp R Jolivet J, see Bélanger K
Japan Clinical Oncology Group, see Takada M see de Bono JS
Jaques DP, see Stojadinovic A see Giles FJ
Jargens H, see Bielack SS Joly F, Héron JF, Kalusinski L, Bottet P, Brune D, Allouache
Jarnagin W, see Heffernan N N, Macé-Lesec’h J, Couëtte JE, Pény J, Henry-
Jasiewicz Y, see Laack E Amar M. Quality of Life in Long-Term Survivors
Jaspan T, see Lashford LS of Testicular Cancer: A Population-Based Case-
Jass JR, see Lindor NM Control Study, 73
Jatoi A, Loprinzi C, Windschitl H. In Reply (correspon- Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J,
dence), 2913 Namer M, Fogelman I, de Haes JC, de Matteis A,
Jatoi A, Loprinzi CL. Adenosine Triphosphate: Does It Help Stewart A, Eiermann W, Szakolczai I, Palmer M,
Cancer Patients “Get Bigger and Stronger”? (edi- Schumacher M, Geberth M, Lisboa B. Goserelin
torial), 362 Versus Cyclophosphamide, Methotrexate, and Flu-
Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, orouracil as Adjuvant Therapy in Premenopausal
Mailliard JA, Pundaleeka S, Kardinal CG, Fitch Patients With Node-Positive Breast Cancer: The
TR, Krook JE, Novotny PJ, Christensen B. Dron- Zoladex Early Breast Cancer Research Association
abinol Versus Megestrol Acetate Versus Combina- Study, 4628
tion Therapy for Cancer-Associated Anorexia: A Jones C, see Shaw E
North Central Cancer Treatment Group Study, 567 Jones H, see Machtay M
Jaubert J, see Fermé C Jones RB, see Nieto Y
Jeffrey J, see Pearcey R Jones S, see O’Shaughnessy J
Jeha S, see Schover LR Jones SE, see Holmes FA
Jelinek DF, see Ansell SM see Osborne CK
Jenkins V, Fallowfield L. Can Communication Skills Train- Jones V, see Mitchell MS
ing Alter Physicians’ Beliefs and Behavior in Jordhøy MS, Kaasa S, Loge JH, Fayers P. In Reply (corre-
Clinics?, 765 spondence), 1704
Jenney MEM, see Bhatia S Jordon VC, Marrow M. Chemoprevention of Breast Cancer:
Jennings MT, Sposto R, Boyett JM, Vezina LG, Holmes E, A Model for Change (editorial), 1
Berger MS, Bruggers CS, Bruner JM, Chan K-W, Joshi U, see Bos R
Dusenbery KE, Ettinger LJ, Fitz CR, Lafond D, Josting A, see Sieber M
Downloaded DE, Massey V, McGuire
from W,2008
on June 28, Mc-. ForJosting
only. NoJ,other
M, without
Koch P, Beykirch MK, Heinz
Neely L, MoultonCopyright © 2002
T, Pollack IF,byShen
the American Society of Clinical Oncology.
V. Preradia- All rights
J, Rudolph reserved.
C, Diehl V, Engert A. New Prognostic

Score Based on Treatment Outcome of Patients Kanazawa Y, see Tsuchiya H

With Relapsed Hodgkin’s Lymphona Registered in Kandatsu S, see Kamada T
the Database of the German Hodgkin’s Lymphona Kandel RA, see Davis AM
Study Group, 221 Kane RL, see Bhatia S
Jouvet A, see Lashford LS Kaneko M, see Sobue T
Jovanovic BD, see Bennett CL Kang Y-K, see Lee Jung-Hee
Joyce R, see Witzig TE Kanis JA, see Powles T
Julyan PJ, see Seymour LW Kantarjian HM, see Giles FJ
Junck LR, see Chan JL Kantarjian HM. Treatment of Myelodysplastic Syndrome:
Jürchott K, see Stein U Questions Raised by the Azacitidine Experience
Jürgens H, see Bielack SS (editorial), 2415
Juusela H, see Mäkinen T Kanz L, see Bokemeyer C
see Kollmannsberger C
Kanzer B, see Narasimhan P
K Kapiteijn E, see Marijnen CAM
see Nagtegaal ID
Kaplan R, see Quinn JA
Kaasa S, see Jordhøy MS
see Sateren WB
see Sundstrøm S
Kadin ME, see Lones MA Kaplan RS, see Potosky AL
see Nachman JB Kappelle AC, see Dorresteijn LDA
Kahn KA, see Malin JL Karabelis A, see Bafaloukos D
Kahn KL, see Pearson ML Karageorgis P, see Antonadou D
Kahn MJ, see Rozans M Karakas T, see Kaiser U
Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay Karakiewicz PI, see Cagiannos I
P-B, Possinger K, Roots I, Brockmöller J. Patient- see Graefen M
Tailored Antiemetic Treatment With 5-Hydroxy- Karapetis C, see Price T
tryptamine Type 3 Receptor Antagonists According Kardinal CG, see Jatoi A
to Cytochrome P-450 2D6 Genotypes, 2805 Kardos G, see Kunst PWA
Kaiser U, Uebelacker I, Abel U, Birkmann J, Trümper L, Karim ABMF, see Pignatti F
Schmalenberg H, Karakas T, Metzner B, Hossfeld Karkantaris C, see Dimopoulos MA
DK, Bischoff HG, Franke A, Reiser M, Müller P, Karlan, BY, see Liede A
Mantovani L, Grundeis M, Rothmann F, von Sey- Karlsson MO, see Friberg LE
dewitz C-U, Mesters RM, Steinhauer EU, Krahl D, see Mathijssen RHJ
Schumacher K, Kneba M, Baudis M, Schmitz N, see Xie R
Pfab R, Köppler H, Parwaresch R, Pfreundschuh Karnad AB. House Calls by Oncologists: A Home-Visit
M, Havemann K. Randomized Study to Evaluate Primer, 3745
the Use of High-Dose Therapy as Part of Primary Karnicka-Mlodkowska H, see Ardizzoni A
Treatment for “Aggressive” Lymphoma, 4413 Karrison T, Ratain M. Troxacitabine in Patients With Refrac-
Kakinuma R, see Sobue T tory Leukemia (correspondence), 3356
Kakolyris S, see Souglakos J Kashani-Sabet M, Sagebiel RW, Ferreira CMM, Nosrati M,
see Stathopoulou A Miller JR III. Tumor Vascularity in the Prognostic
Kalapurakal JA, see Green DM Assessment of Primary Cutaneous Melanoma,
see Kletzel M 1826
Kalbakis K, see Souglakos J Kashiwamura M, see Aoyama H
Kalemkerian GP, see Reddy P Katakura H, see Shoji T
see Sirachainan E Kates RE, see Harbeck N
Kalman LA, see Hainsworth JD Kato H, see Kamada T
Kalofonos C, see Bafaloukos D Kato M, see Imashuku S
Kalophonos C, see Kosmidis P Kattan M. Statistical Prediction Models, Artificial Neural
Kalusinski L, see Joly F Networks, and the Sophism “I Am a Patient, Not a
Kamada T, Tsujii H, Tsuji H, Yanagi T, Mizoe J, Miyamoto Statistic” (editorial), 885
T, Kato H, Yamada S, Morita S, Yoshikawa K, Kattan MW, see Cagiannos I
Kandatsu S, Tateishi A. Efficacy and Safety of see Graefen M
Carbon Ion Radiotherapy in Bone and Soft Tissue see Shariat SF
Sarcomas, 4466 see Smaletz O
Kamin D, seeDownloaded
Einhorn LH Kattan MW,
from on June 28, 2008 . For personal Leung
use only. DHY,uses
No other Brennan
without MF. Postoperative No-
Kan-Mitchell J, see Mitchell MS © 2002 by the American Society of Clinical Oncology.
mogram All forrights reserved.
12-Year Sarcoma-Specific Death, 791

Katz A, see Buchholz TA gical Resection of Hepatic Metastases in Combina-

Katzenstein HM, see Kletzel M tion With Continuous Infusion of Chemothera-
Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, py—An Intergroup Study, 1499
Liu-Mares W, Douglass EC, Feusner JH, Reynolds Kempf RA, see Sondak VK
M, Quinn JJ, Newman K, Finegold MJ, Haas JE, see Sosman JA
Sensel MG, Castleberry RP, Bowman LC. Hepato- Kempf-Bielack B, see Bielack SS
cellular Carcinoma in Children and Adolescents: Kench JG, see Biankin AV
Results From the Pediatric Oncology Group and the Keogan MT, see Eder JP Jr
Children’s Cancer Group Intergroup Study, 2789 Kepner JL, see Furman WL
Katzenstein HM, London WB, Douglass EC, Reynolds M, Kerkhofs LGM, see Agteresch HJ
Plaschkes J, Finegold MJ, Bowman LC. Treatment Kerr DJ, see Seymour LW
of Unresectable and Metastatic Hepatoblastoma: A Kerr J, Engel J, Hölzel D. Colostomies May Influence Patient
Pediatric Oncology Group Phase II Study, 3438 Quality of Life More Than Poor Sphincter Function
Kauff N, see Scheuer L (correspondence), 3930
Kauff ND, see Scheuer L Kersemaekers A-M, see Mayer F
Kaufmann M, see Jonat W Kersemaekers A-MF, Mayer F, Molier M, van Weeren PC,
Kaufmann R, see Spieth K Oosterhuis JW, Bokemeyer C, Looijenga LHJ.
Kaushal V, Kohli M, Zangari M, Fink L, Mehta P. Endothe- Role of P53 and MDM2 in Treatment Response of
lial Dysfunction in Antiangiogenesis-Associated Human Germ Cell Tumors, 1551
Thrombosis (correspondence), 3042 Kershaw T, see Northouse LL
Kawahara M, see Takada M Kessinger A, see Vose JM
Kawano Y, see Shoji T Kessler C, see Rizvi NA
Kaye SB, see Baselga J Keus RB, see Dorresteijn LDA
see Kolomainen DF Kha NN, see Love RR
see Vasey PA Khang HX, see Love RR
Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Khayat D, see Marx GM
Langer W, Leber B, Maughan T, Rai K, Tjønnfjord see Steer CB
G, Bekradda M, Itzhaki M, Hérait P. Campath-1H Khayat D, Bernard-Marty C, Meric J-B, Rixe O. Biochemo-
Treatment of T-Cell Prolymphocytic Leukemia in therapy for Advanced Melanoma: Maybe It Is Real
Patients for Whom at Least One Prior Chemother- (editorial), 2411
apy Regimen Has Failed, 205 Khouri I. In Reply (correspondence), 1427
Keating NL, Guadagnoli E, Landrum MB, Borbas C, Weeks Khuri FR, see Herbst RS
JC. Treatment Decision Making in Early-Stage see Glisson BS
Breast Cancer: Should Surgeons Match Patients’ see Shin DM
Desired Level of Involvement?, 1473 Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L,
Kedde MA, see Kuenen BC Klippenstein D, Litwin A, Smith J, Nava E,
Keefe D, see Seidman A Pendyala L, Smith P, Greco W, Berdzik J, Doug-
see Timoney JP lass H, Leichman L. Oxaliplatin in Combination
Keeling J, see Czauderna P With Protracted-Infusion Fluorouracil and Radia-
Kehrer DFS, Bos AM, Verweij J, Groen HJ, Loos WJ, tion: Report of a Clinical Trial for Patients With
Sparreboom A, de Jonge MJA, Hamilton M, Cam- Esophageal Cancer, 2844
eron T, de Vries EGE. Phase I and Pharmacologic Kiamouris C, see Dimopoulos MA
Study of Liposomal Lurtotecan, NX 211: Urinary Kieback DG, see Baselga J
Excretion Predicts Hematologic Toxicity, 1222 Kiely M, see Stark D
Kehrer DFS, Mathijssen RHJ, Verweij J, de Bruijn P, Kies MS, see Socinski MA
Sparreboom A. Modulation of Irinotecan Metabo- Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins
lism by Ketoconazole, 3122 MA, Ruckdeschel JC, Sock DE, Nease RF Jr,
Keilholz U, see Kruijtzer CMF Weeks JC. Quality-of-Life-Adjusted Survival
Keith G, see Mohr S Analysis of High-Dose Adjuvant Interferon
Kelly B, see Scheuer L Alfa-2b for High-Risk Melanoma Patients Using
Kelly WK, see Smaletz O Intergroup Clinical Trial Data, 1311
Kelsen D, see Schwartz GK Kildal W, see Sudbø J
Kelsen DP, see Minsky BD Kim CY, see Lee H-S
Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Kim H, see Ramanathan RK
Lipsitz S, Sigurdson ER, O’Dwyer PJ, Benson AB Kim H-W, see Herbst RS
Combined-Modality Treatmentonfor
from Resectable
June 28, 2008 . ForKim J, see
personal useShariat
only. NoSFother uses without permission.
Metastatic Colorectal © 2002 byto
Carcinoma the American
the Liver: Society
Sur- of Clinical
Kim J-C,Oncology.
see Lee All rights reserved.

Kim J-H, see Lee Jung-Hee Klein P, see Allegra CJ

Kim KBS, see Ballo MT Kleinberg L, Grossman SA, Carson K, Lesser G, O’Neill A,
Kim KM, see Lee H-S Pearlman J, Phillips P, Herman T, Gerber M.
Kim S, see Bennett CL Survival of Patients With Newly Diagnosed Glio-
Kim S-H, see Lee Jung-Hee blastoma Multiforme Treated With RSR13 and
Kim T-W, see Lee Jung-Hee Radiotherapy: Results of a Phase II New Ap-
Kim W-K, see Lee Jung-Hee proaches to Brain Tumor Therapy CNS Consortium
Kim Y-C, see Bepler G Safety and Efficacy Study, 3149
Kinchla N, see Eder JP Jr Klersy C, see Cesana C
Kindler HL, see Schilsky RL Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E,
King DM, see Kolomainen DF Reynolds M, Geissler G, Marymount MH, Liu D,
King K, see Sarris AH Kalapurakal JA, Shore RM, Bardo DME, Schmoldt
Kinugawa N, see Imashuku S J, Rademaker AW, Cohn SL. Treatment of High-
Kiproff PM, see Deitcher SR Risk Neuroblastoma With Triple-Tandem High-
Kirchner H, see Sieber M Dose Therapy and Stem-Cell Rescue: Results of the
Kirk SB, see Stanton AL Chicago Pilot II Study, 2284
Kirkbride P, see Vallis KA Klijanienko J, see Rouzier R
Kirkwood JM, see Agarwala SS Klima K-M, see Sucker C
see Kilbridge KL Klimo P, see Shenkier TN
see Rao UNM Klimstra DS, see Hochwald SN
Kirkwood JM, Agarwala SS, Ibrahim J, Manola J, Sondak see Holen KD
VK, Ernstoff MS, Ross MK. In Reply (correspon- Klippenstein D, see Khushalani NI
dence), 2209 Klokman WJ, see Dorresteijn LDA
Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe- Kneba M, see Kaiser U
Spotloe J, Smelko B, Donnelly S, Stover L. Mech- Knisely J. Conformal Radiotherapy for High-Grade Gliomas:
anisms and Management of Toxicities Associated How Much Is Too Much? (correspondence), 3357
With High-Dose Interferon Alfa-2b Therapy, 3703 Knop C, see Liptay MJ
Kirkwood JM, Ibrahim J, Sondak VK, Ernstoff MS, Flaherty Knutson KL, see Disis ML
L, Haluska FJ. Use and Abuse of Statistics in Kobayashi T, see Sobue T
Evidence-based Medicine (correspondence), 4123 Kobrinsky N, see Woods WG
Kirn DH, see Vasey PA Koc H, see Ringdén O
Kirsch C-M, see Samnick S Koch M, see Laroia ST
Kirstein M, see Furman WL Koch P, see Josting A
Kirvan M, see Eder JP Jr see Sieber M
Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Koch T, see Sieber M
Messner HA. Long-Term Medical Outcomes and Kodish E, see Friebert S
Quality-of-Life Assessment of Patients With Koduri J, Baumann MA. Cisplatin and Dacarbazine With or
Chronic Myeloid Leukemia Followed at Least 10 Without Subcutaneous Interleukin-2 and Interferon
Years After Allogeneic Bone Marrow Transplanta- Alfa-2b in Advanced Melanoma Patients (corre-
tion, 2334 spondence), 3560
Kittas C, see Rassidakis GZ Koedoot CG, de Haes JCJM, Heisterkamp SH, Bakker PJM,
Kjeldsberg CR, see Lones MA de Graeff A, de Haan RJ. Palliative Chemotherapy
Klang M, see Timoney JP or Watchful Waiting? A Vignettes Study Among
Klasa R, see Shenkier TN Oncologists, 3658
Klasa RJ, Meyer RM, Shustik C, Sawka CA, Smith A, Köhler D, see Trümper L
Guévin R, Maksymiuk A, Rubinger M, Samosh M, Kohli M, see Kaushal V
Laplante S, Grenier J-F. Randomized Phase III Köhne C-H, see Steiner M
Study of Fludarabine Phosphate Versus Cyclophos- Koivistoinen A, see Auvinen MI
phamide, Vincristine, and Prednisone in Patients Kolitz JE, see Morrison VA
With Recurrent Low-Grade Non-Hodgkin’s Lym- Kölling-Schlebusch K, see Dunst J
phoma Previously Treated With an Alkylating Kollmannsberger C, Rick O, Derigs H-G, Schleucher N,
Agent or Alkylator-Containing Regimen, 4649 Schöffski P, Beyer J, Schoch R, Sayer HG, Gerl A,
Kleeberg UR, see Howell A Kuczyk M, Spott C, Kanz L, Bokemeyer C. Activ-
Klein E, see Graefen M ity of Oxaliplatin in Patients With Relapsed or
Klein EA, see Kupelian PA Cisplatin-Refractory Germ Cell Cancer: A Study of
see Thomas J the only.
Downloaded from on June 28, 2008 . For personal use German Testicular
No other Cancer
uses without Study Group, 2031
Klein JP, see Berry DA Copyright © 2002 by the American Society of Clinical Oncology.
Kolomainen All rightsJMG,
DF, Larkin reserved.
Badran M, A’Hern RP, King

DM, Fisher C, Bridges JA, Blake PR, Barton DPJ, Krook JE, see Goldberg RM
Shepherd JH, Kaye SB, Gore ME. Epithelial Ovar- see Hobday TJ
ian Cancer Metastasizing to the Brain: A Late see Jatoi A
Manifestation of the Disease With an Increasing Krown SE, see Evans SR
Incidence, 982 see Cianfrocca M
Komaki R, see Minsky BD see Hwu W-J
Koo J, see Goodwin PJ Kruijtzer CMF, Beijnen JH, Rosing H, ten Bokkel Huinink
Koppang HS, see Sudbø J WW, Schot M, Jewell RC, Paul EM, Schellens
Köppler H, see Kaiser U JHM. Increased Oral Bioavailability of Topotecan
Kopreski M, see Hudes G in Combination With the Breast Cancer Resistance
Korn EL, see Freidlin B Protein and P-Glycoprotein Inhibitor GF120918,
Kornblith AB, see Silverman LR 2943
Kornblith AB, Herndon JE II, Silverman LR, Demakos EP, Kruijtzer CMF, Schellens JHM, Mezger J, Scheulen ME,
Odchimar-Reissig R, Holland JF, Powell BL, De- Keilholz U, Beijnen JH, Rosing H, Mathôt RAA,
Castro C, Ellerton J, Larson RA, Schiffer CA, Marcus S, van Tinteren H, Baas P. Phase II and
Holland JC. Impact of Azacytidine on the Quality Pharmacologic Study of Weekly Oral Paclitaxel
of Life of Patients With Myelodysplastic Syndrome Plus Cyclosporine in Patients With Advanced Non-
Treated in a Randomized Phase III Trial: A Cancer Small-Cell Lung Cancer, 4508
and Leukemia Group B Study, 2441 Krych M, see Wendtner C-M
Kornek GV, see Gedlicka C Krzakowski M, see Shepherd FA
see Scheithauer W Kuball J, Wen SF, Leissner J, Atkins D, Meinhardt P,
Korst RJ, see Martin J Quijano E, Engler H, Hutchins B, Maneval DC,
Kortmann R-D, see Timmermann B Grace MJ, Fritz MA, Störkel S, Thüroff JW, Huber
Koslowsky TC, see Weihrauch MR C, Schuler M. Successful Adenovirus-Mediated
Kosmidis P, see Bafaloukos D Wild-Type p53 Gene Transfer in Patients With
Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Bladder Cancer by Intravesical Vector Instillation,
Samantas E, Boukovinas J, Fountzilas G, Skarlos 957
D, Economopoulos T, Tsavdaridis D, Papakostas P, Kubista E, see Jakesz R
Bacoyiannis C, Dimopoulos M. Paclitaxel Plus Kuczyk M, see Kollmannsberger C
Carboplatin Versus Gemcitabine Plus Paclitaxel in Kuenen B, Giaccone G. In Reply (correspondence), 3042
Advanced Non-Small-Cell Lung Cancer: A Phase Kuenen BC, Rosen L, Smit EF, Parson MRN, Levi M, Ruijter
III Randomized Trial, 3578 R, Huisman H, Kedde MA, Noordhuis P, van der
Kotsakis A, see Stathopoulou A Vijgh WJF, Peters GJ, Cropp GF, Scigalla P,
Kottaridis PD, see Branson K Hoekman K, Pinedo HM, Giaccone G. Dose-Find-
Kotz R, see Bielack SS ing and Pharmacokinetic Study of Cisplatin, Gem-
Kourousis C, see Souglakos J citabine, and SU5416 in Patients With Solid Tu-
see Stathopoulou A mors, 1657
Kovacsovics T, see Keating MJ Kuerer HM, see Buchholz TA
Krahl D, see Kaiser U Kufe DW, see Eder JP Jr
Krailo MD, see Katzenstein HM Kugler C, see Laack E
Kraljevic SO, see Stupp R Kugler JW, see Allegra CJ
Kramar A, see Culine S see Berlin JD
Kranenbarg EK, see Marijnen CAM see Hobday TJ
Kraus D, see Osman I Kühl J, see Timmermann B
Kraus DH, see Wong RJ Kühn R, see Rödel C
Kraut E, see Nadella P Kuhn-Regnier F, see Weihrauch MR
Kretschmer L, Neumann C. Sentinel-Node Technique Will Kun L, see Donaldson SS
Change the Design of Clinical Trials in Malignant see Friedmann AM
Melanoma (correspondence), 2208 Kung F, see Furman WL
Kris M, see Ranson M Kunst PWA, Sutedja G, Golding RP, Risse E, Kardos G,
Kris MG, see Martin J Postmus PE. Unusual Pulmonary Lesions; Case 1.
Kristal AR. Diet and Trend in Prostate-Specific Antigen: A Juvenile Bronchopulmonary Fibrosarcoma, 2745
Inferences for Prostate Cancer Risk (editorial), Kuntz KM, see Esnaola NF
3570 Kuo S-H, see Yuan A
Kröger K, Grütter R, Rudofsky G, Fink H, Niebel W. Kupelian P, see Graefen M
Follow-Up After
Downloaded fromPort-a-Cath-Induced Thrombosis on June 28, 2008 . ForKupelian PA,only.
personal use see No
Graefen M without permission.
other uses
(correspondence), Copyright
2605 © 2002 by the American Society of Clinical Oncology.
see Thomas J All rights reserved.

Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Lamar L, see Einhorn LH
Comparison of the Efficacy of Local Therapies for Lamb DJ, see Shariat SF
Localized Prostate Cancer in the Prostate-Specific Lamba J, see Goh B-C
Antigen Era: A Large Single-Institution Experience Lamborn KR, see Donaldson SS
With Radical Prostatectomy and External-Beam Lammertsma AA, see Bos R
Radiotherapy, 3376 Lamont A, see Shepherd FA
Kuperstein G, see Liede A Lamont EB, see Iwashyna TJ
Kurie JM, see Rizvi NA Landman-Parker J, see Perel Y
Kuriyama K, see Imashuku S Landoni F, see Benedetti-Panici P
Kurzawinski TR, see Brett BT Landrum MB, see Keating NL
Kusumoto M, see Sobue T see Silliman RA
Kutok JL, Aster JC. Molecular Biology of Anaplastic Lym- Lang F, see Scheithauer W
phoma Kinase-Positive Anaplastic Large-Cell Lange BJ, see Ruers TJM
Lymphoma, 3691 see Woods WG
Kuttesch JF, see Athale UH
Langenhoff BS, Oyen WJG, Jager GJ, Strijk SP, Wobbes Th,
Kuzel T, see Hinton S
Corstens FHM, Ruers TJM. Efficacy of Fluorine-
Kwan W, Jackson J, Weir LM, Dingee C, McGregor G,
18-Deoxyglucose Positron Emission Tomography
Olivotto IA. Chronic Arm Morbidity After Cura-
in Detecting Tumor Recurrence After Local Abla-
tive Breast Cancer Treatment: Prevalence and Im-
tive Therapy for Liver Metastases: A Prospective
pact on Quality of Life, 4242
Study, 4453
Kwan WH, see Chan ATC
Langer AS, see Winer EP
Kwasny W, see Jakesz R
Kwiatkowski F, see Curé H Langer W, see Keating MJ
Kwok AKH, see Hon C Lanza E, see Shike M
Kwong R, see Leighl NB Laplanche A, see Culine S
Kwong YL, see Chim CS see Patte C
Kyle RA, see Berenson JR Laplante S, see Klasa RJ
see Rajkumar SV Larkin JMG, see Kolomainen DF
Larocca LM, see Teofili L
Laroia ST, Potti A, Rabbani M, Mehdi SA, Koch M. Unusual
Pulmonary Lesions; Case 3. Pulmonary Vein
Leiomyosarcoma Presenting as a Left Atrial Mass,
Laack E, Nikbakht H, Peters A, Kugler C, Jasiewicz Y, Edler Larson RA, see Kornblith AB
L, Brümmer J, Schumacher U, Hossfeld DK. Ex- see Morrison VA
pression of CEACAM1 in Adenocarcinoma of the see Silverman LR
Lung: A Factor of Independent Prognostic Signif-
Larson SM, see Wong RJ
icance, 4279
Lash TL, see Silliman RA
Labianca R, see Cascinu S
Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D,
see Ridolfi R
Griffiths PD, Doz F, Ironside J, Robson K, Hobson
Labopin M, see Ringdén O
R, Dugan M, Pearson ADJ, Vassal G, Frappaz D.
see Rocha V
Temozolomide in Malignant Gliomas of Child-
LaCombe MA. Radiotherapy Dose Escalation in High-Grade
hood: A United Kingdom Children’s Cancer Study
Gliomas (correspondence), 3358
Lacy MQ, see Rajkumar SV Group and French Society for Pediatric Oncology
Lafond D, see Jennings MT Intergroup Study, 4684
Lai M, see Chan ATC Lathan B, see Sieber M
Laidlaw IJ, see Harper-Wynne CL Latkany L, see Shike M
Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Lau C, see Poon RT-P
Osin PP, McGuffog L, Easton DF for the Breast Lau H, see El-Sayed S
Cancer Linkage Consortium. The Pathology of Lau WH, see Chan ATC
Familial Breast Cancer: Predictive Value of Immu- Laughlin MJ, see Rizzieri DA
nohistochemical Markers Estrogen Receptor, Pro- Laurent-Puig P, see Etienne M-C
gesterone Receptor, HER-2, and p53 in Patients Lauriola L, see Ferrandina G
With Mutations in BRCA1 and BRCA2, 2310 see Piantelli M
Lam CCK, see Chim CS Lauwers GY, see Vauthey J-N
Lamagnere J-P, Y on June 28, 2008 . ForLawlor
see Perelfrom
Downloaded personalP,use
No other Suses without permission.
Lamaj E, see Belli F Copyright © 2002 by the American Society of Clinical Oncology.
Lawrence All rights
G, Crawford J, reserved.
Shennan F. Evaluating Neoadju-

vant Chemotherapy in Breast Cancer (correspon- Lee T-R, see Lee H-S
dence), 2905 Lee WR. Quality of Life After Prostate Cancer Treatment
Lazarides SN, see Esnaola NF (correspondence), 3038
Lazarovici D, see Zisman A Lee Y-C, see Yuan A
Lazarus HM, see Berry DA Leer JWH, see Marijnen CAM
Lazzari I, see Belli F Legault S, see Powles T
Leahy TL, see Carducci MA Legge F, see Ferrandina G
Lebas F-X, see Depierre A Leggett BA, see Lindor NM
Lebeau B, see Depierre A Legha SS, see Eton O
Leber B, see Keating MJ Legrand C, see Ardizzoni A
Leblanc T, see Perel Y Lehky T, see Grem JL
LeClerc JM, Billett AL, Gelber RD, Dalton V, Tarbell N, see Wilson RH
Lipton JM, Barr R, Clavell LA, Asselin B, Hurwitz Lehman H, see Datta RV
C, Schorin M, Lipshultz SE, Declerck L, Silverman Lehman MJ, see Orlowski RZ
LB, Cohen HJ, Sallan SE. Treatment of Childhood Lehmann W, see Allal AS
Acute Lymphoblastic Leukemia: Results of Dana- Leibel SA, see Zelefsky MJ
Farber ALL Consortium Protocol 87-01, 237 Leibenhaut M, see Mehta MP
Leclerc P, see Depierre A Leichman CG, see Khushalani NI
Lederlin P, see Fermé C Leichman L, see Khushalani NI
see Gisselbrecht C Leighl NB, Shepherd FA, Goodwin PJ. In Reply (correspon-
Lee H-S, see Goh B-C dence), 3751
Lee H-S, Kim KM, Yoon J-H, Lee T-R, Suh KS, Lee KU, Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R,
Chung JW, Park JH, Kim CY. Therapeutic Efficacy Goodwin PJ. Economic Analysis of the TAX 317
of Transcatheter Arterial Chemoembolization as Trial: Docetaxel Versus Best Supportive Care as
Compared With Hepatic Resection in Hepatocellu- Second-Line Therapy of Advanced Non-Small-Cell
lar Carcinoma Patients With Compensated Liver Lung Cancer, 1344
Function in a Hepatitis B Virus-Endemic Area: A Leikauf GD, see Mohr S
Prospective Cohort Study, 4459 Leis J, see Levine JE
Lee J, see Socinski MA Leissner J, see Kuball J
Lee J-H, see Socinski MA Leitzel K, see Lipton A
Lee J-S, see Lee Jung-Hee Lemarié E, see Depierre A
Lee JE, see Ballo MT Lembersky BC, see Douillard J-Y
see Pisters PWT Lenauer A, see Scheithauer W
Lee Je-Hwan, see Lee Jung-Hee Lens MB, Dawes M. In Reply (correspondence),4121, 4123
Lee JH, Glick HA, Hayman JA, Solin LJ. Decision-Analytic Lens MB, Dawes M. Interferon Alfa Therapy for Malignant
Model and Cost-Effectiveness Evaluation of Post- Melanoma: A Systematic Review of Randomized
mastectomy Radiation Therapy in High-Risk Pre- Controlled Trials, 1818
menopausal Breast Cancer Patients, 2713 Lenzi R, see Baile WF
Lee JJ, see Eton O see Pisters PWT
see Shin DM Leonard GD, Zhuang SH, Grem JL. Epirubicin, Cisplatin,
Lee JS, see Rizvi NA and Protracted Venous-Infusion Fluorouracil in
Lee Jung-Hee, Lee Je-Hwan, Ahn J-H, Bahng H, Kim T-W, Advanced Esophagogastric Cancer (correspon-
Kang Y-K, Lee K-H, Kim J-C, Yu C-S, Kim J-H, dence), 4124
Ahn S-D, Kim W-K, Kim S-H, Lee J-S. Random- Leonard R, see O’Shaughnessy J
ized Trial of Postoperative Adjuvant Therapy in Leone DM, see Timoney JP
Stage II and III Rectal Cancer to Define the Leone G, see Teofili L
Optimal Sequence of Chemotherapy and Radio- Leontovich O, see Lindor NM
therapy: A Preliminary Report, 1751 Leopold KA, see Vokes EE
Lee JY, see Cianfrocca M Lepage E, see Gisselbrecht C
Lee K-H, see Lee Jung-Hee Lerman C, see Berry DA
Lee KU, see Lee H-S see Schwartz MD
Lee S-C, see Biankin AV Lersch C, see Schmelz R
see Goh B-C Lertora JJL, see Rozans M
Lee SJ, see Loberiza FR Jr Lesimple T, see Culine S
see Rizzo JD Lesser G, see Kleinberg L
Lee SM, see Downloaded
Bomanji JBfrom on June 28, 2008 . ForLester E, use
personal seeonly.
other uses without permission.
Lee SW, see Chan JL Copyright © 2002 by the American Society of Clinical Oncology.
Letoublon All rights M-C
C, see Etienne reserved.

Letscher-Bru V, see Herbrecht R Liang R, see Au WY

Leung D, see Alektiar KM see Chim CS
Leung DHY, see Kattan MW Liang RHS, see Hon C
see Stojadinovic A Liang W, Burnett CB, Rowland JH, Meropol NJ, Eggert L,
Leung SF, see Chan ATC Hwang Y-T, Silliman RA, Weeks JC, Mandelblatt
Leung TW, see Chan ATC JS. Communication Between Physicians and Older
Leung W, Rose SR, Zhou Y, Hancock ML, Burstein S, Women With Localized Breast Cancer: Implica-
Schriock EA, Lustig R, Danish RK, Evans WE, tions for Treatment and Patient Satisfaction, 1008
Hudson MM, Pui C-H. Outcome of Growth Hor- Lichinitser MR, see Menssen HD
mone Replacement Therapy in Survivors of Child- Lichtenegger W, see Fuchs IB
hood Acute Lymphoblastic Leukemia, 2959 Lichtin A, see Schover LR
Levavi H, see Chetrit A Lichtin AE, see Rizzo JD
Level M-C, see Depierre A Lie AKW, see Hon C
Levenback C, see Eifel PJ Lieberman IH, see Dudeney S
Levenback C, Coleman RL, Burke TW, Lin WM, Erdman W, Liebisch C, see Fröhling S
Deavers M, Delpassand ES. Lymphatic Mapping Liebmann PM, see Wölfler A
and Sentinel Node Identification in Patients With Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G,
Cervix Cancer Undergoing Radical Hysterectomy Narod SA. Cancer Incidence in a Population of
and Pelvic Lymphadenectomy, 688 Jewish Women at Risk of Ovarian Cancer, 1570
Levenback C, Coleman RL. In Reply (correspondence), 2603 Lieskovsky G, see Graefen M
Leverger G, see Perel Y Lim F, see Ramanathan RK
Lévi F, see Chevalier V Lim H-L, see Goh B-C
see Curé H Lim JF, see Sorensen PHB
Levi M, see Kuenen BC Lim R, see Goh B-C
Levin HS, see Thomas J Lima CMSR, Savarese D, Bruckner H, Dudek A, Eckardt J,
Levin J, see Rivera E Hainsworth J, Yunus F, Lester E, Miller W, Saville
see Schilsky RL W, Elfring GL, Locker PK, Compton LD, Miller
Levin VA, see Groves MD LL, Green MR. Irinotecan Plus Gemcitabine In-
Levin W, see Fyles A duces Both Radiographic and CA 19-9 Tumor
Levine JE, see Yanik GA Marker Responses in Patients With Previously
Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino Untreated Advanced Pancreatic Cancer, 1182
R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Lin DT, see Wong RJ
Leis J, Holmes HE, Johnson M, Horowitz M, Lin PP, see Ahmad SA
Collins RH Jr. Prospective Trial of Chemotherapy Lin WM, see Levenback C
and Donor Leukocyte Infusions for Relapse of Linch DC, see Branson K
Advanced Myeloid Malignancies After Allogeneic Lindner LH, see Wendtner C-M
Stem-Cell Transplantation, 405 Lindor NM, Burgart LJ, Leontovich O, Goldberg RM,
Levine JE, Collins RH Jr. In Reply (correspondence), 2756 Cunningham JM, Sargent DJ, Walsh-Vockley C,
Levine M, see Davidson NE Petersen GM, Walsh MD, Leggett BA, Young JP,
Levine MN, Ganz PA. Beyond the Development of Quality- Barker MA, Jass JR, Hopper J, Gallinger S, Bapat
of-Life Instruments: Where Do We Go From Here? B, Redston M, Thibodeau SN, Cooperative Family
(editorial), 2215 Registry for Colon Cancer Studies. Immunohisto-
Levine MN, Ganz PA. In Reply (correspondence), 4127 chemistry Versus Microsatellite Instability Testing
Levinson J, see Einhorn LH in Phenotyping Colorectal Tumors, 1043
Levitt G, see Owens CM Lingenfelter B, see Frank TS
Levitt R, see Allegra CJ Link M, see Goorin AM
Levoir D, see Louvet C Link MP, see Baker KS
Lewis JJ, see Belli F see Donaldson SS
see Stojadinovic A see Friedmann AM
Leyvraz S, see Stupp R Linker C, Damon L, Ries C, Navarro W. Intensified and
Lhommé C, see Gutierrez M Shortened Cyclical Chemotherapy for Adult Acute
Li FP, see Chen WY Lymphoblastic Leukemia, 2464
see Emmons K Linkesch W, see Jäger G
Li KH, see Au WY see Wölfler A
Li S, see Einhorn LH Linthorst GAM, see de Gast GC
Li X, see Deitcher SR from on June 28, 2008 . ForLioure
Downloaded personal B,useseeonly.
No otherR uses without permission.
Liang BC, see Holmes FA Copyright © 2002 by the American Society of ClinicalI,Oncology.
Lipkus All rights reserved.
see Chlebowski RT

Lippman SM, see Shin DM Livingston PO, see Hwu W-J

Lipshultz LI, see Schover LR Livingston RB, see Albain KS
Lipshultz SE, see LeClerc JM see Ellis GK
Lipshultz SE, Giantris AL, Lipsitz SR, Dalton VK, Asselin Lledo G, see Louvet C
BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi Lo Re G, see Ridolfi R
A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Lobchuk MM, Degner LF. Symptom Experiences: Perceptual
Colan SD. Doxorubicin Administration by Contin- Accuracy Between Advanced-Stage Cancer Pa-
uous Infusion Is Not Cardioprotective: The Dana- tients and Family Caregivers in the Home Care
Farber 91-01 Acute Lymphoblastic Leukemia Pro- Setting, 3495
tocol, 1677 Lobe TE, see Baker KS
Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC II, Shaikh Loberiza FR Jr, Rizzo JD, Bredeson CN, Antin JH, Horowitz
SL, Mone SM, Gelber RD, Colan SD. Long-Term MM, Weeks JC, Lee SJ. Association of Depressive
Enalapril Therapy for Left Ventricular Dysfunction Syndrome and Early Deaths Among Patients After
in Doxorubicin-Treated Survivors of Childhood Stem-Cell Transplantation for Malignant Diseases,
Cancer, 4517 2118
Lipsitz S, see Kemeny MM Locker PK, see Lima CMSR
Lipsitz SR, see Lipshultz SE Lodge MA, see Galbraith SM
Liptay MJ, Grondin SC, Fry WA, Pozdol C, Carson D, Knop Loebbecke M, see Fuchs IB
C, Masters GA, Perlman RM, Watkin W. Intraop- Loeffler JS, see Chakravarti A
erative Sentinel Lymph Node Mapping in Non- Loeffler M, see Sieber M
Small-Cell Lung Cancer Improves Detection of Loehrer PJ Jr, see Von Roenn JH
Micrometastases, 1984 Loehrer PJ Sr, see Hinton S
Lipton A, see Berenson JR
Loesch D, Robert N, Asmar L, Gregurich MA, O’Rourke M,
see Costa L
Dakhil S, Cox E. Phase II Multicenter Trial of a
Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle
Weekly Paclitaxel and Carboplatin Regimen in
L, Harvey HA, Brady C, Nalin CM, Dugan M,
Patients With Advanced Breast Cancer, 3857
Carney W, Allard J. Elevated Serum HER-2/neu
Loffredo M, see D’Amico AV
Level Predicts Decreased Response to Hormone
Lofts F, see Ross P
Therapy in Metastatic Breast Cancer, 1467
Loge JH, see Jordhøy MS
Lipton A, Ali SM, Leitzel K, Engle L, Chinchilli V. In Reply
Logothetis CJ, see Pagliaro LC
(correspondence), 3357
see Papandreou CN
Lipton A, Ali SM, Leitzel K. In Reply (correspondence),
see Siefker-Radtke AO
Logothetis CJ. Challenge of Locally Persistent Prostate Can-
Lipton JH, see Kiss TL
cer: An Unresolved Clinical Dilemma (editorial),
Lipton JM, see LeClerc JM
Lisboa B, see Jonat W 3187
Lister TA, see Radford JA Loh K, see Vose JM
Litchy S, see Greco FA Lohrisch C, see Biganzoli L
Litman H, see Diller L Lombardi AV, see Perrone F
Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Lombardi D, see Spazzapan S
Rapoport B, Epoetin Alfa Study Group. In Reply Lombardo C, see Belli F
(correspondence), 602 London WB, see Katzenstein HM
Litwin A, see Khushalani NI Lones MA, Perkins SL, Sposto R, Tedeschi N, Kadin ME,
Litwin MS, see Burkhardt JH Kjeldsberg CR, Wilson JF, Zwick DL, Cairo MS.
see Wei JT Non-Hodgkin’s Lymphoma Arising in Bone in
Liu D, see Bennett CL Children and Adolescents Is Associated With an
see Kletzel M Excellent Outcome: A Children’s Cancer Group
see Seiter K Report, 2293
see Shin DM Lønning PE, see Geisler J
Liu H-S, see Cheng H-L Lønning PE, Geisler J, Dowsett M. In Reply (correspon-
Liu K-L, see Herbrecht R dence), 3040
Liu-Mares W, see Katzenstein HM Looijenga LHJ, see Kersemaekers A-MF
Liu P-Y, see Green S see Mayer F
see Sondak VK Loos WJ, see Kehrer DFS
see Sosman JA see Mathijssen RHJ
Liver TumorsDownloaded
Study Group of the International
from 28, 2008of. ForLopez
on June M,use
personal seeonly.
ViciNoPother uses without permission.
Pediatric Oncology, © 2002 by the
see Czauderna P American Society of Clinical
Lopez M,Oncology.
Vici P, All
Di rights
L, Carpano S. Increasing Single

Epirubicin Doses in Advanced Soft Tissue Sarco- see Spreafico F

mas, 1329 Luongo M, see Teofili L
Lopez-Graniel CM, see Duenas-Gonzalez A Lust JA, see Rajkumar SV
López-Guillermo A, see Bessell EM Lustig R, see Leung W
Loprinzi CL, see Jatoi A Lutz P, see Herbrecht R
see Sloan JA Lux ML, see Singer S
Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Lyckholm L, see Neff P
Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Lynch CF, see Dores GM
Rummans TA. Phase III Evaluation of Fluoxetine see Potosky AL
for Treatment of Hot Flashes, 157 Lynch HT, see Berry DA
Lorence RM, see Pecora AL Lynch JC, see Sorensen PHB
Lorenz G, see Sucker C see Vose JM
Loretelli C, see Scartozzi M see Weekes CD
Lortholary A, see Culine S
LoRusso P, see Albanell J
LoRusso PM, see Herbst RS M
Lorusso V, see Berruti A
Lotan R, see Shin DM
Ma C, see Chiou WL
Loughran T, see Seiter K
Ma ESK, see Hon C
Louie O, see Hochwald SN
Maas H, see Friberg LE
Louis DN, see Betensky RA Maat APWM, see van der Sijp JRM
Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Määttänen L, see Mäkinen T
Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Mabuchi O, see Yamamoto K
Gramont A. Gemcitabine Combined With Oxali- Macdonald JS, see Kemeny MM
platin in Advanced Pancreatic Adenocarcinoma: see Tepper JE
Final Results of a GERCOR Multicenter Phase II Macdonald JS. Vive La Difference: Sex and Fluorouracil
Study, 1512 Toxicity (editorial), 1439
Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, MacDonald S, see Toso JF
Brunet R, François E, Jacob JH, Levoir D, Taamma Macé-Lesec’h J, see Joly F
A, Rougier P, Cvitkovic E, de Gramont A. Phase II Machin D, see Tan SB
Study of Oxaliplatin, Fluorouracil, and Folinic Machtay M, Glatstein E. Reply 1 (correspondence), 1428
Acid Administered According to the FOLFOX6 Machtay M, Rosenthal DI, Hershock D, Jones H, Williamson
Regimen in Locally Advanced or Metastatic Gas- S, Greenberg MJ, Weinstein GS, Aviles VM,
tric Cancer Patients, 4543 Chalian AA, Weber RS. Organ Preservation Ther-
Love RR, Duc NB, Allred DC, Binh NC, Dinh NV, Kha NN, apy Using Induction Plus Concurrent Chemoradia-
Thuan TV, Mohsin SK, Roanh LD, Khang HX, tion for Advanced Resectable Oropharyngeal Car-
Tran TL, Quy TT, Thuy NV, Thé PN, Cau TT, cinoma: A University of Pennsylvania Phase II
Tung ND, Huong DT, Quang LM, Hien NN, Trial, 3964
Thuong L, Shen T, Xin Y, Zhang Q, Havighurst Machtay M. The Early Rad Catches the Tumor? (editorial),
TC, Yang YF, Hillner BE, DeMets DL. Oophorec- 3045
tomy and Tamoxifen Adjuvant Therapy in Pre- Macis G, see Trodella L
menopausal Vietnamese and Chinese Women With MacKenzie R, see El-Sayed S
Operable Breast Cancer, 2559 Mackenzie S, see Zelek L
Love RR. In Reply (correspondence), 3934 Mackillop WJ, see Huang J
Love RR. Meeting Highlights: International Consensus Panel Mackinlay G, see Czauderna P
on the Treatment of Primary Breast Cancer (corre- Mackinnon S, see Branson K
spondence),879, 1955 see Peggs KS
Lovegren M, see Hensley ML MacLean G, see Pearcey R
Lowe FM, see Harper-Wynne CL Maclean M, see Bélanger K
Lubin F, see Chetrit A MacNamara E, see Andermann A
Lucarelli CD, see Timoney JP MacNeill FA, see Harper-Wynne CL
Lucie NP, see Radford JA Macpherson N, see Mirza I
Luh K-T, see Yuan A Madarnas Y, see Goodwin PJ
Lui W-Y, see O’Shaughnessy J Madden T, see Herbst RS
Luke M, see Abramson N Madden TL, see Herbst RS
Lukka H, seeDownloaded
Pearcey Rfrom on June 28, 2008 . ForMaddox
personal A-M, seeNoHerbst
use only. RS without permission.
other uses
Luksch R, see MassiminoCopyright
M © 2002 by the American Society of ClinicalE,
Madon Oncology. All rights
see Fagioli F reserved.

Madsen LT, see Izawa JI Maneval DC, see Kuball J

Maeder P, see Stupp R Mangioni C, see Benedetti-Panici P
Maggiano N, see Ferrandina G Maniero A, see Douillard J-Y
Magné N, see Etienne M-C Mannel RS, see Bloss JD
Magnusson I, see Edler D Männistö E, see Powles T
Magri MD, see Spazzapan S Manola J, see Kirkwood JM
Maher MM, see McDermott RS Mansfield PF, see Ballo MT
Mahon FX, Delbrel X, Cony-Makhoul P, Fabères C, Boiron Mantovani L, see Kaiser U
JM, Barthe C, Bilhou-Nabéra C, Pigneux A, Marit Mao J, see Toso JF
G, Reiffers J. Follow-Up of Complete Cytogenetic Marangolo M, see Ravaioli A
Remission in Patients With Chronic Myeloid Leu- see Scagliotti GV
kemia After Cessation of Interferon Alfa, 214 Maraninchi D, see Viens P
Mahoney MR, see Allegra CJ Marberger M, see Djavan B
see Goldberg RM Marchianó A, see Belli F
see Hobday TJ Marcus KC, see Donaldson SS
Maibach R, see Bernhard J see Ng AK
Maillard I, see Stupp R Marcus S, see Kruijtzer CMF
Mailliard JA, see Hobday TJ Margaritora S, see Trodella L
see Jatoi A Margolese RG, see Fisher B
see Loprinzi CL Mariani T, see Motzer RJ
Main D, see Schwartz MD Marijnen CAM, Kapiteijn E, van de Velde CJH, Martijn H,
Maio M, see Belli F Steup WH, Wiggers T, Kranenbarg EK, Leer JWH,
Maione P, see Perrone F Cooperative Investigators of the Dutch Colorectal
Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Cancer Group, Acute Side Effects and Complica-
Hickish T, Iveson T, O’Brien M, Tebbutt N, tions After Short-Term Preoperative Radiotherapy
Harrington A, Hill M. Multicenter Randomized Combined With Total Mesorectal Excision in Pri-
Phase III Trial Comparing Protracted Venous Infu- mary Rectal Cancer: Report of a Multicenter Ran-
sion (PVI) Fluorouracil (5-FU) With PVI 5-FU domized Trial, 817
Plus Mitomycin in Inoperable Pancreatic Cancer, Marincola FM, see Toso JF
3130 Marit G, see Cany L
Maki R, see Hensley ML see Mahon FX
Mäkinen T, Tammela TLJ, Stenman U-H, Määttänen L, Markman M, see Alberts DS
Rannikko S, Aro J, Juusela H, Hakama M, Auvinen see Barakat RR
A. Family History and Prostate Cancer Screening see Bloss JD
With Prostate-Specific Antigen, 2658 Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L,
Maksymiuk A, see Klasa RJ Baker M. Phase II Trial of Weekly Single-Agent
Malak SF, see Walshe LJ Paclitaxel in Platinum/Paclitaxel-Refractory Ovar-
Malamos N, see Stathopoulou A ian Cancer, 2365
Malamos NA, see Stathopoulos GP Markman M. Safety Issues in Using Complementary and
Malik AA, see Moazzam N Alternative Medicine, 39s
Malin JL, Schuster MA, Kahn KA, Brook RH. Quality of Markowitz AB, see Vaughn DJ
Breast Cancer Care: What Do We Know?, 4381 Marks AR, see Abramson N
Malin JR, see Pearson ML Marrow M, see Jordon VC
Malingré MM, Beijnen JH, Schellens JHM. In Reply (corre- Marsh JCW, see Branson K
spondence), 1952 Marshall D, see Stojadinovic A
Malkin MG, see Timoney JP Marshall E, see Small EJ
Malkowicz SB, see Cross CK Marshall JL, see Pecora AL
Malogolowkin MH, see Katzenstein HM see Rizvi NA
Maltoni M, see Tassinari D Martell RE, see Ingram SS
Mamounas EP, see Fisher B Martenson J, see Minsky BD
see Winer EP Martenson JA, see Tepper JE
Manchul L, see Fyles A Martijn H, see Marijnen CAM
Mancuso S, see Ferrandina G Martin C, see Carmichael J
Mandelbaum DE, see Jennings MT Martin J, Ginsberg RJ, Venkatraman S, Bains MS, Downey
Mandelblatt JS, see Liang W RJ, Korst RJ, Kris MG, Rusch VW. Long-Term
Mandeli J, see Ferrari AC Results
Downloaded from on June 28, 2008 . For personal use of other
only. No Combined-Modality Therapy in Resect-
uses without permission.
Manegold C, see Ardizzoni Copyright
A © 2002 by the American Society of Clinical Oncology. All rights reserved.
able Non-Small-Cell Lung Cancer, 1989

Martini M, see Teofili L Mauro MJ, O’Dwyer M, Heinrich MC, Druker BJ. STI571: A
Martino B, see Oliva EN Paradigm of New Agents for Cancer Therapeutics,
Martino R, see Levine JE 325
Martins H, see Shepherd FA Mavroudis D, see Souglakos J
Martone M, see Heffernan N see Stathopoulou A
Marty M, see Zelek L Mavroukakis S, see Toso JF
Marx GM, see Steer CB May JT, see Osborne CK
Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat May M, see Josting A
D. Unexpected Serious Toxicity With Chemother- Mayer F, see Kersemaekers A-MF
apy and Antiangiogenic Combinations: Time to Mayer F, Kersemaekers A-M, Oosterhuis JW, Bokemeyer C,
Take Stock! (editorial), 1446 Looijenga LHJ. In Reply (correspondence), 3928
Marymount MH, see Kletzel M Mayer RJ, see Goessling W
Masaki KH, see Rajq V see Tepper JE
Mascaro JM, see Albanell J Mazumdar M, see Dalbagni G
Masi G, see Falcone A see Motzer RJ
Maslak P, see Schwartz GK see Vuky J
Massey V, see Jennings MT Mazza E, see Massimino M
Massimino M, see Spreafico F McCabe M, see Sateren WB
Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro- McCachren S, see Mikulski SM
Tess JD, Gandolo L, Riva D, Ruggiero A, Valentini McCarthy PL Jr, see Berry DA
L, Mazza E, Genitori L, Di Rocco C, Navarria P, McCarthy WH, see Hersey P
Casanova M, Ferrari A, Luksch R, Terenziani M, McCloskey E, see Powles T
Balestrini MR, Colosimo C, Fossati-Bellani F. McCluskey ER, see Deitcher SR
High Response Rate to Cisplatin/Etoposide Regi- McConkey DJ, see Herbst RS
men in Childhood Low-Grade Glioma, 4209 McDermott RS, Maher MM, Dunleavy K, O’Keane CJ, Stack
Master V, see Damani MN JP, Carney DP. Unusual Presentations of Lym-
Masters GA, see Liptay MJ phoma; Case 2. Non-Hodgkin’s Lymphoma Pre-
Masuda N, see Noura S senting as Liver Disease, 1943
Masullo L, see Buchholz TA McGowan TS, see Brierley JD
Matano E, see Scagliotti GV McGregor G, see Kwan W
Mathijssen RHJ, see Kehrer DFS McGuffog L, see Lakhani SR
see Xie R McGuigan K, see Pearson ML
Mathijssen RHJ, Loos WJ, Sparreboom A, Verweij J, Karls- McGuire EJ, see Izawa JI
son MO. In Reply (correspondence), 4609 McGuire W, see Jennings MT
Mathijssen RHJ, Verweij J, de Jonge MJA, Nooter K, Stoter McGuirt C, see Rivera E
G, Sparreboom A. Impact of Body-Size Measures McGuirt PV, see Schilsky RL
on Irinotecan Clearance: Alternative Dosing Rec- McIntyre LM, see Bepler G
ommendations, 81 McKee PH, see Goessling W
Mathôt RAA, see Kruijtzer CMF McLaughlin P, see Rassidakis GZ
see van Kesteren Ch see Sarris AH
Matsui E, see Sobue T McLaughlin PW, see Sanda MG
Matsumoto T, see Noura S see Wei JT
Matsuura N, see Noura S McLendon RE, see Quinn JA
Matthay KK, see Yanik GA see Reardon DA
Matthes S, see Nieto Y McLeod HL. Genetic Strategies to Individualize Supportive
Mattke A, see Ferrari A Care (editorial), 2765
Matulonis U, see Diller L McLeod R, see Hersey P
Mauch P, see Diller L McMillan A, see Smaletz O
Mauch PM, see Ng AK McMullen A, see Hersey P
Maughan T, see Keating MJ McNeely L, see Jennings MT
Maunsell E, Drolet M, Brisson J, Robert J, Deschênes L. McNeese MD, see Buchholz TA
Dietary Change After Breast Cancer: Extent, Pre- McNeish IA, Strickland S, Holden L, Rustin GJS, Foskett M,
dictors, and Relation With Psychological Distress, Seckl MJ, Newlands ES. Low-Risk Persistent Ges-
1017 tational Trophoblastic Disease: Outcome After Ini-
Maurer HM, see Sorensen PHB tial Treatment With Low-Dose Methotrexate and
Mauriac L, see Howell A Folinic
Downloaded from on June 28, 2008 . For personal use Acid
only. No From
other uses1992 to permission.
without 2000, 1838
see O’Shaughnessy J Copyright © 2002 by the American Society of Clinical Oncology.
McQuaker G, see All rights reserved.
Branson K

McSweeney PA, see Nieto Y Menzel C, see Jakesz R

McTiernan A, see Chlebowski RT Merchant TE, see Spunt SL
Meade CD, see Jacobsen PB Mercier RJ, see Rai KR
Meadows AT, see Vaughn DJ Mercuri M, see Ferrari S
Meazza C, see Ferrari A Méresse V, see Viens P
Mechinaud F, see Patte C Meric J-B, see Khayat D
Mechtersheimer G, see Viardot A Meropol NJ, see Liang W
Medeiros LJ, see Rassidakis GZ see Pecora AL
see Sarris AH see Rothenberg ML
Meeks SL, see Buatti JM see Schuchter LM
Mehdi SA, see Laroia ST Merrouche Y, see Culine S
see Moazzam N Mertens AC, see Emmons K
Mehta J, Singhal S. Chronic Graft-Versus-Host Disease After Mesina O, see Rassidakis GZ
Allogeneic Peripheral-Blood Stem-Cell Transplan- see Sarris AH
tation: A Little Methotrexate Goes a Long Way Messinger D, see Österborg A
(correspondence), 603 Messmann R, see Tan AR
Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner Messner HA, see Kiss TL
MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut Mesters RM, see Kaiser U
M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Metayer C, see Dores GM
Renschler MF. Lead-In Phase to Randomized Trial Metzner B, see Kaiser U
of Motexafin Gadolinium and Whole-Brain Radia- Meuli R, see Stupp R
tion for Patients With Brain Metastases: Central- Meyer L, Zuberbier T, Worm M, Oettle H, Riess H. Hyper-
ized Assessment of Magnetic Resonance Imaging, sensitivity Reactions to Oxaliplatin: Cross-Reactiv-
Neurocognitive, and Neurologic End Points, 3445 ity to Carboplatin and the Introduction of a Desen-
Mehta P, see Kaushal V sitization Schedule (correspondence), 1146
Meinhardt P, see Kuball J Meyer M, see Rödel C
Meisner C, see Timmermann B Meyer RM, see Klasa RJ
Melanoma Group, see Mellado B Meyer W, see Athale UH
Melillo G, see Tan AR Meyer WH, see Baker KS
Mellado B, del Carmen Vela M, Colomer D, Gutierrez L, Meyers CA, see Herbst RS
Castel T, Quintó L, Fontanillas M, Reguart N, see Mehta MP
Domingo-Domènech JM, Montagut C, Estapé J, Meyers P. Prognostic Factors for Sarcomas: Hard and Soft
Gascón P. Tyrosinase mRNA in Blood of Patients (editorial), 627
With Melanoma Treated With Adjuvant Interferon, Meyskens F, see Agarwala SS
4032 Meza L, see Holmes FA
Mellon S, see Northouse LL Mezger J, see Kruijtzer CMF
Menczer J, see Chetrit A Miall S, see Harper-Wynne CL
Mendelsohn J. Targeting the Epidermal Growth Factor Re- Miaskowski C. In Reply (correspondence), 2908
ceptor for Cancer Therapy, 1s Michaeli D, see Brett BT
Mendelson D, see Einhorn LH Michel G, see Perel Y
Mendenhall WM, Morris CG, Stringer SP, Amdur RJ, Hin- Michon J, see Patte C
erman RW, Villaret DB, Robbins KT. Voice Re- Mielke S, see Gelderblom H
habilitation After Total Laryngectomy and Postop- Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S,
erative Radiation Therapy, 2500 Taub RN, Chun H, Mittelman A, Panella T, Puccio
Mendoza TR, see Wang XS C, Fine R, Shogen K. Phase II Trial of a Single
Menell JH, see Hwu W-J Weekly Intravenous Dose of Ranpirnase in Patients
Meng MV, see Damani MN With Unresectable Malignant Mesothelioma, 274
Menges M, see Trümper L Milano G, see Etienne M-C
Menssen HD, Sakalová A, Fontana A, Herrmann Z, Boewer Miles D, see O’Shaughnessy J
C, Facon T, Lichinitser MR, Singer CRJ, Euller- Miller AA, see Vokes EE
Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Miller AR, see Esnaola NF
Thiel E, Delmas PD for the Myeloma Ibandronate Miller CB, see Giles FJ
Study Group. Effects of Long-Term Intravenous see Rizzo JD
Ibandronate Therapy on Skeletal-Related Events, Miller ID, see Smith IC
Survival, and Bone Resorption Markers in Patients Miller JR III, see Kashani-Sabet M
With Advancedfrom
Downloaded Multiple Myeloma, on 2353
June 28, 2008 . ForMiller L,use
personal seeonly.
Hudes G uses without permission.
No other
Mentzer SJ, see Esnaola NFCopyright © 2002 by the American Society of Clinical
Miller LL,Oncology. All rights
see Lima CMSR reserved.

Miller RA, see Mehta MP Modè A, see Federico M

Miller V, see Ranson M Modi S, Panageas KS, Duck ET, Bach A, Weinstock N,
Miller W, see Lima CMSR Dougherty J, Cramer L, Hudis C, Norton L, Seid-
Milleron B, see Depierre A man A. Prospective Exploratory Analysis of the
Milligan DW, see Branson K Association Between Tumor Response, Quality of
Millikan RE, see Pagliaro LC Life, and Expenditures Among Patients Receiving
see Siefker-Radtke AO Paclitaxel Monotherapy for Refractory Metastatic
Milosevic M, see Fyles A Breast Cancer, 3665
Minden MD, see Kiss TL Moghrabi A, see Athale UH
Minsky BD. In Reply (correspondence), 3931 see Gururangan S
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Marten- see Lipshultz SE
son J, Komaki R, Okawara G, Rosenthal SA, Mohar A, see Duenas-Gonzalez A
Kelsen DP. INT 0123 (Radiation Therapy Oncol- Mohr S, Leikauf GD, Keith G, Rihn BH. Microarrays as
ogy Group 94-05) Phase III Trial of Combined- Cancer Keys: An Array of Possibilities, 3165
Modality Therapy for Esophageal Cancer: High- Mohsin SK, see Love RR
Dose Versus Standard-Dose Radiation Therapy, Moiseyenko V, see O’Shaughnessy J
1167 Mok T, see Chan ATC
Minsky BD. Sphincter Preservation for Rectal Cancer: Fact Mok TSK, Zee B. Adequate Lymph Node Staging Is Funda-
or Fiction? (editorial), 1971 mental to Comparative Study on Resectable Non-
Miralbell R, see Stupp R Small-Cell Lung Cancer (correspondence), 2604
Mirimanoff RO, see Stupp R Moldawer N, see Zisman A
Mirza A, see Fata F Molier M, see Kersemaekers A-MF
Mirza AN, see Esnaola NF Molina T, see Gisselbrecht C
Mirza I, Macpherson N, Paproski S, Gascoyne RD, Yang B, Moll I, see Thies A
Finn WG, Hsi ED. Primary Cutaneous Follicular Möller P, see Viardot A
Lymphoma: An Assessment of Clinical, His- Molostova V, see Österborg A
topathologic, Immunophenotypic, and Molecular Molthoff CFM, see Bos R
Features, 647 Monchâtre M, see Depierre A
Mirza N, see Vauthey J-N Monden M, see Noura S
Mirza S, see Rubin BP Mone SM, see Lipshultz SE
Misset J-L, see Zelek L Monfardini S, see Repetto L
Mitchell BS, see Orlowski RZ Monk P, see Nadella P
see Rai KR Montagut C, see Mellado B
Mitchell JB, see Coleman CN Montana GS, see Ingram SS
Mitchell M, see Agarwala SS Montgomery JS, see Bennett CL
Mitchell MS, Darrah D, Yeung D, Halpern S, Wallace A, Montie JE, see Wei JT
Voland J, Jones V, Kan-Mitchell J. Phase I Trial of Montserrat E, see Bessell EM
Adoptive Immunotherapy With Cytolytic T Lym- Montz FJ, see Bristow RE
phocytes Immunized Against a Tyrosinase Epitope, Mood D, see Northouse LL
1075 Moore DF Jr, see Siefker-Radtke AO
Mitchell MS. In Reply (correspondence), 3176 Moore JO, see Bass AJ
Mitchell T, see Ahles TA see Rizzieri DA
Mitra N, see Neugut AI Moore M, see Bélanger K
Mitsouli C, see Dimopoulos MA see Holmes FA
Mittelman A, see Mikulski SM see Socinski MA
Miyahara R, see Shoji T Mor V, see Silliman RA
Miyake Y, see Noura S Morán A, see González-Quevedo R
Miyamoto T, see Kamada T Morant R, see Borner MM
Miyasaka K, see Aoyama H Moreira IM, see Mortuza FY
Mizoe J, see Kamada T Morey AL, see Biankin AV
Mlineritsch B, see Jäger G Morgan E, see Kletzel M
see Jakesz R Mori K, see Sekine I
Mo F, see Chan ATC Moringlane JR, see Samnick S
Moazzam N, Malik AA, Mehdi SA, Potti A. Treatment Side Morita S, see Kamada T
Effects; Case 3. Fluorouracil-Induced Exacerbation see Wong JH
of Systemic Lupus Erythematosus, 3032
Downloaded from on June 28, 2008 . For personalT,use
Morita Akechi T,other
only. No Sugawara Y, Chihara
uses without S, Uchitomi Y.
Modan B, see Chetrit A Copyright © 2002 by the American Society of Clinical Oncology.
reserved. of Japanese Oncologists

and Palliative Care Physicians Concerning Termi- Mounier N, Simon D, Haioun C, Gaulard P, Gisselbrecht C.
nal Sedation: A Nationwide Survey, 758 Impact of High-Dose Chemotherapy on Peripheral
Morita T, Shima Y, Adachi I. Attitudes of Japanese Physi- T-Cell Lymphomas (correspondence), 1426
cians Toward Terminal Dehydration: A Nationwide Mouridsen H, Chaudri-Ross HA. In Reply (correspondence),
Survey, 4699 877
Moriyama N, see Sobue T Moynihan TJ, see Fanale MA
Morkas M, Fleming D, Hahl M. Challenges in Oncology; Mross K, see Gelderblom H
Case 2. Radiation Recall Associated With Do- Mueller J, see Rosenberg R
cetaxel, 867 Muggia F, see Alberts DS
Moro G, see Berruti A Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase II Trial
Moro-Sibilot D, see Depierre A of the Pegylated Liposomal Doxorubicin in Previ-
Morra E, see Cesana C ously Treated Metastatic Endometrial Cancer: A
Morris C, see Badros A Gynecologic Oncology Group Study, 2360
see Howell A Mullan BP, see Anderson PM
see Osborne CK Mullani NA, see Herbst RS
see Ranson M Muller MJ, see Detmar SB
Morris CG, see Mendenhall WM Müller P, see Kaiser U
Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Muller RJ, see Timoney JP
Appelbaum FR, Hines JD, Shepherd L, Larson RA, Müller S, see Borner MM
Schiffer CA. Therapy-Related Myeloid Leukemias Multani P, see Witzig TE
Are Observed in Patients With Chronic Lympho- Multani PS, see Witzig TE
cytic Leukemia After Treatment With Fludarabine Mundy GR. Bisphosphonates and Tumor Burden (editorial),
and Chlorambucil: Results of an Intergroup Study, 3191
Cancer and Leukemia Group B 9011, 3878 Munier S, see Carmichael J
Morrissey LH, see Greco FA Munker R, see Sieber M
see Hainsworth JD Murace R, see Santini D
Morrow M, see Singletary SE Murgo AJ, see Tan AR
Morton DL, see DiFronzo LA Muriel AC, see Rauch PK
see Hsueh EC Murphy BA, see Glisson BS
Morton KE, see Toso JF see Motzer RJ
Morton RF, see Goldberg RM Murphy M, see Osoba D
Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, see Seidman A
Gameiro P, Gandini D, Prentice HG, Goldstone A, see Vogel CL
Hoffbrand AV, Foroni L. Minimal Residual Dis- Murray JL, see Esteva FJ
ease Tests Provide an Independent Predictor of Murray PL, see Ranson M
Clinical Outcome in Adult Acute Lymphoblastic Musi M. Lack of Adherence With the Analgesic Regimen:
Leukemia, 1094 The Cancer Patients’ Perspective on a Two-Sided
Moschel RC, see Quinn JA Problem (correspondence), 2907
Mutchnick S, see Sepucha KR
Moser C, see Trümper L
Myeloma Ibandronate Study Group, see Menssen HD
Mota A, see Duenas-Gonzalez A
Myers J, see Shin DM
Motosue AM, see Spunt SL
Mylonakis N, see Kosmidis P
Mott LA, see Ahles TA
Motzer RJ, see Vuky J
Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M,
Reuter V. Treatment Outcome and Survival Asso- N
ciated With Metastatic Renal Cell Carcinoma of
Non-Clear-Cell Histology, 2376 Nabholtz J-M, see Bonneterre J
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Nabid A, see El-Sayed S
Interferon-Alfa as a Comparative Treatment for Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL,
Clinical Trials of New Therapies Against Ad- Thomson J, Kadin ME, Pattengale P, Davis PC,
vanced Renal Cell Carcinoma, 289 Hutchinson RJ, White K. Randomized Comparison
Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, of Low-Dose Involved-Field Radiotherapy and No
Bacik J, Mazumdar M. Phase II Trial of Thalido- Radiotherapy for Children With Hodgkin’s Disease
mide for Patients With Advanced Renal Cell Car- Who Achieve a Complete Response to Chemother-
cinoma, 302 apy, 3765
Moulton T, see Jennings MT
Downloaded from on June 28, 2008 . For personal use see
Nadali G-P, only.Rassidakis
No other usesGZwithout permission.
Mounier N, see Fermé C Copyright © 2002 by the American Society of Clinical Oncology.
Nadella P, Shapiro All V,
rights reserved.GA, Hauger M, Erdal S,

Kraut E, Clinton S, Shah M, Stanek M, Monk P, Neglia JP, see Nagarajan R

Villalona-Calero MA. Pharmacobiologically Based Nekarda H, see Rosenberg R
Scheduling of Capecitabine and Docetaxel Results Nelken B, see Patte C
in Antitumor Activity in Resistant Human Malig- see Perel Y
nancies, 2616 Nelson D, see Shaw E
Nagai K, see Sobue T see Silverman LR
Nagarajan R, Neglia JP, Clohisy DR, Robison LL. Limb Nelson JB, see Carducci MA
Salvage and Amputation in Survivors of Pediatric Nemunaitis J, see Bukowski R
Lower-Extremity Bone Tumors: What Are the see DiPaola RS
Long-Term Implications?, 4493 Nesbitt L, see Fisher B
Nagorney DM, see Vauthey J-N Ness E, see Rizvi NA
Nagtegaal ID, van de Velde CJH, van der Worp E, Kapiteijn Neuberg D, see Diller L
E, Quirke P, van Krieken JHJM. Macroscopic Neuberg DS, see Howard OM
Evaluation of Rectal Cancer Resection Specimen: Neudorf S, see Woods WG
Clinical Significance of the Pathologist in Quality Neugut AI, see Grann VR
Control, 1729 see Hershman D
Nair S, see Sloan JA see Sundararajan V
Nakagawa T, see Shoji T Neugut AI, Fleischauer AT, Sundararajan J, Mitra N, Heitjan
Nakano G, see Rajq V DF, Jacobson JS, Grann VR. Use of Adjuvant
Nakatsuka S, Yao M, Hoshida Y, Yamamoto S, Iuchi K, Chemotherapy and Radiation Therapy for Rectal
Aozasa K. Pyothorax-Associated Lymphoma: A Cancer Among the Elderly: A Population-Based
Review of 106 Cases, 4255 Study, 2643
Nalin CM, see Lipton A Neugut AI, Grann VR. Referral to Medical Oncologists: Are
Namer M, see Jonat W There Barriers at the Gate? (editorial), 1716
Nan B, see Green DM Neumann C, see Kretschmer L
Nancarrow CM, see Diller L Neumann HJ, see Jäger G
Nanni O, see Ridolfi R Neumann PJ, see Earle CC
Narasimhan P, Hitti IF, Gheewala P, Pulakhandam U, Kanzer Neumann TA, see Holmes FA
B. Unusual Presentations of Lymphoma; Case 3. Neumeister P, see Jäger G
Splenic Hematoma Associated With Non- Nevalainen J, see Powles T
Hodgkin’s Lymphoma, 1946 Nevantaus A, see Powles T
Naredi P, see Agarwala SS Newlands ES, see McNeish IA
Narod SA, see Liede A Newman C, see Suarez-Almazor ME
Nasiri N, see Harper-Wynne CL see Viens P
Natarajan-Amé S, see Herbrecht R Newman DJ, see Schwartsmann G
Nathan D, see Bennett CL Newman K, see Katzenstein HM
Nathan PD, Gore ME, Eisen TG. Unexpected Toxicity of Newman RA, see Herbst RS
Combination Thalidomide and Interferon Alfa-2a Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B,
Treatment in Metastatic Renal Cell Carcinoma Marcus KC, Tarbell NJ, Friedberg J, Canellos GP,
(correspondence), 1429 Mauch PM. Long-Term Survival and Competing
Nathanson KL, see Shih HA Causes of Death in Patients With Early-Stage
National Israeli Study of Ovarian Cancer, see Chetrit A Hodgkin’s Disease Treated at Age 50 or Younger,
National Surgical Adjuvant Breast and Bowel Project, see 2101
Fisher B Ng IO-L, see Poon RT-P
Natoli C, see Piantelli M Ngan RK, see Chan ATC
Nava E, see Khushalani NI Nguyen C, see Shariat SF
Nava H, see Khushalani NI Nguyen L, see Friberg LE
Navarria P, see Massimino M Nguyen TV, Trinh GN. Clinical Evaluation of Once-Weekly
Navarro W, see Linker C and Three-Times-Weekly Dosings of Epoetin Alfa
Nawaz S, see Nieto Y in Chemotherapy Patients: Problems of Study De-
Nease RF Jr, see Kilbridge KL sign and Interpretation (correspondence), 878
Nebraska Lymphoma Study Group, see Weekes CD Nicholls J, see Chim CS
Neeleman N, see Ruers TJM Nicholls JM, see Chim CS
Neff P, Lyckholm L, Smith T. Truth or Consequences: What Nichols C, see Vose JM
to Do When the Patient Doesn’t Want to Know, Nichols CR, see Bokemeyer C
Downloaded from on June 28, 2008 . ForNichols
personalD,usesee Shaw
only. E uses without permission.
No other
Neftel KA, see Emmenegger Copyright
U © 2002 by the American Society of Clinical Oncology.
Nicholson RI, see All rights reserved.
Albanell J

Nicolaides C, see Kosmidis P Transcriptase Polymerase Chain Reaction and Im-

Nicolaou N, see Freedman GM munohistochemistry, 4232
Nicolini M, see Ravaioli A Novick SC, see Orlowski RZ
Nicolson M, see Ross P Novotny PJ, see Jatoi A
Niebel W, see Kröger K see Loprinzi CL
Nieder C. Treatment of Newly Diagnosed Glioblastoma see Sloan JA
Multiforme (correspondence), 3179 Novotny WF, see Vogel CL
Niedzwiecki D, see Tepper JE Noyes RD, see Sondak VK
Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, Nozza A, see Bertuzzi A
McSweeney PA, Barón A, Razook C, Matthes S, Nuzzo F, see Berruti A
Bearman SI. Prognostic Model for Relapse After Nyquist L, see Wei JT
High-Dose Chemotherapy With Autologous Stem-
Cell Transplantation for Stage IV Oligometastatic
Breast Cancer, 707 O
Niezgodzki G, see Curé H
Nikbakht H, see Laack E
Oates RD, see Damani MN
Nishiwaki Y, see Sekine I
Oberhuber G, see Birner P
see Takada M
Oberlin O. When Quality of Life Is the Major Challenge
Nishiyama H, see Sobue T
(editorial), 3051
Nissan A, see Stojadinovic A
Oberling F, see Viens P
Nitschke R. The Art of Oncology: When the Tumor Is Not O’Brien M, see Maisey N
the Target—The Power of Silence (correspon- O’Brien MER, see Waters JS
dence), 1952 O’Brien SM, see Giles FJ
Nobile F, see Oliva EN Ochs J, see Herbst RS
Noda K, see Takada M see Ranson M
Noll E, see Chakravarti A O’Connell M, see Tepper JE
Nomdedeu B, see Bessell EM O’Connell MJ, see Allegra CJ
Nooijen W, see de Gast GC see Goldberg RM
Noordhuis P, see Kuenen BC see Hobday TJ
Nooter K, see Mathijssen RHJ see Sloan JA
Nordle O, see Hudes G O’Connor OA, see Orlowski RZ
Nordlinger B, Rougier P. Liver Metastases From Colorectal O’Day SJ, see Agarwala SS
Cancer: The Turning Point (editorial), 1442 see DiFronzo LA
Norman A, see Maisey N see Hsueh EC
see Ross P Odchimar-Reissig R, see Kornblith AB
Normolle DP, see Chan JL see Silverman LR
Northouse LL, Mood D, Kershaw T, Schafenacker A, Mellon Odom L, see Heffernan N
S, Walker J, Galvin E, Decker V. Quality of Life of O’Dwyer M, see Mauro MJ
Women With Recurrent Breast Cancer and Their O’Dwyer PJ, see Kemeny MM
Family Members, 4050 see Stevenson JP
Nortier JWR, see Littlewood TJ Oettle H, see Meyer L
Nortilli R, see Ridolfi R O’Fallon J, see Shaw E
Norton L, see Berry DA Offit K, see Scheuer L
see Guidi AJ Ogino T, see Sekine I
see Modi S Ogston KN, see Smith IC
see Scheuer L Ohmatsu H, see Sobue T
see Van Poznak C Ohnishi T, see Noura S
Norwegian Lung Cancer Study Group, see Sundstrøm S Ohori M, see Cagiannos I
Norwood TH, see Rubin BP Ohta S, see Yamamoto K
Nosari AM, see Cesana C Okawara G, see Minsky BD
Nosrati M, see Kashani-Sabet M O’Keane CJ, see McDermott RS
Nottage M, Siu LL. Principles of Clinical Trial Design, 42s Olejnik T, see Witzig TE
Noura S, Yamamoto H, Ohnishi T, Masuda N, Matsumoto T, Oliva EN, D’Angelo A, Martino B, Nobile F, Dimitrov BD,
Takayama O, Fukunaga H, Miyake Y, Ikenaga M, Perna A. More Concern About Transfusion Re-
Ikeda M, Sekimoto M, Matsuura N, Monden M. quirement When Evaluating Quality of Life in
Comparative Detection of Lymph Node Microme- Anemic
Downloaded from on June 28, 2008 . For personal use Patients
only. No (correspondence),
other uses 3182
without permission.
tastases of StageCopyright © 2002 Cancer
II Colorectal by the American Society of
by Reverse ClinicalRTD,
Oliver Oncology. All rights
Shamash J, reserved.
Berney DM. p53 and MDM2 in

Germ Cell Cancer Treatment Response (correspon- Mucosa-Associated Lymphoid Tissue Lymphoma
dence), 3928 of the Bladder After Antibiotic Therapy (corre-
Oliver T, see Warde P spondence), 882
Oliverio G, see Ravaioli A O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub
Olivotto IA, see Kwan W J-P, Cervantes G, Fumoleau P, Jones S, Lui W-Y,
see Van Patten CL Mauriac L, Twelves C, Van Hazel G, Verma S,
see Weir L Leonard R. Superior Survival With Capecitabine
Ollila DW, see Hsueh EC Plus Docetaxel Combination Therapy in Anthracy-
O’Neil JD, see Pecora AL cline-Pretreated Patients With Advanced Breast
O’Neill A, see Kleinberg L Cancer: Phase III Trial Results, 2812
O’Neill B, see Shaw E O’Shaughnessy JA, see Holmes FA
O’Neill V, see Vasey PA Osin PP, see Lakhani SR
Oneschuk D, see Watanabe S Osman I, Sherman E, Singh B, Venkatraman E, Zelefsky M,
Ong A-B, see Goh B-C Bosl G, Scher H, Shah J, Shaha A, Kraus D,
Oo TH, Aish LS, Hassoun H. Unusual Presentations of Cordon-Cardo C, Pfister DG. Alteration of p53
Lymphoma; Case 1. Sea-Blue Histiocytes in Non- Pathway in Squamous Cell Carcinoma of the Head
Hodgkin’s Lymphoma, 1942 and Neck: Impact on Treatment Outcome in Pa-
Ooi CGC, see Au WY tients Treated With Larynx Preservation Intent,
Ooi GC, see Chim CS 2980
Oosterhuis JW, see Kersemaekers A-MF Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on
see Mayer F Quality of Life of Combined Trastuzumab and
Oprea C, see Herbrecht R Chemotherapy in Women With Metastatic Breast
Order SE, Court W. When the Mirror Doesn’t Reflect It at All
Cancer, 3106
(correspondence), 1144
Österborg A, Brandberg Y, Molostova V, Iosava G,
O’Reilly E, see Schwartz GK
Abdulkadyrov K, Hedenus M, Messinger D for
O’Reilly MS, see Herbst RS
the Epoetin Beta Hematology Study Group. Ran-
O’Reilly SE, see Shenkier TN
domized, Double-Blind, Placebo-Controlled
Orel SG, see Tillman GF
Trial of Recombinant Human Erythropoietin,
Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC,
Epoetin Beta, in Hematologic Malignancies,
Baldwin AS, Stahl S, Adams J, Esseltine D-L,
Elliott PJ, Pien CS, Guerciolini R, Anderson JK,
Ostermann-Kraljevic S, see Stupp R
Depcik-Smith ND, Bhagat R, Lehman MJ, Novick
O’Sullivan B, see Brierley JD
SC, O’Connor OA, Soignet SL. Phase I Trial of the
see Davis AM
Proteasome Inhibitor PS-341 in Patients With Re-
O’Sullivan J, see Green S
fractory Hematologic Malignancies, 4420
Ornstein DL, see Garrison MA Otake Y, see Shoji T
O’Rourke M, see Loesch D Ott G, see Viardot A
Ortega JA, see Katzenstein HM Ottaiano A, see Perrone F
Ortmann E, Hohenberg G. In Reply (correspondence), 4130 Otte JB, see Czauderna P
Ortmann E, Hohenberg G. Treatment Side Effects; Case 1. Otterson GA, see Nadella P
Radiation Recall Phenomenon After Administra- Ottestad L, see Powles T
tion of Capecitabine, 3029 Owen RG. Extramedullary Sites of Involvement in Hema-
Osaki T, Oyama T, Gu C-D, Yamashita T, So T, Takenoyama tologic Malignancies; Case 2. Lymphocyte Mor-
M, Sugio K, Yasumoto K. Prognostic Impact of phology in Splenic Marginal Zone Lymphoma,
Micrometastatic Tumor Cells in the Lymph Nodes 342
and Bone Marrow of Patients With Completely Re- Owens CM, Veys PA, Pritchard J, Levitt G, Imeson J,
sected Stage I Non-Small-Cell Lung Cancer, 2930 Dicks-Mireaux C. Role of Chest Computed To-
Osborne C, see Du XL mography at Diagnosis in the Management of
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come Wilms’ Tumor: A Study by the United Kingdom
S, Gertler SZ, May JT, Burton G, Dimery I, Children’s Cancer Study Group, 2768
Webster A, Morris C, Elledge R, Buzdar A. Dou- Oyama T, see Osaki T
ble-Blind, Randomized Trial Comparing the Effi- Oyen WJG, see Langenhoff BS
cacy and Tolerability of Fulvestrant Versus Anas- see Ruers TJM
trozole in Postmenopausal Women With Advanced Oza A, see Carmichael J
Breast Cancer Progressing on Prior Endocrine Ozols RF. Recurrent Ovarian Cancer: Evidence-Based Treat-
Therapy: Results
a North American Trial,
on June ment
3386. For personal use
28, 2008 (editorial),
only. 1161
No other uses without permission.
Oscier D, Bramble J, HodgesCopyright
E, ©Wright
2002 byD.
American Society
of of Clinical Oncology.
Ozyilkan All rightsSreserved.
O, see Saglam

P Park JH, see Lee H-S

Park MS, see Sosman JA
Parker A, see Branson K
Padhani AR, see Galbraith SM
Parker LM, see Osborne CK
Padilla G, see Sarna L
Parker PA, see Baile WF
Padley RJ, see Carducci MA
Parkinson DR, see Schwartsmann G
Padre N, see Witzig TE
Parma G, see Cantù MG
Paganini-Hill A, see Ursin G
Parmiani G, see Belli F
Page DL, see Singletary SE
Parmigiani G, see Berry DA
Page E, Assouline D, Brun O, Coeffic D, Fric D, Winckel P.
Parnes H, see Berry DA
Cardiac Dysfunction in Clinical Trials of Trastu-
Parodi S, see Repetto L
zumab (correspondence), 4119
Parr AL, see Allegra CJ
Pagliaro LC, Millikan RE, Tu S-M, Williams D, Daliani D,
Parra HS, see Bertuzzi A
Papandreou CN, Logothetis CJ. Cisplatin, Gemcitab-
Parson MRN, see Kuenen BC
ine, and Ifosfamide As Weekly Therapy: A Feasibil-
Parwaresch R, see Kaiser U
ity and Phase II Study of Salvage Treatment for
Pasquini E, see Ravaioli A
Advanced Transitional-Cell Carcinoma, 2965
Passik S, see Heffernan N
Pagnucco G, see Federico M
Pastorino U, see De Pas T
Paik S, see Fisher B
Paillot N, see Depierre A Patchell RA, see Mehta MP
Pajak TF, see Minsky BD Patel SG, see Wong RJ
Pajunen M, see Powles T Patel SR, see Ahmad SA
Palchak D, see Small EJ Pater J, see Davis AM
Palmer JL, see Bruera E see El-Sayed S
see Sweeney C see Roche K
Palmer M, see Jonat W Paterson S, see Powles T
Palmer PA, see Crul M Patnaik A, see de Bono JS
Palmero A, see Fagioli F Paton V, see Seidman A
Panageas KS, see Modi S Patte C, Laplanche A, Bertozzi AI, Baruchel A, Frappaz D,
Panageas KS, see Hwu W-J Schmitt C, Mechinaud F, Nelken B, Boutard P,
see Van Poznak C Michon J. Granulocyte Colony-Stimulating Factor
Panasci LC. HER-2/neu Serum Levels Vis-à-Vis Hormonal in Induction Treatment of Children With Non-
Response in Metastatic Breast Cancer (correspon- Hodgkin’s Lymphoma: A Randomized Study of the
dence), 3357 French Society of Pediatric Oncology, 441
Panella T, see Mikulski SM Patten CA, see Cox LS
Pangalis GA, see Rassidakis GZ Pattengale P, see Nachman JB
Pantuck AJ, see Zisman A Paul EM, see Kruijtzer CMF
Panzarella T, see Brierley JD Paul N, see Roche K
see Warde P Pauli G, see Iamandi C
Panzini I, see Ravaioli A Paulino AC. Induction Chemotherapy and Involved-Field
see Tassinari D Radiotherapy for Intracranial Germinoma, 2911
Papadopoulos NE, see Ballo MT Paulus U, see Sieber M
see Eton O Pautier P, see Gutierrez M
Papadopoulos T, see Rödel C Pavlakis N, see Marx GM
Papaioannou M, see Mortuza FY Payne N, see Bass AJ
Papakostas P, see Kosmidis P Payne S, see Smith IC
Papandreou CN, see Pagliaro LC Pazdur R, see Schilsky RL
Papandreou CN, Daliani DD, Thall PF, Tu S-M, Wang X, see Schwartsmann G
Reyes A, Troncoso P, Logothetis CJ. Results of a Peabody EM, see Green DM
Phase II Study With Doxorubicin, Etoposide, and Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D,
Cisplatin in Patients With Fully Characterized Lukka H, MacLean G, Souhami L, Stuart G, Tu D.
Small-Cell Carcinoma of the Prostate, 3072 Phase III Trial Comparing Radical Radiotherapy
Papies A, see Kaiser R With and Without Cisplatin Chemotherapy in Pa-
Pappo AS, see Spunt SL tients With Advanced Squamous Cell Cancer of the
Paproski S, see Mirza I Cervix, 966
Paradis A-J, see Cremin C Pearlman J, see Kleinberg L
M, see Antonadou D
from on June 28, 2008 . ForPearson
personalADJ, seeNo
use only. Lashford LSwithout permission.
other uses
Park J, see Press MF Copyright © 2002 by the American Society of Clinical ML,
Pearson Oncology.
reserved. K, Malin JR, Adams J,

Kahn KL. The Case Identification Challenge in Perry MC, see Berry DA
Measuring Quality of Cancer Care, 4353 see Vokes EE
Pecora A, see Berry DA Peshkin BN, see Berry DA
Pecora AL, Rizvi N, Cohen GL, Meropol NJ, Sterman D, see Schwartz MD
Marshall JL, Goldberg S, Gross P, O’Neil JD, Pestalozzi BC, see Borner MM
Groene WS, Roberts MS, Rabin H, Bamat MK, Pestalozzi BC. Looking at the Dying Patient: The Ferdinand
Lorence RM. Phase I Trial of Intravenous Admin- Hodler Paintings of Valentine Godé-Darel, 1948
istration of PV701, an Oncolytic Virus, in Patients Pestalozzi BC. Oxaliplatin: Bimonthly, Biweekly, or Semi-
With Advanced Solid Cancers, 2251 monthly? (correspondence), 2758
Pegg AE, see Quinn JA Peterman A, see Socinski MA
Peggs KS, Mackinnon S, Yong K. Reduced Intensity Condi- Peters A, see Laack E
tioning and Allogeneic Stem-Cell Transplantation: Peters GJ, see Kuenen BC
Determining Its Role in Multiple Myeloma (corre- Peters L, see Rischin D
spondence), 4268 Peters LJ, see Rischin D
Pegram CN, see Reardon DA Peters MEWJ, see de Jonge MJA
Peltomäki P, see Percesepe A Petersen GM, see Lindor NM
Pendyala L, see Khushalani NI Petersen JH, see Petersen PM
Penn Cancer Center Clinical Trials Group, see Machtay M Petersen PM, Giwercman A, Daugaard G, Rørth M, Petersen
Pensabene M, see Perrone F JH, Skakkebæk NE, Hansen SW, von der Maase H.
Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Ayers GD, Effect of Graded Testicular Doses of Radiotherapy
Herbst RS, Abbruzzese JL. Study of the Media’s in Patients Treated for Carcinoma-In-Situ in the
Potential Influence on Prospective Research Partic- Testis, 1537
ipants’ Understanding of and Motivations for Par- Peterson BL, see Morrison VA
ticipation in a High-Profile Phase I Trial, 3785 see Silverman LR
Pény J, see Joly F Peterson N, see Wang XS
Penz M, see Jäger G Peterson P, see Groves MD
Penza SL, see Levine JE Peterson S, see Green DM
Percesepe A, Ponz de Leon M, Peltomäki P. In Reply Petit J, see Bessell EM
(correspondence), 1706 Petros W, see Rizvi NA
Perel Y, Auvrignon A, Leblanc T, Vannier J-P, Michel G, Petros WP, see Rizzieri DA
Nelken B, Gandemer V, Schmitt C, Lamagnere J-P, Petrylak D, see Small EJ
De Lumley L, Bader-Meunier B, Couillaud G, Pettengell R, see Branson K
Schaison G, Landman-Parker J, Thuret I, Dalle J-H, Pezet D, see Curé H
Baruchel A, Leverger G for the Group LAME of see Etienne M-C
the French Society of Pediatric Hematology and Pezzella G, see Vici P
Immunology. Impact of Addition of Maintenance Pfab R, see Kaiser U
Therapy to Intensive Induction and Consolidation Pfanner E, see Falcone A
Chemotherapy for Childhood Acute Myeloblastic Pfister DG, see Chlebowski RT
Leukemia: Results of a Prospective Randomized see Osman I
Trial, LAME 89/91, 2774 see Wong RJ
Perez EA, see Loprinzi CL Pfistner B, see Sieber M
Perez EA. In Reply (correspondence), 4405 Pfreundschuh M, see Kaiser U
Pergantas N, see Stathopoulos GP see Sieber M
Perilongo G, see Czauderna P see Trümper L
Perkins G, see Buchholz TA Phan A, see Sarris AH
Perkins P, see Schwartz GK Phan S, see Mehta MP
Perkins SL, see Lones MA Phillips E, see Eder JP Jr
Perlman RM, see Liptay MJ Phillips P, see Kleinberg L
Perna A, see Oliva EN Piantelli M, Iacobelli S, Almadori G, Iezzi M, Tinari N,
Perotti J, see Winer EP Natoli C, Cadoni G, Lauriola L, Ranelletti FO.
Perpoint B, see Curé H Lack of Expression of Galectin-3 Is Associated
Perraki M, see Stathopoulou A With a Poor Outcome in Node-Negative Patients
Perrone F, De Maio E, Maione P, Di Maio M, Ottaiano A, With Laryngeal Squamous-Cell Carcinoma, 3850
Pensabene M, Di Lorenzo G, Lombardi AV, Gallo Pica A, see Stupp R
C. Survey of Modalities of Toxicity Assessment Piccart MJ, see Biganzoli L
Noncomparative Prospective
on June 28, 2008 . ForPicci P, see
personal use Fagioli
only. No F
other uses without permission.
Copyright © in
Studies of Chemotherapy 2002 by theCancer,
Breast American
52Society of Clinical
Pien CS,Oncology. All rights
see Orlowski RZreserved.

Piepkorn M, see Disis ML see Gandhi V

Pierotti MA, see Daidone MG Pohlman BL, see Witzig TE
Pierri MK, see Seidman A Polastri D, see Spreafico F
see Seidman AD Pollack IF, see Jennings MT
Pietsch T, see Timmermann B Pollock RE, see Ahmad SA
Piga A, see Porfiri E Polyp Prevention Trial Study Group, see Shike M
see Scartozzi M Pont J, see Bokemeyer C
Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester Ponz de Leon M, see Percesepe A
R, Therasse P, Áfra D, Cornu P, Bolla M, Vecht C, Pool GE, see Smith TJ
Karim ABMF. Prognostic Factors for Survival in Poon MA, see Sloan JA
Adult Patients With Cerebral Low-Grade Glioma, Poon RT-P, Ng IO-L, Lau C, Yu W-C, Yang Z-F, Fan S-T,
2076 Wong J. Tumor Microvessel Density as a Predictor
Pigneux A, see Mahon FX of Recurrence After Resection of Hepatocellular
Pike MC, see Ursin G Carcinoma: A Prospective Study, 1775
Pilla L, see Belli F Poor C, see Howard OM
Pilz T, see Ferrari A Popiela T, see Carmichael J
Pinedo HM, see Kuenen BC Poplin EA, see Rothenberg ML
Pintilie M, see Fyles A Porchet F, see Stupp R
see Vallis KA Porfiri E, see Scartozzi M
Pippen J, see Osborne CK Porfiri E, Scartozzi M, Piga A, Cellerino R. In Reply
Piris A, see Belli F (correspondence), 3178
Pisanksy TM, see Fisher B Portenoy RK, see Indelicato RA
Pisansky TM, see Minsky BD Portenoy RK, Indelicato RA. In Reply to Daniell and Wa-
Pisconti S, see Vici P tanabe et al (correspondence), 2409
Pisters LL, see Izawa JI Porter DL, see Levine JE
Pisters PWT, see Ahmad SA Possinger K, see Kaiser R
Pisters PWT, Wolff RA, Janjan NA, Cleary KR, Charnsangavej see Sezer O
C, Crane CN, Lenzi R, Vauthey JN, Lee JE, Abbruzz- Postmus PE, see Ardizzoni A
ese JL, Evans DB. Preoperative Paclitaxel and Con- see Codrington H
current Rapid-Fractionation Radiation for Resectable see Kunst PWA
Pancreatic Adenocarcinoma: Toxicities, Histologic Postmus PE, Sutedja T. In Reply (correspondence), 4269
Response Rates, and Event-Free Outcome, 2537 Potosky AL, see Warren JL
Pitot HC, see Adjei AA Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF.
Pitterle DM, see Bepler G Age, Sex, and Racial Differences in the Use of
Piura B, see Chetrit A Standard Adjuvant Therapy for Colorectal Cancer,
Piva L, see Ferrari A 1192
Pizzichetta MA, Canzonieri V, Gatti A, de Giacomi C, Potter DM, see Ramanathan RK
Trevisan G, Veronesi A, Soyer HP. Skin Lesions in Potti A, see Laroia ST
Melanoma and Kaposi’s Sarcoma; Case 2. Dermo- see Moazzam N
scopic Features of Metastases From Cutaneous Pouillard P, see Viens P
Melanoma Mimicking Benign Nevi and Primary Pounder RE, see Brett BT
Melanoma, 1412 Powell BL, see Kornblith AB
Pizzolato G, see Stupp R see Silverman LR
Pizzolo G, see Rassidakis GZ Powles R, see Rocha V
Plager C, see Eton O Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S,
Planting AST, see de Jonge MJA Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S,
Plaschkes J, see Czauderna P Pajunen M, Nevantaus A, Männistö E, Suovuori A,
see Katzenstein HM Atula S, Nevalainen J, Pylkkänen L. Randomized,
Platt LD, see Liede A Placebo-Controlled Trial of Clodronate in Patients
Platzer E, see Viens P With Primary Operable Breast Cancer, 3219
Pluda J, see Herbst RS Powles TJ, see Winer EP
see Quinn JA Poyner R, see Seymour LW
Pluda JM, see Cianfrocca M Poynor EA, see Dizon DS
Plummer R, see Hughes A Pozdol C, see Liptay MJ
Plunkett TA, Ellis PA. CEACAM1: A Marker With a Pratt C, see Athale UH
Difference or More
Downloaded of the Same? on
from (editorial), 4273. For personal
June 28, 2008 see Furman WL
use only. No other uses without permission.
Plunkett W, see Crews KR Copyright © 2002 by the American Society of Clinical
Pratt CB,Oncology. All SL
see Spunt rights reserved.

Prentice HG, see Mortuza FY Q

Press M, see Vogel CL
Press MF, Bernstein L, Flonn K, Slamon D. In Reply Quagliuolo V, see Bertuzzi A
(correspondence), 4607 Qualman SJ, see Baker KS
Press MF, Slamon DJ, Flom KJ, Park J, Zhou J-Y, Bernstein see Sorensen PHB
L. Evaluation of HER-2/neu Gene Amplification Quang LM, see Love RR
and Overexpression: Comparison of Frequently Quehenberger F, see Jäger G
Used Assay Methods in a Molecularly Character- Queirolo P, see Belli F
ized Cohort of Breast Cancer Specimens, 3095 Quella SK, see Loprinzi CL
Price A, see Camidge R Quesnel B, see Gisselbrecht C
Price DK, see Bennett CL Quijano E, see Kuball J
Price T, see Ross P Quinn CJ, see Hwu W-J
Price T, Karapetis C. Chronomodulated Chemotherapy in Quinn DI, see Graefen M
Advanced Colorectal Carcinoma (correspondence), Quinn JA, see Reardon DA
3937 Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN,
Friedman AH, Reardon DA, Sampson JH, Colvin
Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera E,
OM, Haglund MM, Pegg AE, Moschel RC,
Gastó C. Psychiatric Morbidity and Impact on
McLendon RE, Provenzale JM, Gururangan S,
Hospital Length of Stay Among Hematologic Can-
Tourt-Uhlig S, Herndon JE II, Bigner DD, Fried-
cer Patients Receiving Stem-Cell Transplantation,
man HS. Phase II Trial of Carmustine Plus O6-
Benzylguanine for Patients With Nitrosourea-Re-
Prieto VG, see Ballo MT
sistant Recurrent or Progressive Malignant Glioma,
see Ellerhorst JA 2277
Prior JC, see Van Patten CL Quinn JJ, see Katzenstein HM
Pritchard J, see Czauderna P Quinn M, see Grem JL
see Owens CM Quinn MG, see Wilson RH
Pritchard KI, see Goodwin PH Quintó L, see Mellado B
see Winer EP Quirke P, see Nagtegaal ID
Pritchard KI. Adjuvant Therapy for Premenopausal Women Quoix E, see Depierre A
With Breast Cancer: Is It Time for Another Para- see Iamandi C
digm Shift? (editorial), 4611 Quy TT, see Love RR
Proper J, see Eder JP Jr
Prosnitz LR. Reducing Treatment-Related Morbidity and
Mortality in Early-Stage Hodgkin’s Disease and R
Why the Recent Southwest Oncology Group Trial
Is Not the Way to Go (editorial), 2225 Raanani P, Goldman JM, Ben-Bassat I. Challenges in Oncol-
Proulx G, see Khushalani NI ogy; Case 3. Depigmentation in a Chronic Myeloid
Provenzale JM, see Quinn JA Leukemia Patient Treated With STI-571, 869
see Reardon DA Rabbani F, see Cagiannos I
Pruss DR, see Frank TS see Dalbagnni G
Pruthi S, see Loprinzi CL Rabbani F, Herr HW, Almahmeed T, Russo P. Temporal
Puccio C, see Mikulski SM Change in Risk of Metachronous Contralateral
Puchalski TA, see Eder JP Jr Renal Cell Carcinoma: Influence of Tumor Char-
Puduvalli VK, see Groves MD acteristics and Demographic Factors, 2370
see Herbst RS Rabbani M, see Laroia ST
Pui C-H, see Crews KR Rabin H, see Pecora AL
see Leung W Rademaker AW, see Kletzel M
see Rubnitz JE Rader JS, see Bloss JD
Pukkala E, see Dores GM Raderer M, see Jäger G
Pulakhandam U, see Narasimhan P see Scheithauer W
Pundaleeka S, see Jatoi A Radford JA, Rohatiner AZS, Ryder WDJ, Deakin DP, Barbui
Pungolino E, see Cesana C T, Lucie NP, Rossi A, Dunlop DJ, Cowan RA,
Wilkinson PM, Gupta RK, James RD, Shamash J,
Punt C, see van Kesteren Ch
Chang J, Crowther D, Lister TA. ChlVPP/EVA
Punt CJA, see de Jonge MJA
Hybrid Versus the Weekly VAPEC-B Regimen for
Pusztai L, see Esteva FJ
Previously Untreated Hodgkin’s Disease, 2988
Pylkkänen L,Downloaded
see Powlesfrom
on June 28, 2008 . For personal use
© 2002 by the American Society of
only. No other
ClinicalP,Oncology. All rights
uses without permission.
Radice see Daidone MGreserved.

Radstone D, see Carmichael J Rassidakis GZ, see Sarris AH

Raffin L, see Toffoli G Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali
Ragnhammar P, see Edler D G-P, Vassilakopoulos TP, Mesina O, Herling M,
Rago R, see Small EJ Angelopoulou MK, Giardini R, Chilosi M, Kittas
Rai K, see Keating MJ C, McLaughlin P, Rodriguez MA, Romaguera J,
Rai KR, see Morrison VA Bonadonna G, Gianni AM, Pizzolo G, Pangalis
Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, GA, Cabanillas F, Sarris AH. CD20 Expression in
Stadtmauer EA, Santábarbara P, Wacker B, Brett- Hodgkin and Reed-Sternberg Cells of Classical
man L. Alemtuzumab in Previously Treated Hodgkin’s Disease: Associations With Presenting
Chronic Lymphocytic Leukemia Patients Who Features and Clinical Outcome, 1278
Also Had Received Fludarabine, 3891 Ratain M, see Karrison T
Raimondi SC, see Crews KR see Rosner GL
see Rubnitz JE see Schellens JHM
Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy see Schilsky RL
MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, see Schwartsmann G
Lust JA, Kyle RA, Witzig TE. Combination Ther- see Small EJ
apy With Thalidomide Plus Dexamethasone for Ratain MJ. Dear Doctor: We Really Are Not Sure What Dose
Newly Diagnosed Myeloma, 4319 of Capecitabine You Should Prescribe for Your
Rajq V, China C, Masaki KH, Nakano G. Unusual Presenta- Patient (editorial), 1434
tions of Uncommon Tumors; Case 1. Benign Me- Ratain MJ. Irinotecan Dosing: Does the CPT in CPT-11
tastasizing Pleomorphic Adenoma, 2400 Stand for “Can’t Predict Toxicity”? (editorial), 7
Rakowski W, see Silliman RA Ratner L, see Cianfrocca M
Ramanathan RK, Potter DM, Belani CP, Jacobs SA, Graven- Rattner B, see Eder JP Jr
stein S, Lim F, Kim H, Savona S, Evans T, Rauch PK, Muriel AC, Cassem NH. Parents With Cancer:
Buchbarker D, Simon MB, Depee JK, Trump DL. Who’s Looking After the Children?, 4399
Randomized Trial of Influenza Vaccine With Gran- Rauck RL, see Smith TJ
ulocyte-Macrophage Colony-Stimulating Factor or Ravaioli A, see Tassinari D
Placebo in Cancer Patients, 4313 Ravaioli A, Marangolo M, Pasquini E, Rossi A, Amadori D,
Ramaswamy S, Golub TR. DNA Microarrays in Clinical Cruciani G, Tassinari D, Oliverio G, Giovanis P,
Oncology, 1932 Turci D, Zumaglini F, Nicolini M, Panzini I. Bolus
Ramella S, see Trodella L Fluorouracil and Leucovorin With Oxaliplatin as
Rämö JO, see Auvinen MI First-Line Treatment in Metastatic Colorectal Can-
Ranelletti FO, see Ferrandina G cer, 2545
see Piantelli M Ravic M, see Raymond E
Raney RB, see Baker KS see van Kesteren Ch
Rannikko S, see Mäkinen T Raymond E, see Baselga J
Ranson M, see Baselga J see van Kesteren Ch
Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray Raymond E, Boige V, Faivre S, Sanderink G-J, Rixe O,
PL, Miller V, Averbuch S, Ochs J, Morris C, Vernillet L, Jacques C, Gatineau M, Ducreux M,
Feyereislova A, Swaisland H, Rowinsky EK. Armand JP. Dosage Adjustment and Pharmacoki-
ZD1839, a Selective Oral Epidermal Growth Factor netic Profile of Irinotecan in Cancer Patients With
Receptor-Tyrosine Kinase Inhibitor, Is Well Toler- Hepatic Dysfunction, 4303
ated and Active in Patients With Solid, Malignant Raymond E, ten Bokkel Huinink WW, Taäieb J, Beijnen JH,
Tumors: Results of a Phase I Trial, 2240 Faivre S, Wanders J, Ravic M, Fumoleau P, Ar-
Rao BN, see Spunt SL mand JP, Schellens JHM. Phase I and Pharmaco-
Rao UNM, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM. kinetic Study of E7070, a Novel Chloroindolyl
Implications of Microscopic Satellites of the Pri- Sulfonamide Cell-Cycle Inhibitor, Administered as
mary and Extracapsular Lymph Node Spread in a One-Hour Infusion Every Three Weeks in Pa-
Patients With High-Risk Melanoma: Pathologic tients With Advanced Cancer, 3508
Corollary of Eastern Cooperative Oncology Group Rayson D. Sweet Time Unafflicted, 4603
Trial E1690, 2053 Rayter Z, see Harper-Wynne CL
Rapoport B, see Littlewood TJ Razook C, see Nieto Y
Rarick MU, see Rizzo JD Razzouk BI, see Crews KR
Rashid A, see Herbst RS see Rubnitz JE
see Vauthey J-N Re D, see Weihrauch MR
Rasnke M, see Garrison from
Downloaded on June 28, 2008 . ForRead N, see
personal El-Sayed
use only. S uses without permission.
No other
Copyright © P2002 by the American Society of
Raspagliesi F, see Benedetti-Panici Clinical Oncology.
Reardon All rights reserved.
D, see Gururangan S

Reardon D, Bigner DD. Reply 2 (correspondence), 3181 see Vuky J

Reardon DA, see Quinn JA Revzin M, see Barakat RR
Reardon DA, Akabani G, Coleman RE, Friedman AH, Reyes A, see Papandreou CN
Friedman HS, Herndon JE II, Cokgor I, McLendon Reyes F, see Gisselbrecht C
RE, Pegram CN, Provenzale JM, Quinn JA, Rich Reynolds M, see Katzenstein HM
JN, Regalado LV, Sampson JH, Shafman TD, see Kletzel M
Wikstrand CJ, Wong TZ, Zhao X-G, Zalutsky MR, Reynolds R. Comparative Efficacy of Dronabinol and Meges-
Bigner DD. Phase II Trial of Murine 131I-Labeled trol Acetate (correspondence), 2912
Antitenascin Monoclonal Antibody 81C6 Admin- Ribaud P, see Bergeron A
istered Into Surgically Created Resection Cavities Ribeiro RC, see Crews KR
of Patients With Newly Diagnosed Malignant Gli- see Rubnitz JE
omas, 1389 Ribrag V, see Aloulou S
Rebbeck TR, see Shih HA Riccardi R, see Massimino M
Recht A, see Singletary SE Ricci S, see Scagliotti GV
see Vicini FA Rich JN, see Quinn JA
Reddy CA, see Kupelian PA see Reardon DA
see Thomas J Richards J, see Rao UNM
Reddy P, Kalemkerian GP. Unusual Presentations of Lung Richards P, see Greco FA
Cancer: Case 1. Diabetes Insipidus as the Initial Richie JP, see Cross CK
Manifestation of Non-Small-Cell Lung Cancer, Rick O, see Kollmannsberger C
4597 Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labi-
Redman BG, see Sondak VK anca R, Freschi A, Lo Re G, Nortilli R, Brugnara S,
Redston M, see Lindor NM Vitali P, Nanni O. Cisplatin, Dacarbazine With or
Reese T, see Dunst J Without Subcutaneous Interleukin-2, and Inter-
Regalado LV, see Reardon DA feron Alfa-2b in Advanced Melanoma Outpatients:
Regan DH, see Rizzo JD Results From an Italian Multicenter Phase III Ran-
Regan K, see Smaletz O domized Clinical Trial, 1600
Regimbeau J-M, see Vauthey J-N Ridolfi R, Nanni O. In Reply (correspondence), 3560
Regli L, see Stupp R Riedel E, see Shike M
Reguart N, see Mellado B Ries C, see Linker C
Reid GC, see Muggia FM Riess H, see Meyer L
Reid JE, see Frank TS Rietveld T, see Agteresch HJ
Reid JM, see Adjei AA Rifas-Shiman S, see Schrag D
Reiffers J, see Mahon FX Riftin R, see Vose JM
see Rocha V Rigatos SK, see Stathopoulos GP
Reinhard J-O, see Trümper L Rihn BH, see Mohr S
Reinhardt M-K, see Dudeney S Riley GF, see Warren JL
Reiser M, see Kaiser U Rinaldi M, see Scagliotti GV
Reiter RJ, see Vijayalaxmi Rinehart J, see DiPaola RS
Reith A, see Sudbø J Ring SE, see Eton O
Reman O, see Fermé C Ringdén O, see Rocha V
Remzi M, see Djavan B Ringdén O, Labopin M, Bacigalupo A, Arcese W, Schaefer
Renée N, see Etienne M-C UW, Willemze R, Koc H, Bunjes D, Gluckman E,
Renschler MF, see Mehta MP Rocha V, Schattenberg A, Frassoni F. Transplan-
Renshaw AA, see Cross CK tation of Peripheral Blood Stem Cells as Compared
see D’Amico AV With Bone Marrow From HLA-Identical Siblings
Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, in Adult Patients With Acute Myeloid Leukemia
Vercelli M, Parodi S, Dal Lago D, Gioia F, Mon- and Acute Lymphoblastic Leukemia, 4655
fardini S, Aapro MS, Serraino D, Zagonel V. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogel-
Comprehensive Geriatric Assessment Adds Infor- zang NJ. Allogeneic Stem-Cell Transplantation of
mation to Eastern Cooperative Oncology Group Renal Cell Cancer After Nonmyeloablative Che-
Performance Status in Elderly Cancer Patients: An motherapy: Feasibility, Engraftment, and Clinical
Italian Group for Geriatric Oncology Study, 494 Results, 2017
Reppa D, see Stathopoulou A Rinn K, see Disis ML
Resegotti L, see Federico M Ripamonti C, Sweeney C, Bruera E. Use of Trade Names of
Restifo NP, see Toso JF Drugs
Downloaded from on June 28, 2008 . For personal use only.and the Scientific
No other Content
uses without of Medical Con-
Reuter V, see Motzer RJ Copyright © 2002 by the American Society of Clinical Oncology. All rights reserved. 1707
gresses (correspondence),

Risberg B, see Sudbø J Robertson J, see Bonneterre J

Rischin D, see Albanell J Robertson JFR, see Howell A
see Baselga J Robison LL, see Bhatia S
Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. see Emmons K
Excellent Disease Control and Survival in Patients see Nagarajan R
With Advanced Nasopharyngeal Cancer Treated Robson K, see Lashford LS
With Chemoradiation, 1845 Robson M, see Scheuer L
Rischin D, Peters LJ. The Local-Regionally Advanced Robson ME, see Scheuer L
Nasopharyngeal Carcinoma Jigsaw Puzzle: Where Rocha V, see Ringdén O
Does the Chemotherapy Piece Fit? (editorial), 1968 Rocha V, Labopin M, Gluckman E, Powles R, Arcese W,
Risse E, see Codrington H Bacigalupo A, Reiffers J, Iriondo A, Ringdén O,
see Kunst PWA Ruutu T, Frassoni F. Relevance of Bone Marrow
Risse J, see Spieth K Cell Dose on Allogeneic Transplantation Outcomes
Ristow KM, see Ansell SM for Patients With Acute Myeloid Leukemia in First
Riva D, see Massimino M Complete Remission: Results of a European Sur-
Rivera E, Sutton L, Colwell B, Graham M, Frye D, Somer- vey, 4324
ville M, Conklin HS, McGuirt C, Levin J, Horto- Roché H, see van Kesteren Ch
bagyi GN. Multicenter Phase II Study of a 28-Day Roche K, Paul N, Smuck B, Whitehead M, Zee B, Pater J,
Regimen of Orally Administered Eniluracil and Hiatt M-A, Walker H. Factors Affecting Workload
Fluorouracil in the Treatment of Patients With of Cancer Clinical Trials: Results of a Multicenter
Anthracycline- and Taxane-Resistant Advanced Study of the National Cancer Institute of Canada
Breast Cancer, 987 Clinical Trials Group, 545
Rivoltini L, see Belli F Rock CL, Demark-Wahnefried W. Nutrition and Survival
Rixe O, see Khayat D After the Diagnosis of Breast Cancer: A Review of
see Marx GM the Evidence, 3302
see Raymond E Rockwood TH, see Bhatia S
Rizvi N, see Pecora AL Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst
Rizvi NA, Marshall JL, Ness E, Hawkins MJ, Kessler C, J, Meyer M, Schrott KM, Sauer R. Combined-
Jacobs H, Brenckman WD Jr, Lee JS, Petros W, Modality Treatment and Selective Organ Preserva-
Hong WK, Kurie JM. Initial Clinical Trial of Oral tion in Invasive Bladder Cancer: Long-Term Re-
TAC-101, a Novel Retinoic Acid Receptor-Alpha sults, 3061
Selective Retinoid, in Patients With Advanced Rodenhuis S, see de Gast GC
Cancer, 3522 Rodier J-M, see Depierre A
Rizzieri DA, see Bass AJ Rodrigues GB, see Brierley JD
Rizzieri DA, Bass AJ, Rosner GL, Gockerman JP, DeCastro Rodriguez MA, see Rassidakis GZ
CM, Petros WP, Adams DJ, Laughlin MJ, Davis P, Rodriguez-Bigas MA. Pathologic Evaluation of Total Meso-
Foster T, Jacobson R, Hurwitz H, Moore JO. Phase rectal Excision: Big Brother is Watching (editori-
I Evaluation of Prolonged-Infusion Gemcitabine al), 1714
With Mitoxantrone for Relapsed of Refractory Rodriguez-Hanley A, see Stanton AL
Acute Leukemia, 674 Rogers T, see Carducci MA
Rizzo JD, see Loberiza FR Jr Rogers TE, see Dean A
Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Rohatiner AZS, see Radford JA
Cella D, Djulbegovic B, Goode MJ, Jakubowski Rojo F, see Albanell J
AA, Lee SJ, Miller CB, Rarick MU, Regan DH, see Baselga J
Browman GP, Gordon MS. Use of Epoetin in see Herbst RS
Patients With Cancer: Evidence-Based Clinical Romaguera J, see Rassidakis GZ
Practice Guidelines of the American Society of see Sarris AH
Clinical Oncology and the American Society of Romanini A, see Ridolfi R
Hematology, 4083 Romeike BFM, see Samnick S
Roa WH, see Mehta MP Rönnholm R, see Auvinen MI
Roach J, see Herbst RS Roodman GD. In Reply (correspondence), 354
Roanh LD, see Love RR Roots I, see Kaiser R
Robbins KT, see Mendenhall WM Rørth M, see Petersen PM
Robert J, see Maunsell E Rosati S, see Scartozzi M
Robert N, see Loesch D Rose CM, see Burkhardt JH
Roberts MS, Downloaded
see Pecora from
AL on June 28, 2008 . ForRose PG,use
personal Bundy
only. BN. Chemoradiation
No other for Locally Advanced
uses without permission.
Robertson C, see De Pas Copyright
T © 2002 by the American Society of Clinical Oncology.
Cervical All rights reserved.
Cancer: Does It Help? (editorial), 891

Rose SR, see Leung W Rowland JH, see Hewitt M

Rosen L, see Kuenen BC see Liang W
Rosenberg R, Hoos A, Mueller J, Baier P, Stricker D, Werner Rowlings P, see Berry DA
M, Nekarda H, Siewart J-R. Prognostic Signifi- Rozans M, Dreisbach A, Lertora JJL, Kahn MJ. Palliative
cance of Cytokeratin-20 Reverse Transcriptase Uses of Methylphenidate in Patients With Mantle-
Polymerase Chain Reaction in Lymph Nodes of Cell Lymphoma, 335
Node-Negative Colorectal Cancer Patients, 1049 Rubin BP, see Singer S
Rosenberg SA, see Horning SJ Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S,
see Toso JF Conrad EU, Bruckner JD. Molecular Targeting
Rosenqvist K, see Powles T of Platelet-Derived Growth Factor B by Imatinib
Rosenthal DI, see Machtay M Mesylate in a Patient With Metastatic Dermato-
Rosenthal P, see Hoecht S fibrosarcoma Protuberans, 3586
Rosenthal SA, see Minsky BD Rubin E, see DiPaola RS
Rosing H, see Kruijtzer CMF Rubin EH, see Herbst RS
Rosner G, see Small EJ Rubin J, see Adjei AA
Rosner GL, see Bass AJ Rubin S, see Shepherd FA
see Rizzieri DA Rubinger M, see Klasa RJ
Rosner GL, Stadler W, Ratain MJ. Randomized Discontinu- Rubinstein W, see Berry DA
ation Design: Application to Cytostatic Antineo- Rubinstein WS, see Berry DA
plastic Agents, 4478 Rubnitz JE, see Crews KR
Ross MI, see Ballo MT Rubnitz JE, Raimondi SC, Tong X, Srivastava DK, Raz-
Ross MK, see Kirkwood JM zouk BI, Shurtleff SA, Downing JR, Pui C-H,
Ross P, Nicolson M, Cunningham D, Valle J, Seymour M,
Ribeiro RC, Behm FG. Favorable Impact of the
Harper P, Price T, Anderson H, Iveson T,
t(9;11) in Childhood Acute Myeloid Leukemia,
Hickish T, Lofts F, Norman A. Prospective
Randomized Trial Comparing Mitomycin, Cis-
Ruckdeschel JC, see Jacobsen PB
platin, and Protracted Venous-Infusion Fluorou-
see Kilbridge KL
racil (PVI 5-FU) With Epirubicin, Cisplatin, and
Rudek MA, see Cianfrocca M
PVI 5-FU in Advanced Esophagogastric Cancer,
Rudofsky G, see Kröger K
Rudolph C, see Josting A
Ross PJ, Cunningham D. In Reply (correspondence), 4125
Rueffer U, see Sieber M
Ross RK, see Ursin G
Ruers TJM, see Langenhoff BS
Rossi A, see Radford JA
Ruers TJM, Langenhoff BS, Neeleman N, Jager GJ, Strijk
see Ravaioli A
S, Wobbes T, Corstens FHM, Oyen WJG. Value
Rossi R, see Cantù MG
Rosty C, see Etienne M-C of Positron Emission Tomography With
Roth AD, see Borner MM 关F-18兴Fluorodeoxyglucose in Patients With
Rothenberg ML, see Alberts DS Colorectal Liver Metastases: A Prospective
see Herbst RS Study
Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Ruggiero A, see Massimino M
Wadler S. In Reply (correspondence), 1145 Ruijter R, see Kuenen BC
Rothmann F, see Kaiser U Rummans TA, see Loprinzi CL
Rougier P, see Louvet C Runowiez CD, see Wickerham DL
see Nordlinger B Ruohtula T, see Auvinen MI
Rousselot Ph, see Bergeron A Rusch VW, see Martin J
Rouzier R, Extra J-M, Klijanienko J, Falcou M-C, Asselain Russell N, see Bruera E
B, Vincent-Salomon A, Vielh P, Bourstyn E. Inci- Russo P, see Dalbagni G
dence and Prognostic Significance of Complete see Motzer RJ
Axillary Downstaging After Primary Chemother- see Rabbani F
apy in Breast Cancer Patients With T1 to T3 Rusthoven J, see Hughes A
Tumors and Cytologically Proven Axillary Meta- Rustin GJS, see Galbraith SM
static Lymph Nodes, 1304 see McNeish IA
Rovira M, see Prieto JM Ruutu T, see Rocha V
Rowe JM, see Dann EJ Ruymann FB, see Baker KS
Rowinsky EK, see de Bono JS Ryan DP, see Eder JP Jr
see Ranson M
Downloaded from on June 28, 2008 . ForRyder WDJ,
personal see Radford
use only. JA without permission.
No other uses
see Tolcher AW Copyright © 2002 by the American Society of Clinical
Ryken TC,Oncology. All rights
see Buatti JM reserved.

S Sanda MG, McLaughlin PW. In Reply (correspondence),

Sanderink G-J, see Raymond E
Sabbatini P, see Barakat RR
Sanders J, see Woods WG
see Dizon DS
Sandler HM, see Chan JL
see Hensley ML
see Wei JT
Sackmann M, see Trümper L
Sandmaier B, see Appelbaum FR
Sacks NPM, see Harper-Wynne CL
Sadura A, see Davis AM Santábarbara P, see Rai KR
see Shepherd FA Santantonio C, see Belli F
Sagebiel RW, see Kashani-Sabet M Santini D, Tonini G, Vincenzi B, Murace R, Ferranti G, Baldi
Saghatchian M, see Culine S A. Skin Lesions in Melanoma and Kaposi’s Sar-
Saglam S, Yetis B, Ozyilkan O, Akçali Z. Cost-Effectiveness coma; Case 1. Detection of Circulating Malignant
of Chemotherapy in Non-Small-Cell Lung Cancer Cells by RT-PCR in a Case of Cutaneous Mela-
(correspondence), 3750 noma in Complete Regression, 1411
Said JW, see Zisman A Santoro A, see Bertuzzi A
Saijo N, see Schwartsmann G Sappino AP, see Bouchardy C
see Sekine I Sargent DJ, see Allegra CJ
see Takada M see Goldberg RM
Saito M, see Sekine I see Hobday TJ
Sakalová A, see Menssen HD see Lindor NM
Sako M, see Imashuku S see Sloan JA
Salas J, see Buchholz TA Sarkar TK, see Smith IC
Saleh MN, see Witzig TE Sarna L, Padilla G, Holmes C, Tashkin D, Brecht ML,
Saletti P, see Borner MM Evangelista L. Quality of Life of Long-Term Sur-
Sallan SE, see LeClerc JM vivors of Non-Small-Cell Lung Cancer, 2920
see Lipshultz SE Sarobba MG, see Berruti A
Salles G, see Fermé C Sarokhan B, see Gabrilove JL
Salminen JT, see Auvinen MI Sarris AH, see Rassidakis GZ
Salo JA, see Auvinen MI Sarris AH, Phan A, Duvic M, Romaguera J, McLaughlin P,
Salter J, see Harper-Wynne CL Mesina O, King K, Medeiros LJ, Rassidakis GZ,
Saltz L, see Schrag D Samuels B, Cabanillas F. Trimetrexate in Relapsed
see Schwartz GK T-Cell Lymphoma With Skin Involvement, 2876
Saltz LB, see Holen KD Sarris G, see Antonadou D
see Timoney JP Sartor F, see Toffoli G
Salzer-Kuntschik M, see Bielack SS Sartor O, see Bennett CL
Samantas E, see Bafaloukos D
Sartori S, see Tassinari D
see Kosmidis P
Satagopan J, see Scheuer L
Samnick S, Bader JB, Hellwig D, Moringlane JR, Alexander
Sateren WB, Trimble EL, Abrams J, Brawley O, Breen N,
C, Romeike BFM, Feiden W, Kirsch C-M. Clinical
Ford L, McCabe M, Kaplan R, Smith M, Unger-
Value of Iodine-123-Alpha-Methyl-L-Tyrosine
leider R, Christian MC. How Sociodemographics,
Single-Photon Emission Tomography in the Differ-
Presence of Oncology Specialists, and Hospital
ential Diagnosis of Recurrent Brain Tumor in
Cancer Programs Affect Accrual to Cancer Treat-
Patients Pretreated for Glioma at Follow-Up, 396
Samonigg H, see Jakesz R ment Trials, 2109
Samonis G, see Souglakos J Sauer R, see Rödel C
Samosh M, see Klasa RJ Sauerbrei W, see Jonat W
Samowitz WS, Slattery ML. Missense Mismatch Repair Sauleda S, see Albanell J
Gene Alterations, Microsatellite Instability, and Sausville EA, see Tan AR
Hereditary Nonpolyposis Colorectal Cancer (corre- Sauven P, see Harper-Wynne CL
spondence), 3178 Savarese D, see Lima CMSR
Sampson JH, see Quinn JA Saville W, see Lima CMSR
see Reardon DA Savin M, see Holmes FA
Samson Y, see Lipshultz SE Savona S, see Ramanathan RK
Samuels B, see Sarris AH Sawamura Y, see Aoyama H
Sancar D, see Hoecht S Sawka CA, see Klasa RJ
Sánchez-Pernaute A, seefrom
Downloaded González-Quevedo RJune 28, 2008 . ForSawyers on personal CL. Imatinib
use only. GIST
No other Keeps
uses Finding
without New Indications:
Sanda MG, see Wei JT Copyright © 2002 by the American Society of Clinical Oncology. All Treatment
Successful rights reserved.
of Dermatofibrosarcoma Pro-

tuberans by Targeted Inhibition of the Platelet- Scheuer L, Kauff N, Robson M, Kelly B, Barakat R,
Derived Growth Factor Receptor (editorial), 3568 Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P,
Sayer HG, see Kollmannsberger C Norton L, Offit K. Outcome of Preventive Surgery
Saykin AJ, see Ahles TA and Screening for Breast and Ovarian Cancer in
Scadden DT, see Cianfrocca M BRCA Mutation Carriers, 1260
Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Scheuer L, Kauff ND, Robson ME, Offit K. In Reply
Ricci S, Matano E, Boni C, Marangolo M, Failla G, (correspondence), 3753
Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Scheulen ME, see Kruijtzer CMF
Costanzo F, Frontini L, Tonato M. Phase III Ran- Schey S, see Branson K
domized Trial Comparing Three Platinum-Based Schiffer CA, see Kornblith AB
Doublets in Advanced Non-Small-Cell Lung Can- see Morrison VA
cer, 4285 see Silverman LR
Scambia G, see Ferrandina G Schiffman K, see Disis ML
Scappaticci FA. Mechanisms and Future Directions for An- Schildberg FW, see Heiss MM
giogenesis-Based Cancer Therapies, 3906 Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain
Scarcella DL, see Gururangan S MJ. Dose-Escalating Study of Capecitabine Plus
Scardino PT, see Cagiannos I Gemcitabine Combination Therapy in Patients
see Graefen M With Advanced Cancer, 582
Scartozzi M, see Porfiri E Schilsky RL, Levin J, West WH, Wong A, Colwell B,
Scartozzi M, Bianchi F, Rosati S, Galizia E, Antolini A, Thirlwell MP, Ansari RH, Bell WN, White RL,
Loretelli C, Piga A, Bearzi I, Cellerino R, Porfiri E. Yates BB, McGuirt PV, Pazdur R. Randomized,
Mutations of hMLH1 and hMSH2 in Patients With Open-Label, Phase III Study of a 28-Day Oral
Suspected Hereditary Nonpolyposis Colorectal Regimen of Eniluracil Plus Fluorouracil Versus
Cancer: Correlation With Microsatellite Instability Intravenous Fluorouracil Plus Leucovorin as First-
and Abnormalities of Mismatch Repair Protein Line Therapy in Patients With Metastatic/Ad-
Expression, 1203 vanced Colorectal Cancer, 1519
Schaefer UW, see Ringdén O Schläfke M, see Stein U
Schafenacker A, see Northouse LL Schlegelberger B, see Viardot A
Schaison G, see Perel Y Schlenk RF, see Döhner K
Schalk K-P, see Sieber M see Fröhling S
Schaller G, see Fuchs IB Schlesselman JJ, see Sofer M
Schaller J, see Costa L Schleucher N, see Kollmannsberger C
Schapira L. An Existential Oncologist, 2407 Schmalenberg H, see Kaiser U
Schattenberg A, see Ringdén O Schmelz R, Lersch C. Acute Oxaliplatin-Induced Peripheral-
Schatzkin A, see Shike M Nerve Hyperexcitability (correspondence), 3561
Schauenstein K, see Wölfler A Schmitt C, see Patte C
Scheinberg D, see Von Roenn JH see Perel Y
Scheithauer B, see Shaw E Schmitt M, see Harbeck N
Scheithauer W, see Gedlicka C Schmitz N, see Kaiser U
Scheithauer W, Kornek GV, Raderer M, Ulrich-Pur H, Schmoldt J, see Kletzel M
Fiebiger W, Gedlicka C, Schüll B, Brugger S, Schmoll H-J, see Bokemeyer C
Schneeweiss B, Lang F, Lenauer A, Depisch D. Schnall MD, see Tillman GF
Randomized Multicenter Phase II Trial of Oxali- Schneeweiss B, see Scheithauer W
platin Plus Irinotecan Versus Raltitrexed as First- Schneider KA, see Chen WY
Line Treatment in Advanced Colorectal Cancer, Schnipper L, see Eder JP Jr
165 Schoch R, see Kollmannsberger C
Schelenz C, see Kaiser R Schöder H, see Wong RJ
Schell MJ, see Socinski MA Schöffski P, see Kollmannsberger C
Schellens JHM, see Crul M Schold SC, see DeAngelis LM
see Kruijtzer CMF Scholl C, see Fröhling S
see Malingré MM Scholl T, see Frank TS
see Raymond E Schorin M, see LeClerc JM
see van Kesteren Ch Schorin MA, see Lipshultz SE
Schellens JHM, Ratain MJ. Endostatin: Are the 2 Years Up Schornagel JH, see de Gast GC
Yet? (editorial), 3758 see Detmar SB
Scher H, seeDownloaded
Osman I from on June 28, 2008 . ForSchot M,use
personal seeonly.
Kruijtzer CMF
No other uses without permission.
Scher HI, see Smaletz O Copyright © 2002 by the American Society of Clinical Oncology.
Schover LR, BreyAll K,
rights reserved.
Lichtin A, Lipschultz LI, Jeha S.

Oncologists’ Attitudes and Practices Regarding Scigalla P, see Kuenen BC

Banking Sperm Before Cancer Treatment, 1890 Scita G, see Belli F
Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Scott SS, see Izawa JI
Adjuvant Chemotherapy Use for Medicare Benefi- Scuderi C, see Spazzapan S
ciaries With Stage II Colon Cancer, 3999 Scullin DC Jr, see Greco FA
Schriock EA, see Leung W Seabrooke LF, see Herbst RS
Schröder FH, see Graefen M Seal S, see Shih HA
Schrott KM, see Rödel C Seckl MJ, see McNeish IA
Schuchter LM, Hensley ML, Meropol NJ, Winer EP for the See H-J, see Goldhirsch A
American Society of Clinical Oncology Chemo- Seiden MV, see Vasey PA
therapy and Radiotherapy Expert Panel. 2002 Up- Seidenfeld J, see Rizzo JD
date of Recommendations for the Use of Chemo- Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashbby M,
therapy and Radiotherapy Protectants: Clinical Murphy M, Stewart SJ, Keefe D. Cardiac Dysfunc-
Practice Guidelines of the American Society of tion in the Trastuzumab Clinical Trials Experience,
Clinical Oncology, 2895 1215
Schuck A, see Franzius C see also Modi S
Schuetz E, see Goh B-C Seidman A, Pierri MK, Hudis C. In Reply (correspondence),
Schuetze SM, see Rubin BP 4119
Schuff-Werner P, see Steiner M Seidman A, see Modi S
Schuler M, see Kuball J see Van Poznak C
Schuler U. Cautious Arguments in Favor of Body Surface Seiferheld W, see DeAngelis LM
Area-Based Dosing (correspondence), 4270 Seifert M, see Jakesz R
Schüll B, see Gedlicka C Sein J, see de Gast GC
see Scheithauer W Seipp C, see Toso JF
Schultz CJ, see DeAngelis LM Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed
see Mehta MP T. Phase I Study of Temozolomide in Relapsed/
Schultz D, see D’Amico AV Refractory Acute Leukemia, 3249
Schultz DJ, see Tillman GF Seitz C, see Djavan B
Schulz JJ, see Cartwright TH Seitz J-F, see Etienne M-C
Schulze H-J, see Thies A Sek A, see Trümper L
Schumacher K, see Kaiser U Sekimoto M, see Noura S
Schumacher M, see Jonat W Sekine I, Nishiwaki Y, Ogino T, Yokoyama A, Saito M, Mori
Schumacher U, see Laack E K, Tsukiyama I, Tsuchiya S, Hayakawa K, Yo-
see Thies A shimura K, Ishizuka N, Saijo N. Phase II Study of
Schussler N, see Warren JL Twice-Daily High-Dose Thoracic Radiotherapy Al-
Schuster MA, see Malin JL ternating With Cisplatin and Vindesine for Unre-
Schwartsmann G, Ratain MJ, Cragg GM, Wong JE, Saijo N, sectable Stage III Non-Small-Cell Lung Cancer:
Parkinson DR, Fujiwara Y, Pazdur R, Newman DJ, Japan Clinical Oncology Group Study 9306, 797
Dagher R, Di Leone L. Anticancer Drug Discovery Selby P, see Stark D
and Development Throughout the World, 47s Semba CP, see Deitcher SR
Schwartz CL, see Goorin AM Semenza GL, see Bos R
Schwartz GK, O’Reilly E, Ilson D, Saltz L, Sharma S, Tong Senderowicz AM, see Tan AR
W, Maslak P, Stoltz M, Eden L, Perkins P, Endres Senn H-J, see Goldhirsch A
S, Barazzoul J, Spriggs D, Kelsen D. Phase I Study Sensel MG, see Katzenstein HM
of the Cyclin-Dependent Kinase Inhibitor Fla- Seo PH, see Ingram SS
vopiridol in Combination With Paclitaxel in Pa- Sepkowitz KA, see Walshe LJ
tients With Advanced Solid Tumors, 2157 Sepucha KR, Belkora JK, Mutchnick S, Essennan LJ. Con-
Schwartz JL, see Bichakjian CK sultation Planning to Help Breast Cancer Patients
Schwartz M, see DiPaola RS Prepare for Medical Consultations: Effect on Com-
Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, munication and Satisfaction for Patients and Phy-
Lerman C. Impact of BRCA1/BRCA2 Mutation sicians, 2695
Testing on Psychologic Distress in a Clinic-Based Serraino D, see Repetto L
Sample, 514 Sertoli MR, see Belli F
Schwartzentruber DJ, see Toso JF Sessa C, see Bernhard J
Schwarz RE, Fuller RA, Chu P. Unusual Presentations of Sevastianos VA, see Dourakis SP
DownloadedTumors; Case 2. Gastric
from on JuneCarcinoid
28, 2008 . ForSeymour,
personal useMT. Oxaliplatin:
only. Bimonthly,
No other uses Biweekly, or Semi-
without permission.
Metastatic to theCopyright © 2002 by the American Society of Clinical Oncology.
Liver, 2403 monthly?AllNo,
rights reserved.
Fortnightly!, 3753

Seymour L, see Bélanger K nors JM. Brief Chemotherapy and Involved-Region

see Shepherd FA Irradiation for Limited-Stage Diffuse Large-Cell
Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan Lymphoma: An 18-Year Experience From the Brit-
PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr ish Columbia Cancer Agency, 197
DJ. Hepatic Drug Targeting: Phase I Evaluation of Shennan F, see Lawrence G
Polymer-Bound Doxorubicin, 1668 Shenton K, see Harper-Wynne CL
Seymour M, see Maisey N Shepherd FA, see Leighl NB
see Ross P Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak
Seymour MT, see Scheuer L A, Hirsh V, Smylie M, Rubin S, Martins H, Lamont
Sezer O, see Kaiser R A, Krzakowski M, Sadura A, Zee B. Prospective,
Sezer O, Heider U, Jakob C, Eucker J, Possinger K. Human Randomized, Double-Blind, Placebo-Controlled
Bone Marrow Myeloma Cells Express RANKL Trial of Marimastat After Response to First-Line
(correspondence), 353 Chemotherapy in Patients With Small-Cell Lung
Shadbolt B, Barresi J, Craft P. Self-Rated Health as a Cancer: A Trial of the National Cancer Institute of
Predictor of Survival Among Patients With Ad- Canada-Clinical Trials Group and the European
vanced Cancer, 2514 Organization for Research and Treatment of Can-
Shaffer K, see Diller L cer, 4434
Shafford E, see Czauderna P Shepherd JH, see Kolomainen DF
Shafman TD, see Reardon DA Shepherd L, see Morrison VA
Shah J, see Osman I Sherman E, see Osman I
Shah JP, see Wong RJ Sherry RM, see Toso JF
Shah M, see Nadella P Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Reb-
Shaha A, see Osman I beck TR, Armstrong KA, Calzone K, Stopfer J,
Shaikh SL, see Lipshultz SE Seal S, Stratton MR, Weber BL. BRCA1 and
Shak S, see Seidman A BRCA2 Mutation Frequency in Women Evaluated
see Vogel CL in a Breast Cancer Risk Evaluation Clinic, 994
Shamash J, see Oliver RTD Shike M, Latkany L, Riedel E, Fleisher M, Schatzkin A,
see Radford JA Lanza E, Corle D, Begg CB. Lack of Effect of a
Shapiro B, see Yanik GA Low-Fat, High-Fruit, -Vegetable, and -Fiber Diet
Shapiro V, see Nadella P on Serum Prostate-Specific Antigen of Men With-
Shapiro WR, see Mehta MP out Prostate Cancer: Results From a Randomized
Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Trial, 3592
Wheeler TM, Slawin KM. Association of Preoper- Shima Y, see Morita T
ative Plasma Levels of Insulin-Like Growth Factor Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G,
I and Insulin-Like Growth Factor Binding Pro- Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee
teins-2 and -3 With Prostate Cancer Invasion, JJ, Myers J, Goepfert H, Lotan R, Hong WK,
Progression, and Metastasis, 833 Lippman SM. Phase II and Biologic Study of
Sharma S, see Schwartz GK Interferon Alfa, Retinoic Acid, and Cisplatin in
Sharp G, see Vose JM Advanced Squamous Skin Cancer, 364
Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Shipe-Spotloe J, see Kirkwood JM
Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Shipley WU, see Coen JJ
Nichols D, Ivnik R, Hellman R, Curran W, Abrams Shipp MA, see Howard OM
R. Prospective Randomized Trial of Low- Versus Shirato H, see Aoyama H
High-Dose Radiation Therapy in Adults With Su- Shogan J, see Holmes FA
pratentorial Low-Grade Glioma: Initial Report of a Shogen K, see Mikulski SM
North Central Cancer Treatment Group/Radiation Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y,
Therapy Oncology Group/Eastern Cooperative On- Hanaoka N, Miyahara R, Nakagawa T, Kawano Y,
cology Group Study, 2267 Ishikawa S, Katakura H, Wada H. Clinical Signif-
Shea TC, see Orlowski RZ icance of p21 Expression in Non-Small-Cell Lung
Sheinfeld J, see Dalbagni G Cancer, 3865
see Vuky J Shore RM, see Kletzel M
Shek TW, see Au WY Shpall EJ, see Nieto Y
Shelley W, see El-Sayed S Shulkin BL, see Yanik GA
Shen T, see Love RR Shulman LN, see Eder JP Jr
Shen V, see Jennings MT see Vasey PA
Shenkier TN,Downloaded
Voss N, Fairey R, Gascoyne RD, Hoskins P, Shultz D,use
from on June 28, 2008 . For personal seeonly.
Cross CK uses without permission.
No other
Klasa R, KlimoCopyright © 2002
P, O’Reilly SE,bySutcliffe
the American Society of
S, Con- Clinical Oncology.
Shurtleff All rights reserved.
SA, see Rubnitz JE

Shustik C, see Klasa RJ Simone JV. Understanding Cancer Centers (editorial), 4503
Siddiqui A, see Seiter K Singer CRJ, see Menssen HD
Siddiqui N, see Vasey PA Singer S, Rubin BP, Lux ML, Chen C-J, Demetri GD,
Siderov J. Pharmacokinetics of Irinotecan and Its Metabolites Fletcher CDM, Fletcher JA. Prognostic Value of
(correspondence), 4609 KIT Mutation Type, Mitotic Activity, and Histo-
Sidor C, see Eder JP Jr logic Subtype in Gastrointestinal Stromal Tumors,
Sidranksy D, see Cheng H-L 3898
Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Singh B, see Osman I
Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Singh H, see Ferrari AC
Loeffler M, Engert A, Josting A, Wolf J, Hasen- Singhal S, see Mehta J
clever D, Franklin J, Duehmke E, Georgii A, Singletary SE, see Buchholz TA
Schalk K-P, Kirchner H, Doelken G, Munker R, Singletary SE, Allred C, Ashley P, Bassett LW, Berry D,
Koch P, Herrmann R, Greil R, Anselmo AP, Diehl Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF,
V. Rapidly Alternating COPP/ABV/IMEP Is Not Hughes LL, Hutter RVP, Morrow M, Page DL,
Superior to Conventional Alternating COPP/ Recht A, Theriault RL, Thor A, Weaver DL,
ABVD in Combination With Extended-Field Ra- Wieand HS, Green FL. Revision of the American
diotherapy in Intermediate-Stage Hodgkin’s Lym- Joint Committee on Cancer Staging System for
phoma: Final Results of the German Hodgkin’s Breast Cancer, 3628
Lymphoma Study Group Trial HD5, 476 Sinibaldi V, see Carducci MA
Siebert R, see Viardot A Sirachainan E, Kalemkerian GP. Unusual Presentations of
Siedek M, see Weihrauch MR Lung Cancer: Case 2. Adrenal Insufficiency as the
Siefker-Radtke AO, Millikan RE, Tu S-M, Moore DF Jr, Initial Manifestation of Non-Small-Cell Lung Can-
Smith TL, Williams D, Logothetis CJ. Phase III cer, 4598
Trial of Fluorouracil, Interferon Alfa-2b, and Cis- Siracusano L, see Bertuzzi A
platin Versus Methotrexate, Vinblastine, Doxoru- Sisson JC, see Yanik GA
bicin, and Cisplatin in Metastatic or Unresectable Siu L, see Bélanger K
Urothelial Cancer, 1361 see de Bono JS
Siegal GP, see Goorin AM Siu LL, see Nottage M
Siegel E, see Badros A Sivesind D, see Strasser F
Siewart J-R, see Rosenberg R Skakkebæk NE, see Petersen PM
Sigurdson ER, see Kemeny MM Skalla K, see Ahles TA
Sihvo EIT, see Auvinen MI Skarlos D, see Bafaloukos D
Siivola P, see Auvinen MI see Kosmidis P
Silberfarb PM, see Ahles TA Skelin S, see Fröhling S
Sillar RW, see Hersey P Skibber JM, see Esnaola NF
Silliman RA, see Liang W Skibowski E, see Weihrauch MR
Silliman RA, Guadagnoli E, Rakowski W, Landrum MB, Skillings JR, see Douillard J-Y
Lash TL, Wolf R, Fink A, Ganz PA, Gurwitz J, Skinner DG, see Graefen M
Borbas C, Mor V. Adjuvant Tamoxifen Prescrip- Skovlund E, see Sundstrøm S
tion in Women 65 Years and Older With Primary Skovsgaard T, see Carmichael J
Breast Cancer, 2680 Slamon DJ, see Osoba D
Silver B, see Ng AK see Press MF
Silverman LB, see LeClerc JM see Vogel CL
Silverman LR, see Kornblith AB Slattery ML, see Samowitz WS
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Slawin KM, see Shariat SF
Holland JC, Odchimar-Reissig R, Stone RM, Nel- Sleddens HFBM, see van der Sijp JRM
son D, Powell BL, DeCastro CM, Ellerton J, Sloan J. Asking the Obvious Questions Regarding Patient
Larson RA, Schiffer CA, Holland JF. Randomized Burden (editorial), 4
Controlled Trial of Azacitidine in Patients With the Sloan JA, see Adjei AA
Myelodysplastic Syndrome: A Study of the Cancer see Hobday TJ
and Leukemia Group B, 2429 see Jatoi A
Simbre VC II, see Lipshultz SE see Loprinzi CL
Simes RJ, see Hersey P Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair
Simmons C, see de Bono JS S, Cha SS, Novotny PJ, Poon MA, O’Connell MJ,
Simon D, see Mounier N Loprinzi CL. Women Experience Greater Toxicity
Simon EH, see Heiss MM With
Downloaded from on June 28, 2008 . For personal use Fluorouracil-Based
only. No other uses withoutChemotherapy
permission. for Colo-
Simon MB, see Ramanathan Copyright
RK © 2002 by the American Society of Clinical Oncology. All rights
rectal Cancer, reserved.

Slosman DO, see Allal AS Lung Cancer With Low-Dose Helical Computed
Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Tomography: Anti-Lung Cancer Association
Regan K, Kelly WK, Kattan MW. Nomogram for Project, 911
Overall Survival of Patients With Progressive Met- Socié G, see Bergeron A
astatic Prostate Cancer After Castration, 3972 Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S,
Small BJ, see Jacobsen PB Gitten R, Unger P, Lee J, Lee J-H, Tynan M,
Small EJ, see Herbst RS Moore M, Kies MS. Phase III Trial Comparing a
see Smaletz O Defined Duration of Therapy Versus Continuous
Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak Therapy Followed by Second-Line Therapy in
D, Marshall E, Rago R, Hars V, Wilding G, Advanced-Stage IIIB/IV Non-Small-Cell Lung
Petrylak D, Vogelzang NJ. Randomized Study of Cancer, 1335
Three Different Doses of Suramin Administered Sock DE, see Kilbridge KL
With a Fixed Dosing Schedule in Patients With Sofer M, Hamilton-Nelson KL, Schlesselman JJ, Soloway
Advanced Prostate Cancer: Results of Intergroup MS. Risk of Positive Margins and Biochemical
0159, Cancer and Leukemia Group B 9480, 3369 Recurrence in Relation to Nerve-Sparing Radical
Small TN, see Timoney JP Prostatectomy, 1853
Smaniotto D, see Benedetti-Panici P Soft Tissue Sarcoma Committee, Representing the Childhood
Smelko B, see Kirkwood JM Oncology Group, see Sorensen PHB
Smit EF, see Kuenen BC Sogani P, see Dalbagni G
Smith A, see Barakat RR Soignet S, see Barakat RR
see Klasa RJ Soignet SL, see Orlowski RZ
see Stark D Solin LJ, see Lee JH
Smith DA, see Adjei AA see Tillman GF
Smith I, see Powles T Soloway MS, see Sofer M
Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Somerville M, see Rivera E
Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sondak VK, see Kirkwood JM
Sarkar TK, Eggleton SP, Ogston KN. Neoadjuvant see Sosman JA
Chemotherapy in Breast Cancer: Significantly En- Sondak VK, Liu P-Y, Tuthill RJ, Kempf RA, Unger JM,
hanced Response With Docetaxel, 1456 Sosman JA, Thompson JA, Weiss GR, Redman
Smith J, see Khushalani NI BG, Jakowatz JG, Noyes RD, Flaherty LE. Adju-
see Rischin D vant Immunotherapy of Resected, Intermediate-
Smith JA, see Mehta MP Thickness, Node-Negative Melanoma With an Al-
Smith M, see Sateren WB logeneic Tumor Vaccine: Overall Results of a
Smith ME, see Garrison MA Randomized Trial of the Southwest Oncology
Smith P, see Khushalani NI Group, 2058
Smith R, see de Jonge MJA Soo-Hoo W, see Womer RB
Smith SC, see Brett BT Sood AK, see Bloss JD
Smith T, see Kemeny MM Sorensen PHB, Lynch JC, Qualman SJ, Tirabosco R, Lim JF,
see Neff P Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr
Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz- FG for the Soft Tissue Sarcoma Committee, Rep-
Marx RL, Buchser E, Català E, Bryce DA, Coyne resenting the Childhood Oncology Group. PAX3-
PJ, Pool GE. Randomized Clinical Trial of an FKHR and PAX7-FKHR Gene Fusions Are Prog-
Implantable Drug Delivery System Compared With nostic Indicators in Alveolar Rhabdomyosarcoma:
Comprehensive Medical Management for Refrac- A Report From the Children’s Oncology Group,
tory Cancer Pain: Impact on Pain, Drug-Related 2672
Toxicity, and Survival, 4040 Sorio R, see Toffoli G
Smith TL, see Esteva FJ Sorosky J, see Muggia FM
see Siefker-Radtke AO Soslow R, see Barakat RR
Smithson WA, see Anderson PM Sosman JA, see Sondak VK
Smuck B, see Roche K Sosman JA, Unger JM, Liu P-Y, Flaherty LE, Park MS,
Smylie M, see Shepherd FA Kempf RA, Thompson JA, Terasaki PI, Sondak
Sneige N, see Esteva FJ VK. Adjuvant Immunotherapy of Resected, Inter-
Snow P, see Djavan B mediate-Thickness, Node-Negative Melanoma
So T, see Osaki T With an Allogeneic Tumor Vaccine: Impact of
Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi HLA Class I Antigen Expression on Outcome,
T, Tsuchiya R, Kakinuma R, Ohmatsu H, Nagai K, 2067
Downloaded from on June 28, 2008 . For personal use only. No other uses without permission.
Nishiyama H, Matsui E,©Eguchi
2002 byK.
American Society
for of Clinical Oncology.
Souglakos All rights
J, Mavroudis D,reserved.
Kakolyris S, Kourousis C, Vard-

akis N, Androutakis N, Agelaki S, Kalbakis K, BN, Pratt CB, Merchant TE, Pappo AS. Clinical
Tsetis D, Athanasiadis N, Samonis G, Georgoulias Features and Outcome of Initially Unresected Non-
V. Triplet Combination With Irinotecan Plus Ox- metastatic Pediatric Nonrhabdomyosarcoma Soft
aliplatin Plus Continuous-Infusion Fluorouracil and Tissue Sarcoma, 3225
Leucovorin as First-Line Treatment in Metastatic Srivastava DK, see Crews KR
Colorectal Cancer: A Multicenter Phase II Trial, see Rubnitz JE
2651 Srivastava P, see Belli F
Souhami L, see Pearcey R Staats PS, see Smith TJ
Soulières D, see Bélanger K Stack JP, see McDermott RS
Southwest Oncology Group, see Sosman JA Stadler W, see Rosner GL
Soyer HP, see Pizzichetta MA Stadler WM, see Rini BI
Spaeth PJ, see Emmenegger U Stadtmauer E, see Berry DA
Spaggiari L, see De Pas T see Rai KR
Spalding S, see Yanik GA Stahl S, see Orlowski RZ
Sparreboom A, see de Jongh FE Stalmeier PFM, see van Roosmalen MS
see Gelderblom H Stamatoullas A, see Fermé C
see Kehrer DFS Stanek M, see Nadella P
see Mathijssen RHJ Stanton AL, Danoff-Burg S, Sworowski LA, Collins CA,
see Xie R Branstetter AD, Rodriguez-Hanley A, Kirk SB,
Sparreboom A, de Jongh F, Verweij J. In Reply (correspon- Austenfeld JL. Randomized, Controlled Trial of
dence), 4270 Written Emotional Expression and Benefit Finding
Spazzapan S, Crivellari D, Lombardi D, Scuderi C, Magri in Breast Cancer Patients, 4160
MD, Veronesi A, Gatti A. Nail Toxicity Related to Stark D, Kiely M, Smith A, Velikova G, House A, Selby P.
Weekly Taxanes: An Important Issue Requiring a Anxiety Disorders in Cancer Patients: Their Na-
Change in Common Toxicity Criteria Grading?, ture, Associations, and Relation to Quality of Life,
4404 3137
Specht L, see Warde P Stathopoulos GP, Rigatos SK, Pergantas N, Tsavdarides D,
Speers C, see Weir L Athanasiadis I, Malamos NA, Stathopoulos JG.
Sperone P, Gorzegno G, Berruti A, Familiari U, Dogliotti L. Phase II Trial of Biweekly Administration of Vi-
Reversible Pancytopenia Caused by Oral Letrozole norelbine and Gemcitabine in Pretreated Advanced
Assumption in a Patient With Recurrent Breast Breast Cancer, 37
Cancer (correspondence), 3747 Stathopoulos JG, see Stathopoulos GP
Speyer J. Cardiac Dysfunction in the Trastuzumab Clinical Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M,
Experience (editorial), 1156 Kouroussis C, Apostolaki S, Malamos N, Kakolyris
Spielmann M, see Zelek L S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V.
Spieth K, Risse J, Kaufmann R, Gille J. Challenging Cases Molecular Detection of Cytokeratin-19-Positive
and Diagnostic Dilemmas; Case 3. Positron Emis- Cells in the Peripheral Blood of Patients With
sion Tomography Scan Mimicking Lymph Node Operable Breast Cancer: Evaluation of Their Prog-
Metastases in a High-Risk Melanoma Patient, 3349 nostic Significance, 3404
Spitz D, see Markman M Stavrianeas N, see Dourakis SP
Spitzer G, see Berry DA Stea B, see Thomas R
Sposto R, see Jennings MT Stearns LJ, see Smith TJ
see Lones MA Stearns V, Hayes DF. Cooling Off Hot Flashes (editorial),
see Nachman JB 1436
Spott C, see Kollmannsberger C Steensma DP, see Daugherty CK
Spreafico F, see Massimino M Steensma DP. Why Me?, 873
Spreafico F, Massimino M, Luksch R, Casanova M, Cefalo Steer CB, see Marx GM
GS, Collini P, Ferrari A, Polastri D, Terenziani M, Steer CB, Marx GM, Galani E, Harper PG, Khayat D. Quality
Gasparini M, Fossati-Bettani F. Intensive, Very of Life: It’s Never Too Late (editorial), 2915
Short-Term Chemotherapy for Advanced Burkitt’s Steger G, see Jakesz R
Lymphoma in Children, 2783 Stein KD, see Jacobsen PB
Spriano M, see Federico M Stein U, Jürchott K, Schläfke M, Hohenberger P. Expression
Spriggs D, see Barakat RR of Multidrug Resistance Genes MVP, MDR1, and
see Schwartz GK MRP1 Determined Sequentially Before, During,
Spriggs DR, see Dizon DS and After Hyperthermic Isolated Limb Perfusion of
see Hensley ML Softonly.
Downloaded from on June 28, 2008 . For personal use Tissue Sarcoma
No other and Melanoma
uses without permission.Patients, 3282
Spunt SL, Hill DA, Motosue Copyright © 2002 by
AM, Billups CA,theCain
AM, Society
Rao of Clinical Oncology.
Steinberg All rights reserved.
M, see Bonneterre J

Steindorfer P, see Jakesz R Stricker D, see Rosenberg R

Steinemann S, see Wong JH Stricker PD, see Graefen M
Steiner M, Schuff-Werner P, Freund M, Köhne C-H. Com- Strickland S, see McNeish IA
bined Chemotherapy Trials Require Combined Strijk S, see Ruers TJM
Pharmacogenetic Approaches (correspondence), Strijk SP, see Langenhoff BS
1425 Stringer SP, see Mendenhall WM
Steinhauer EU, see Kaiser U Strom EA, see Ballo MT; Buchholz TA
Stella PJ, see Loprinzi CL Struewing JP, see Chetrit A
Stenman U-H, see Mäkinen T Stuart G, see Pearcey R
Stephenson J Jr, see de Bono JS Stupp R, see Borner MM
Sterman D, see Pecora AL Stupp R, Dietrich P-Y, Kraljevic SO, Pica A, Maillard I,
Stern SL, see DiFronzo LA Maeder P, Meuli R, Janzer R, Pizzolato G, Miral-
see Hsueh EC bell R, Porchet F, Regli L, de Tribolet N, Miri-
Steuber CP, see Furman WL manoff RO, Leyvraz S. Promising Survival for
Steup WH, see Marijnen CAM Patients With Newly Diagnosed Glioblastoma Mul-
Stevens J, see Harlan LC tiforme Treated With Concomitant Radiation Plus
Stevenson JP, Whitehead AS, O’Dwyer PJ. In Reply (corre- Temozolomide Followed by Adjuvant Temozolo-
spondence), 1425 mide, 1375
Stewart A, see Jonat W Stupp R, Ostermann-Kraljevic S, Dietrich P-Y, Mirimanoff
Stewart C, see Athale UH RO. Reply 1, to Nieder and Beauchesne (corre-
Stewart CF, see Crews KR spondence), 3181
see Furman WL Sturgeon JFG, see Brierley JD
Stewart J, see Rischin D Suarez-Almazor ME, Newman C, Hanson J, Bruera E.
Stewart SJ, see Seidman A Attitudes of Terminally Ill Cancer Patients About
see Vogel CL Euthanasia and Assisted Suicide: Predominance of
Stinchcombe TE, see Orlowski RZ Psychosocial Determinants and Beliefs Over
Stirling JJ, see Galbraith SM Symptom Distress and Subsequent Survival, 2134
Stock F, see Toso JF Sucker C, Klima K-M, Doelken G, Heidecke C-D, Lorenz G,
Stock R, see Ferrari AC Stockschlaeder M. Unusual Sites of Involvement in
Stockschlaeder M, see Sucker C Non-Hodgkin’s Lymphoma; Case 3. Intussuscep-
Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall tion as a Rare Complication of Mantle-Cell Lym-
D, Dudas M, Cordon-Cardo C, Jaques DP, Brennan phoma, 4397
MF. Adrenocortical Carcinoma: Clinical, Morpho- Sudbø A, see Sudbø J
logic, and Molecular Characterization, 941 Sudbø J, Kildal W, Johannessen AC, Koppang HS, Sudbø A,
Stojadinovic A, Leung DHY, Allen P, Lewis JJ, Jaques DP, Danielsen HE, Risberg B, Reith A. Gross Genomic
Brennan MF. Primary Adult Soft Tissue Sarcoma: Aberrations in Precancers: Clinical Implications of
Time-Dependent Influence of Prognostic Variables, a Long-Term Follow-Up Study in Oral Erythropla-
4344 kias, 456
Stokes PK, see Abramson N Sugarman J, see Pentz RD
Stoltenburg-Didinger G, see Fuchs IB Sugawara Y, see Morita T
Stoltz M, see Schwartz GK Sugio K, see Osaki T
Stone N, see Ferrari AC Sugita T, see Tsuchiya H
Stone RM, see Silverman LR Sugiura T, see Takada M
Stopfer J, see Shih HA Suh KS, see Lee H-S
Störkel S, see Kuball J Sun X-F, see Jansson A
Storm H, see Dores GM Sundararajan J, see Neugut AI
Stoter G, see Mathijssen RHJ Sundararajan V, see Hershman D
Stovall M, see Dores GM Sundararajan V, Hershman D, Grann VR, Jacobson JS,
Stover L, see Kirkwood JM Neugut AI. Variations in the Use of Chemotherapy
Strasser F, Fisch M, Bodurka DC, Sivesind D, Bruera E. for Elderly Patients With Advanced Ovarian Can-
E-Motions: Email for Written Emotional Expres- cer: A Population-Based Study, 173
sion, 3352 Sunshine JH, see Burkhardt JH
Stratton MR, see Shih HA Suovuori A, see Powles T
Strauss GM. In Reply (correspondence), 3931 Supko JG, see Eder JP Jr
Strauss GM. The Mayo Lung Cohort: A Regression Analysis Sutcliffe S, see Shenkier TN
Focusing on Lung
Downloaded from Cancer Incidence onand
28, 2008 . ForSutedja
personalG,usesee Kunst
only. PWA
No other uses without permission.
1973 Copyright © 2002 by the American Society of ClinicalT,
Sutedja Oncology. All rights reserved.
see Codrington H

see Postmus PE Iodine-131 Lipiodol in Resectable Hepatocellular

Sutherland RL, see Biankin AV Carcinoma? (correspondence), 1709
see Graefen M Tanaka F, see Shoji T
Sutter T, see Dunst J Tanimura M, see Yamamoto K
Sutton L, see Rivera E Tao J, Flaherty K, Bagg A. Unusual Hematologic Malignan-
Swain SM, see Tan AR cies; Case 1. Hematologic Malignancy Presenting
Swaisland H, see Baselga J With Diarrhea and Bony Lesions: Systemic Mas-
see Herbst RS tocytosis, 3737
Swallow CJ, see Brierley JD Tarabichi A, see Heiss MM
Swart M, see Crul M Tarbell N, see LeClerc JM
Sweeney C, see Bruera E Tarbell NJ, see Diller L
see Ripamonti C see Donaldson SS
Sweeney C, Beattie-Palmer L, Palmer JL, Bruera E. In Reply see Friedmann AM
(correspondence), 882 see Ng AK
Sweet KM, Bradley TL, Westman JA. Identification and Tarhini A, see Kirkwood JM
Referral of Families at High Risk for Cancer Tarumi Y, see Watanabe S
Susceptibility, 528 Tashkin D, see Sarna L
Swiss Group for Clinical Cancer Research, see Bernhard J Tassinari D, see Ravaioli A
Sworowski LA, see Stanton AL Tassinari D, Panzini I, Ravaioli A, Maltoni M, Sartori S.
Syed R, see Bomanji JB Quality of Life at the End of Life: How Is the
Sylvester R, see Pignatti F Solution Far Away? (correspondence), 1704
Szakolczai I, see Jonat W Tateishi A, see Kamada T
Szatrowski TP, see Cartwright TH Tattersall MHN, see Gattellari M
Sznol M, see Toso JF Taub RN, see Mikulski SM
Tauchi-Nishi P, see Wong JH
Tavtigian SV, see Frank TS
T Taylor NJ, see Galbraith SM
Tazi A, see Bergeron A
Taamma A, see Louvet C Tebbutt N, see Maisey N
Tai BC, see Tan SB Tedeschi N, see Lones MA
Taäieb J, see Raymond E Templeton E, see Van Patten CL
Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama ten Bokkel Huinink WW, see Kruijtzer CMF
A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, see Raymond E
Tamura T, Fukuda H, Saijo N. Phase III Study of ten Tije AJ, see Gelderblom H
Concurrent Versus Sequential Thoracic Radiother- Tendler CL, see Bukowski R
apy in Combination With Cisplatin and Etoposide Teo PML, see Chan ATC
for Limited-Stage Small-Cell Lung Cancer: Results Teofili L, Martini M, Luongo M, Di Mario A, Leone G, De
of the Japan Clinical Oncology Group Study 9104, Stefano V, Larocca LM. Overexpression of the
3054 Polycythemia Rubra Vera-1 Gene in Essential
Takata T, see Shoji T Thrombocythemia, 4249
Takayama O, see Noura S Tepper JE, O’Connell M, Niedzwiecki D, Hollis DR, Benson
Takenoyama M, see Osaki T AB III, Cummings B, Gunderson LL, Macdonald
Takimoto CH, see Tolcher AW JS, Martenson JA, Mayer RJ. Adjuvant Therapy in
Tammela TLJ, see Mäkinen T Rectal Cancer: Analysis of Stage, Sex, and Local
Tamura T, see Takada M Control—Final Report of Intergroup 0114, 1744
Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Teramura T, see Imashuku S
Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Terasaki PI, see Sosman JA
Senderowicz AM. Phase I Clinical and Pharmaco- Terenziani M, see Massimino M
kinetic Study of Flavopiridol Administered as a see Spreafico F
Daily 1-Hour Infusion in Patients With Advanced Terrioux P, see Depierre A
Neoplasms, 4074 Tesch H, see Sieber M
Tan H, see Crul M Tesoro-Tess JD, see Massimino M
Tan JE, see Tillman GF Testa MA, see Evans SR
Tan L, see Van Poznak C Testori A, see Belli F
Tan SB, Machin D, Cheung YB, Chung YFA, Tai BC, Thakral H, see Coen JJ
Machin D. Following
Downloaded a Trial ThatonStopped
from June 28,Early:
2008 . ForThall PF,use
personal seeonly.
Papandreou CN without permission.
No other uses
What Next forCopyright
Adjuvant© 2002 by the American
Hepatic Society of
Intra-Arterial Clinical H,
Thames Oncology. All rights
see Eifel PJ reserved.

Thé PN, see Love RR Tissue Sarcoma of the Externality (correspon-

Therasse P, see Pignatti F dence), 3929
Theriault RL, see Singletary SE Timmermann B, Kortmann R-D, Kühl J, Meisner C, Dieck-
Thiberville L, see Depierre A mann K, Pietsch T, Bamberg M. Role of Radio-
Thibodeau SN, see Lindor NM therapy in the Treatment of Supratentorial Primi-
Thiel E, see Menssen HD tive Neuroectodermal Tumors in Childhood:
Thies A, Moll I, Berger J, Wagener C, Brümmer J, Schulze Results of the Prospective German Brain Tumor
H-J, Brunner G, Schumacher U. CEACAM1 Ex- Trials HIT 88/89 and 91, 842
pression in Cutaneous Malignant Melanoma Pre- Timoney JP, Malkin MG, Leone DM, Groeger JS, Heaney
dicts the Development of Metastatic Disease, 2530 ML, Keefe DL, Klang M, Lucarelli CD, Muller RJ,
Thiesse P, see Lashford LS Eng SL, Connor M, Small TN, Brown AE, Saltz
Thiffault I, see Andermann A LB. Safe and Cost Effective Use of Alteplase for
Thirlwell MP, see Schilsky RL the Clearance of Occluded Central Venous Access
Thomas CR Jr, see Vijayalaxmi Devices, 1918
Thomas DA, see Giles FJ Tinari N, see Piantelli M
Thomas J, Gupta M, Grasso Y, Reddy CA, Heston WD, Tirabosco R, see Sorensen PHB
Zippe C, Dreicer R, Kupelian PA, Brainard J, Levin Tirona MT, see Allegra CJ
HS, Klein EA. Preoperative Combined Nested see Hobday TJ
Reverse Transcriptase Polymerase Chain Reaction Tiu C-M, see Chou Y-H
for Prostate-Specific Antigen and Prostate-Specific Tjan-Heijnen VCG, see Ardizzoni A
Membrane Antigen Does Not Correlate With Tjønnfjord G, see Keating MJ
Pathologic Stage or Biochemical Failure in Patients Tobis K, see Döhner K
Toffoli G, Sorio R, Sartor F, Raffin L, Veronesi A, Boiocchi
With Localized Prostate Cancer Undergoing Radi-
M. Carboplatin and Topotecan Combination and
cal Prostatectomy, 3213
Myelosuppression (correspondence), 3558
Thomas JP, see Berlin JD
Tolcher AW, Takimoto CH, Rowinsky EK. The Multifunc-
Thomas R, see Grem JL
tional, Multi-Institutional, and Sometimes Even
Thomas R, Stea B. Radiation Recall Dermatitis From High-
Global Phase I Study: A Better Life for Phase I
Dose Interferon Alfa-2b (correspondence), 355
Evaluations or Just “Living Large”? (editorial),
Thomas RR, see Wilson RH
Thomason D, see Grann VR
Tom P, see Wong JH
Thompson JA, see Sondak VK
Tomacruz RS, see Bristow RE
see Sosman JA
Tomaszewski JE, see Cross CK
Thompson JF, see Hersey P
Tomita K, see Tsuchiya H
Thompson P, see Galbraith SM
Tonato M, see Scagliotti GV
Thompson S, see Douillard J-Y Tong W, see Dalbagni G
Thompson T, see Ellis GK see Hensley ML
Thomson J, see Nachman JB see Schwartz GK
Thor A, see Singletary SE Tong X, see Crews KR
Throuvalas N, see Antonadou D see Rubnitz JE
Thuan TV, see Love RR Tonini G, see Santini D
Thuong L, see Love RR Topalian SL, see Toso JF
Thuret I, see Perel Y Torres A, see González-Quevedo R
Thürlimann B, see Bernhard J Torri V, see Cantù MG
see Bonneterre J Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP,
Thüroff JW, see Kuball J Schwartzentruber DJ, Sherry RM, Topalian SL,
Thuy NV, see Love RR Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C,
Tickoo SK, see Vuky J Haworth L, Mavroukakis S, White D, MacDonald
Tidy A, see Powles T S, Mao J, Sznol M, Rosenberg SA. Phase I Study of
Tienghi A, see Fagioli F the Intravenous Administration of Attenuated Sal-
Tigaud JM, see Louvet C monella typhimurium to Patients With Metastatic
Tillman GF, Orel SG, Schnall MD, Schultz DJ, Tan JE, Solin Melanoma, 142
LJ. Effect of Breast Magnetic Resonance Imaging Tourt-Uhlig S, see Gururangan S
on the Clinical Management of Women With Ear- see Quinn JA
ly-Stage Breast Carcinoma, 3413 Tracy E, see Womer RB
Tilly H, see Gisselbrecht C Tragni
Downloaded from on June 28, 2008 . For personalG,use
NoFother uses without permission.
Timmerman RD. Adjuvant Copyright © 2002for
Radiation by the American
Stage IIB Society
Soft of Clinical
Tran HT,Oncology. All rights
see Herbst RS reserved.

Tran J-P, see Izawa JI Turek P, see Damani MN

Tran TL, see Love RR Turrisi AT III, see Albain KS
Travis LB, see Dores GM Turriziani A, see Trodella L
Tremblay P-B, see Kaiser R Tuthill RJ, see Sondak VK
Treuner J, see Ferrari A Twelves C, see Biganzoli L
Trevisan G, see Pizzichetta MA see O’Shaughnessy J
Triche TJ, see Sorensen PHB Tyldesley S, see Huang J
Tricot G, see Badros A Tynan M, see Socinski MA
Trimble EL, see Bristow RE Tzai T-S, see Cheng H-L
see Sateren WB
Trinh GN, see Nguyen TV
Trink B, see Cheng H-L U
Tripathy D, see Vogel CL
Trodella L, Granone P, Valente S, Turriziani A, Macis G, Ubiali E, see Cascinu S
Corbo GM, Margaritora S, Cesario A, D’Angelillo Uchitomi Y, see Morita T
RM, Gualano G, Ramella S, Galetta D, Cellini N. Uebelacker I, see Kaiser U
Phase I Trial of Weekly Gemcitabine and Concur- Ulrich-Pur H, see Scheithauer W
rent Radiotherapy in Patients With Inoperable Non- Ulrich R, see Döhner K
Small-Cell Lung Cancer, 804 Unger JM, see Sondak VK
Troncoso P, see Papandreou CN see Sosman JA
Trudeau ME, see Goodwin PJ Unger P, see Socinski MA
Trump DL, see Ramanathan RK Ungerleider R, see Sateren WB
Trümper L, see Kaiser U Urba WJ, Alvord WG. Are All Hypotheses Generated Before
Trümper L, Menges M, Daus H, Köhler D, Reinhard J-O, Data Analysis Prospective? (editorial), 1431
Sackmann M, Moser C, Sek A, Jacobs G, Zeitz M, Ursin G, Tseng C-C, Paganini-Hill A, Enger S, Wan PC,
Pfreundschuh M. Low Sensitivity of the ki-ras Formenti S, Pike MC, Ross RK. Does Menopausal
Polymerase Chain Reaction for Diagnosing Pancre- Hormone Replacement Therapy Interact With
atic Cancer From Pancreatic Juice and Bile: A Known Factors to Increase Risk of Breast Cancer?,
Multicenter Prospective Trial, 4331 699
Tsavdarides D, see Stathopoulos GP Uzan S, see Barranger E
see Kosmidis P
Tschetter LK, see Hobday TJ
Tseng C-C, see Ursin G V
Tseng JE, see Herbst RS
Tsetis D, see Souglakos J Vaishampayan U, Dan ME, Hussain M. Unusual Hemato-
Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, Asada N, Abe logic Malignancies; Case 2. Mediastinal Germ Cell
S, Isu K, Sugita T, Tomita K. Effect of Timing of Tumor, Malignant Histiocytosis, and Acute Leuke-
Pulmonary Metastases Identification on Prognosis mia, 3739
of Patients With Osteosarcoma: The Japanese Mus- Valente S, see Trodella L
culoskeletal Oncology Group Study, 3470 Valentini L, see Massimino M
Tsuchiya R, see Sobue T Valentini M, see Cesana C
Tsuchiya S, see Sekine I Valerio MR, see Vici P
Tsujii H, see Kamada T Valero V, see Esteva FJ
Tsukiyama I, see Sekine I Valle J, see Ross P
Tu D, see Davis AM Vallières E. Adjuvant Radiation Therapy After Complete
see El-Sayed S Resection of Non-Small-Cell Lung Cancer (corre-
see Pearcey R spondence), 1427
Tu S-M, see Pagliaro LC Vallis KA, Pintilie M, Chong N, Holowaty E, Douglas PS,
see Papandreou CN Kirkbride P, Wielgosz A. Assessment of Coronary
see Siefker-Radtke AO Heart Disease Morbidity and Mortality After Radi-
Tubiana-Hulin M, see Zelek L ation Therapy for Early Breast Cancer, 1036
Tubiana-Mathieu N, see Curé H Van Cutsem E, see Rothenberg ML
Tucker SL, see Buchholz TA van Daal WAJ, see van Roosmalen MS
Tullo A, see Ranson M van de Schraaf J, see de Jonge MJA
Tung ND, see Love RR van de Velde CJH, see Marijnen CAM
Turci D, see Downloaded
Ravaioli A from on June 28, 2008 . For personal
see Nagtegaal ID other uses without permission.
use only. No
Turcotte R, see Davis AMCopyright © 2002 by the American Society of Clinical
see vanOncology.
der HageAll rights
JA reserved.

van de Vijver MJ, see Lakhani SR van Weeren PC, see Kersemaekers A-MF
van den Bent M, see Pignatti F van Zomeren DM, see Gelderblom H
van den Berg JWO, see Agteresch HJ Vandenberg T, see Winquist E
van den Bogaard CJC, see de Gast GC Vanel D, see Aloulou S
Van der Auwera P, see Viens P Vannetzel J-M, see Zelek L
van der Groep P, see Bos R Vannier J-P, see Perel Y
van der Hage JA, van de Velde CJH. In Reply (correspon- van’t Veer LJ, see Crul M
dence), 2906 van’t Veer MB, see Dores GM
van der Hage JA, van de Velde CJH. Perioperative Chemo- Vanuytsel L, see Achten R
therapy in Patients With Node-Negative Postmeno- Vardakis N, see Souglakos J
pausal Breast Cancer (correspondence), 2210 Vargas-Chanes, see Sloan JA
van der Hoeven JJM, see Bos R Varkey JA, see Cartwright TH
van der Kwast TH, see Graefen M Vasey PA, Shulman LN, Campos S, Davis J, Gore M,
van der Sijp JRM, van Meerbeeck JPAM, Maat APWM, Johnston S, Kirn DH, O’Neill V, Siddiqui N,
Zondervan PE, Sleddens HFBM, van Geel AN, Seiden MV, Kaye SB. Phase I Trial of Intraperito-
Eggermont AMM, Dinjens WNM. Determination neal Injection of the E1B-55-kd-Gene-Deleted Ad-
of the Molecular Relationship Between Multiple enovirus ONYX-015 (dl1520) Given on Days 1
Tumors Within One Patient Is of Clinical Impor- Through 5 Every 3 Weeks in Patients With Recur-
tance, 1105 rent/Refractory Epithelial Ovarian Cancer, 1562
van der Vijgh WJF, see Kuenen BC Vassal G, see Lashford LS
van der Wall E, see Bos R Vassallo E, see Fagioli F
van der Worp E, see Nagtegaal ID Vassilakopoulos TP, see Rassidakis GZ
van Diest PJ, see Bos R Vaughn D, see Hinton S
van Geel AN, see van der Sijp JRM Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz
Van Hazel G, see O’Shaughnessy J AB. Phase II Trial of Weekly Paclitaxel in Patients
van Kesteren Ch, Mathôt RAA, Raymond E, Armand JP, With Previously Treated Advanced Urothelial Can-
Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, cer, 937
Ravic M, Wanders J, Beijnen JH, Fumoleau P, Vaughn DJ, Meadows AT. Cancer Survivorship Research:
Schellens JHM. Population Pharmacokinetics of The Best Is Yet to Come (editorial), 888
the Novel Anticancer Agent E7070 During Phase I Vauthey J-N, Lauwers GY, Esnaola NF, Do K-A, Belghiti J,
Studies: Model Building and Validation, 4065 Mirza N, Curley SA, Ellis LM, Regimbeau J-M,
van Krieken JHJM, see Nagtegaal ID Rashid A, Cleary KR, Nagorney DM. Simplified
Van Le L, see Markman M Staging for Hepatocellular Carcinoma, 1527
van Leeuwen FE, see Dores GM Vauthey JN, see Pisters PWT
see Dorresteijn LDA Vecht C, see Pignatti F
van Meerbeeck JP, see Ardizzoni A Velikova G, see Stark D
see van der Sijp JRM Veneroni S, see Daidone MG
van Mourik J, see Codrington H Venkatraman E, see Barakat RR
Van Patten CL, Gelmon KA, Olivotto IA. In Reply (corre- see Dizon DS
spondence), 3041 see Hensley ML
Van Patten CL, Olivotto IA, Chambers GK, Gelmon KA, see Osman I
Hislop TG, Templeton E, Wattie A, Prior JC. Effect Venkatraman ES, see Martin J
of Soy Phytoestrogens on Hot Flashes in Postmeno- Venook AP, see Bergsland EK
pausal Women With Breast Cancer: A Random- Venturino A, see Repetto L
ized, Controlled Clinical Trial, 1449 Verbel DA, see Smaletz O
Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Vercammen E, see Littlewood TJ
Norton L, Seidman AD. Assessment of Molecular Vercelli M, see Repetto L
Markers of Clinical Sensitivity to Single-Agent Verger E, see Bessell EM
Taxane Therapy for Metastatic Breast Cancer, 2319 Vergote I, see Howell A
Van Rhee F, see Badros A Verhoef G, see Achten R
van Roosmalen MS, Verhoef LCG, Stalmeier PFM, Hooger- Verhoef LCG, see van Roosmalen MS
brugge N, van Daal WAJ. Decision Analysis of Verkooijen HM, see Bouchardy C
Prophylactic Surgery or Screening for BRCA1 Mu- Verma S, see O’Shaughnessy J
tation Carriers: A More Prominent Role for Oopho- Vernillet L, see Raymond E
rectomy, 2092 Veronesi A, see Pizzichetta MA
Van SomerenDownloaded
N, see Brett BT see Spazzapan
from on June 28, 2008 . For personal S other uses without permission.
use only. No
van Tinteren H, see Kruijtzer CMF© 2002 by the American Society of Clinical Oncology.
see Toffoli G All rights reserved.

Verrill M, see Hughes A Vlastos G, see Bouchardy C

Verweij J, see de Jonge MJA Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris
see de Jongh FE LN, Fehrenbacher L, Slamon DJ, Murphy M,
see Gelderblom H Novotny WF, Burchmore M, Shak S, Stewart SJ,
see Kehrer DFS Press M. Efficacy and Safety of Trastuzumab
see Mathijssen RHJ as a Single Agent in First-Line Treatment of
see Sparreboom A HER2-Overexpressing Metastatic Breast Cancer,
see Xie R 719
Veve R, see Bremnes RM Vogel VG. Why Do We Still Use Hormone Replacement
Veys PA, see Owens CM Therapy? Why Don’t We Use It More? (editorial),
Vezina LG, see Jennings MT 616
Viardot A, Möller P, Högel J, Werner K, Mechtersheimer G, Vogel VG III, see Chlebowski RT
Ho AD, Ott G, Barth TFE, Siebert R, Gesk S, Vogelzang NJ, see Mikulski SM
Schlegelberger B, Döhner H, Bentz M. Clinico- see Rini BI
pathologic Correlations of Genomic Gains and see Schilsky RL
Losses in Follicular Lymphoma, 4523 see Small EJ
Viaro D, see Hudes G Voigt KJ, see Gattellari M
Vici P, see Lopez M Voillat L, see Fermé C
Vici P, Colucci G, Gebbia V, Amodio A, Giotta F, Belli F, Voiss W, see Weihrauch MR
Conti F, Gebbia N, Pezzella G, Valerio MR, Brandi Vokes EE, see Cohen EEW
M, Pisconti S, Durini E, Giannarelli D, Lopez M. Vokes EE, Herndon JE II, Crawford J, Leopold KA, Perry
First-Line Treatment With Epirubicin and Vinorel- MC, Miller AA, Green MR. Randomized Phase
bine in Metastatic Breast Cancer, 2689
II Study of Cisplatin With Gemcitabine or
Vicini FA, Recht A. Age at Diagnosis and Outcome for
Paclitaxel or Vinorelbine as Induction Chemo-
Women With Ductal Carcinoma-In-Situ of the
therapy Followed by Concomitant Chemoradio-
Breast: A Critical Review of the Literature, 2736
therapy for Stage IIIB Non-Small-Cell Lung
Vielh P, see Rouzier R
Cancer: Cancer and Leukemia Group B Study
Viens P, Chabannon C, Pouillard P, Janvier M, Brugger W,
9431, 4191
Blay JY, Oberling F, Capdeville R, Newman C,
Voland J, see Mitchell MS
Méresse V, Xu ZX, Platzer E, Van der Auwera P,
von der Maase H, see Petersen PM
Maraninchi D. Randomized, Controlled, Dose-
see Warde P
Range Study of Ro 25-8315 Given Before and
von Eschenbach AC, see Izawa JI
After a High-Dose Combination Chemotherapy
von Euler M, see Bonneterre J
Regimen in Patients With Metastatic or Recurrent
von Gunten CF. Discussing Hospice Care, 1419
Breast Cancer Patients, 24
Vietti TJ, see Furman WL Von Roenn JH, see Evans SR
Vigander T, see Sundstrøm S Von Roenn JH, Scheinberg D, Loehrer PJ Sr. Role of
Vijayalaxmi, Thomas CR Jr, Reiter RJ, Hennan TS. Melato- Symptom Control and Palliative Care Abstract
nin: From Basic Research to Cancer Treatment Presentations (correspondence), 880
Clinics, 2575 von Seydewitz C-U, see Kaiser U
Vijayalaxmi, Thomas CR Jr, Reiter RJ, Herman TS. In Reply Vose JM, see Weekes CD
(correspondence), 4128 Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards
Vilela G, see Bergeron A D, Riftin R, Bierman PJ, Lynch JC, Weisen-
Villá S, see Bessell EM burger DD, Kessinger A, Armitage JO. Autolo-
Villalona-Calero MA, see Nadella P gous Transplantation for Aggressive Non-
Villard O, see Herbrecht R Hodgkin’s Lymphoma: Results of a Randomized
Villaret DB, see Mendenhall WM Trial Evaluating Graft Source and Minimal Re-
Villeneuve A, see Depierre A sidual Disease, 2344
Vilsvik J, see Sundstrøm S Voss N, see Shenkier TN
Vincent MD, see Douillard J-Y Vukelja S, see Holmes FA
Vincent-Salomon A, see Rouzier R see O’Shaughnessy J
Vincenzi B, see Santini D Vuky J, see Motzer RJ
Vinceti M, see Federico M Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A,
Viniou NA, see Dimopoulos MA Mazumdar M, Reuter V, Bajorin DF, Bosl GJ,
Vitali P, see Ridolfi R Motzer RJ. Salvage Chemotherapy for Patients
Viviani S, see Rassidakisfrom
Downloaded With on June 28, 2008 . For personal use Advanced
only. Purewithout
No other uses Seminoma, 297
Copyright ©
Vlachonikolis I, see Stathopoulou A2002 by the American Society of Clinical Oncology.
Vyth-Dreese All rights
FA, see reserved.
de Gast GC

W Weber RS, see Machtay M

Webster A, see Bonneterre J
see Howell A
Wacker B, see Rai KR
see Osborne CK
Wada H, see Shoji T
Webster K, see Heffernan N
Wadler S, see Rothenberg ML
Weekes CD, Vose JM, Lynch JC, Weisenburger DD, Bier-
Wagener C, see Thies A
man PJ, Greiner T, Bociek G, Enke C, Bast M,
Wainman N, see Bélanger K
Chan WC, Armitage JO, Nebraska Lymphoma
Walker H, see Roche K
Study Group. Hodgkin’s Disease in the Elderly:
Walker J, see Northouse LL
Improved Treatment Outcome With a Doxorubicin-
Walker LG, see Smith IC
Containing Regimen, 1087
Wallace A, see Mitchell MS
Weeks JC, see Earle CC
Waller J, see Herbrecht R
see Keating NL
Walsh MD, see Lindor NM
see Kilbridge KL
Walsh-Vockley C, see Lindor NM
see Liang W
Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication
see Loberiza FR Jr
Rates Among Cancer Patients With Peripherally
Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE,
Inserted Central Catheters, 3276
Litwin MS, Nyquist L, Sanda MG. Comprehensive
Wan PC, see Ursin G
Wanders J, see Raymond E Comparison of Health-Related Quality of Life Af-
see van Kesteren Ch ter Contemporary Therapies for Localized Prostate
Wanek LA, see DiFronzo LA Cancer, 557
Wang L-Z, see Goh B-C Weihrauch MR, Skibowski E, Koslowsky TC, Voiss W, Re
Wang M, see Sundstrøm S D, Kuhn-Regnier F, Bannwarth C, Siedek M, Diehl
Wang TS, see Bichakjian CK V, Bohlen H. Immunomagnetic Enrichment and
Wang X, see Ahmad SA Detection of Micrometastases in Colorectal Cancer:
see Papandreou CN Correlation With Established Clinical Parameters,
Wang XS, Giralt SA, Mendoza TR, Engstrom MC, Johnson 4338
BA, Peterson N, Broemeling LD, Cleeland CS. Weiner S, see Markman M
Clinical Factors Associated With Cancer-Related Weinstein GS, see Machtay M
Fatigue in Patients Being Treated for Leukemia and Weinstein HJ, see Donaldson SS
Non-Hodgkin’s Lymphoma, 1319 see Friedmann AM
Ward BE, see Frank TS Weinstein MC, see Earle CC
Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Weinstock N, see Modi S
Gospodarowicz M, von der Maase H. Prognostic Weir L, Speers C, D’yachkova Y, Olivotto IA. Prognostic
Factors for Relapse in Stage I Seminoma Managed Significance of the Number of Axillary Lymph
by Surveillance: A Pooled Analysis, 4448 Nodes Removed in Patients With Node-Negative
Warren JL, see Takada M Breast Cancer, 1793
Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Weir LM, see Kwan W
Riley GF. Costs of Treatment for Elderly Women Weisenburger DD, see Vose JM
With Early-Stage Breast Cancer in Fee-For-Service see Weekes CD
Settings, 307 Weiss G, see de Bono JS
Watanabe K, see Takada M Weiss GR, see Sondak VK
Watanabe S, Tarumi Y, Oneschuk D, Lawlor P. Opioid Weitzner MA, see Mehta MP
Rotation to Methadone: Proceed With Caution Weller E, see Ng AK
(correspondence), 2409 Wen SF, see Kuball J
Waters JS, O’Brien MER, Ashley S. Management of Anemia Wendtner C-M, Abdel-Rahman S, Krych M, Baumert J,
in Patients Receiving Chemotherapy (correspon- Lindner LH, Baur A, Hiddemann W, Issels RD.
dence), 601 Response to Neoadjuvant Chemotherapy Com-
Watkin W, see Liptay MJ bined With Regional Hyperthermia Predicts Long-
Watkinson AF, see Brett BT Term Survival for Adult Patients With Retroperi-
Watral M, see Gururangan S toneal and Visceral High-Risk Soft Tissue
Watson P, see Berry DA Sarcoma, 3156
Wattie A, see Van Patten CL Werner K, see Viardot A
Weaver DL, see Singletary SE Werner M, see Bielack SS
Weber BL, see DeMichele A see Rosenberg R
see Shih HADownloaded from on June 28, 2008 . For personalM,
Wernli usesee Borner
only. No otherMM uses without permission.
Weber KL, see Ahmad SA Copyright © 2002 by the American Society of Clinical
West WH, Oncology. All rights
see Schilsky RLreserved.

Westeel V, see Depierre A Winer EP, see Bunnell CA

Westman JA, see Sweet KM see Chlebowski RT
Wette V, see Jakesz R see DiGianni LM
Wetterwald M, see Menssen HD see Schuchter LM
Wettstein PJ, see Ansell SM Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN,
Wever LDV, see Detmar SB Edge SB, Mamounas EP, Gralow J, Goldstein LJ,
Wharam MD, see Baker KS Pritchard KI, Braun S, Cobleigh MA, Langer AS,
Wheatley K, Ives N, Hancock B, Gore M. Need for a Perotti J, Powles TJ, Whelan TJ, Browman GP.
Quantitative Meta-Analysis of Trials of Adjuvant American Society of Clinical Oncology Technol-
Interferon in Melanoma (correspondence), 4120 ogy Assessment on the Use of Aromatase Inhibitors
Whedon MB, see Ahles TA as Adjuvant Therapy for Women With Hormone
Wheeler TM, see Cagiannos I Receptor-Positive Breast Cancer: Status Report
see Shariat SF 2002, 3317
Whelan T. A Trial of Two Questions (editorials), 4135 Winkelmann W, see Bielack SS
Whelan TJ, see Winer EP Winkler K, see Bielack SS
White CA, see Witzig TE Winquist E, Bramwell V, Vandenberg T. Anastrozole Versus
White D, see Toso JF Tamoxifen as First-Line Therapy for Advanced
White K, see Nachman JB Breast Cancer: Methodologic Issues (correspon-
White RL, see Schilsky RL dence), 3748
Whitehead AS, see Stevenson JP Wiseman GA, see Anderson PM
Whitehead M, see Roche K see Ansell SM
Whitman E, see Agarwala SS see Witzig TE
Whittington R, see Cross CK Witzig TE, see Ansell SM
Whitton J, see Emmons K see Raikumar SV
Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czucz-
J, Bernstein L, Runowiez CD. Association of Ta- man MS, Saleh MN, Cripe L, Wiseman G, Olejnik
moxifen and Uterine Sarcoma (correspondence), T, Multani PS, White CA. Treatment With Ibritu-
2758 momab Tiuxetan Radioimmunotherapy in Patients
Wickerham L, see Fisher B With Rituximab-Refractory Follicular Non-
Wickersham K, see DiPaola RS Hodgkin’s Lymphoma, 3262
Wieand HS, see Singletary SE Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Em-
Wieder J, see Zisman A manouilides C, Joyce R, Pohlman BL, Bartlett NL,
Wielgosz A, see Vallis KA Wiseman GA, Padre N, Grillo-López AJ, Multani
Wiggers T, see Marijnen CAM P, White CA. Randomized Controlled Trial of
Wiklund T, see Dores GM Yttrium-90-Labeled lbritumomab Tiuxetan Radio-
Wikstrand CJ, see Reardon DA immunotherapy Versus Rituximab Immunotherapy
Wildhagen MF, see Graefen M for Patients With Relapsed or Refractory Low-
Wilding G, see Hinton S; Small EJ Grade, Follicular, or Transformed B-Cell Non-
Wilkinson PM, see Radford JA Hodgkin’s Lymphoma, 2453
Willemze R, see Ringdén O Wiznitzer I, see Holmes FA
Willett CG. Radiation Dose Escalation in Combined-Modal- Wobbes Th, see Langenhoff BS
ity Therapy for Esophageal Cancer (editorial), 1151 see Ruers TJM
Williams A, see DiPaola RS Wolchok JD, Chapman PB. Phase I Trial of Adoptive
Williams CD, see Branson K Immunotherapy With Cytolytic T Lymphocytes
Williams D, see Pagliaro LC Immunized Against a Tyrosinase Epitope (corre-
see Siefker-Radtke AO spondence), 3176
Williams LJ, see Hwu W-J Wold LE, see Allegra CJ
Williamson S, see Machtay M Wolden S, see Wong RJ
Wilson JF, see Lones MA Wolden SL, see Nachman JB
Wilson JHP, see Agteresch HJ Wolf J, see Sieber M
Wilson R, see Grem JL Wolf R, see Silliman RA
Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Wolff RA, see Pisters PWT
Grem JL. Acute Oxaliplatin-Induced Peripheral Wölfler A, Abuja PM, Linkesch W, Schauenstein K, Lieb-
Nerve Hyperexcitability, 1767 mann PM. Questionable Benefit of Melatonin for
Winchell G, see DiPaola RS Antioxidant Pharmacologic Therapy (correspon-
Winckel P, see Page E dence),
Downloaded from on June 28, 2008 . For personal use 4127
only. No other uses without permission.
Windschitl H, see Jatoi ACopyright © 2002 by the American Society of Clinical Oncology.
Wolmark All rights
N, see Fisher B reserved.

see Wickerham DL Yamamoto K, Ohta S, Ito E, Hayashi Y, Asami T, Mabuchi

Wolter TD, see Cox LS O, Higashigawa M, Tanimura M. Marginal De-
Womer RB, see Baker KS crease in Mortality and Marked Increase in Inci-
Womer RB, Tracy E, Soo-Hoo W, Bickert B, DiTaranto S, dence as a Result of Neuroblastoma Screening at 6
Barnsteiner JH. Multidisciplinary Systems Ap- Months of Age: Cohort Study in Seven Prefectures
proach to Chemotherapy Safety: Rebuilding Pro- in Japan, 1209
cesses and Holding the Gains, 4705 Yamamoto S, see Nakatsuka S
Wong A, see Schilsky RL Yamashita T, see Osaki T
Wong F, see El-Sayed S Yanagi T, see Kamada T
Wong J, see Poon RT-P Yanagihara K, see Shoji T
Wong JE, see Schwartsmann G Yang B, see Mirza I
Wong JH, Steinemann S, Tom P, Morita S, Tauchi-Nishi P. Yang JC, see Toso JF
Volume of Lymphatic Metastases Does Not Inde- Yang P-C, see Yuan A
pendently Influence Prognosis in Colorectal Can- Yang YF, see Love RR
cer, 1506
Yang Z-F, see Poon RT-P
Wong N, see Andermann A
Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL,
see Cremin C
Shapiro B, Hubers D, Spalding S, Braun T, Ferrara
Wong RJ, Lin DT, Schöder H, Patel SG, Gonen M, Wolden
JLM, Hutchinson RJ. Pilot Study of Iodine-131-
S, Pfister DG, Shah JP, Larson SM, Kraus DH.
Metaiodobenzylguanidine in Combination With
Diagnostic and Prognostic Value of
Myeloablative Chemotherapy and Autologous
关 F兴Fluorodeoxyglucose Positron Emission To-
Stem-Cell Support for the Treatment of Neuroblas-
mography for Recurrent Head and Neck Squamous
Cell Carcinoma, 4199 toma, 2142
Wong TZ, see Reardon DA Yao M, see Nakatsuka S
Wong WM, see Chim CS Yao S-L, see DiPaola RS
Wood D, see Agarwala SS Yasko AW, see Ahmad SA
Woods WG. Substitute “Prostate Cancer” for “Neuroblasto- Yasumoto K, see Osaki T
ma”? (editorial), 1154 Yates BB, see Schilsky RL
Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrin- Yates S, see Socinski MA
sky N, Arthur DC, Sanders J, Neudorf S, Gold S, Ye X, see Hsueh EC
Lange BJ. Prospective Study of 90 Children Re- Yee GC, see Berenson JR
quiring Treatment for Juvenile Myelomonocytic Yekell S, see Ellerhorst JA
Leukemia or Myelodysplastic Syndrome: A Report Yeo W, see Chan ATC
From the Children’s Cancer Group, 434 Yeslow G, see Hudes G
Woolf SH, see Rizzo JD Yetis B, see Saglam S
Working Group for the Bone and Soft Tissue Sarcomas, see Yeung D, see Mitchell MS
Kamada T Yiu HH, see Chan ATC
Worm M, see Meyer L Yokota S, see Takada M
Wright D, see Oscier D Yokoyama A, see Sekine I
Wu TC, see Chiou WL see Takada M
Wunder JS, see Davis AM Yong K, see Peggs KS
Yoon J-H, see Lee H-S
Yoshikawa K, see Kamada T
X Yoshimura K, see Sekine I
Younes M, see Daidone MG
Xenidis N, see Stathopoulou A Young AM, see Seymour LW
Xie R, Mathijssen RHJ, Sparreboom A, Verweij J, Karlsson Young JA, see Donaldson SS
MO. Clinical Pharmacokinetics of Irinotecan and Young JP, see Lindor NM
Its Metabolites: A Population Analysis, 3293 Yu AL, see Kletzel M
Xin Y, see Love RR Yu C-J, see Yuan A
Xu ZX, see Viens P Yu C-S, see Lee Jung-Hee
Yu KH, see Chan ATC
Yu R, see Motzer RJ
Y Yu W-C, see Poon RT-P
Yuan A, Yu C-J, Luh K-T, Kuo S-H, Lee Y-C, Yang P-C.
Yamada S, see Kamada from
Downloaded Aberrant
T on June 28, 2008 . For personal use only. Nop53
uses withoutCorrelates
permission.With Expres-
Yamamoto H, see Noura Copyright
S © 2002 by the American Society of Clinical Oncology. All rights reserved.
sion of Vascular Endothelial Growth Factor mRNA

and Interleukin-8 mRNA and Neoangiogenesis in Zervas C, see Dimopoulos MA

Non-Small-Cell Lung Cancer, 900 Zhai S, see Tan AR
Yuen KT, see Chan ATC Zhan F, see Eton O
Yung WKA, see Groves MD Zhang Q, see Love RR
Yunus F, see Lima CMSR Zhang-Salomons J, see Huang J
Zhao X-G, see Reardon DA
Zhou J-Y, see Press MF
Z Zhou Y, see Leung W
Zhuang SH, see Leonard GD
Zagars GK, see Ahmad SA Zietman AL, see Coen JJ
see Ballo MT Zilembo N, see Bajetta E
Zagonel V, see Repetto L Zimmerman T, see Rini BI
Zalutsky MR, see Reardon DA Zinzani PL, see Federico M
Zanetti I, see Ferrari A Zippe C, see Kupelian PA
Zangari M, see Badros A see Thomas J
see Kaushal V Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ,
Zannoni GF, see Ferrandina G Moldawer N, Lazarovici D, deKernion JB, Figlin
Zee B, see Chan ATC RA, Belldegrun AS. Mathematical Model to Pre-
see Davis AM dict Individual Survival for Patients With Renal
see Freidlin B Cell Carcinoma, 1368
see Mok TSK Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said
see Roche K JW, deKernion JB, Figlin RA, Belldegrun AS. Risk
see Shepherd FA Group Assessment and Clinical Outcome Algo-
Zee S, see Hochwald SN rithm to Predict the Natural History of Patients
Zeitz M, see Trümper L With Surgically Resected Renal Cell Carcinoma,
Zeldenrust SR, see Fanale MA 4553
Zelefsky MJ, see Alektiar KM Zlotta A, see Djavan B
see Osman I Zola P, see Benedetti-Panici P
Zelefsky MJ, Leibel SA. Comparing Contemporary Surgery Zoladex Early Breast Cancer Research Association Trialists’
to External-Beam Radiotherapy for Clinically Lo- Group, see Jonat W
calized Prostate Cancer (editorial), 3363 Zomas A, see Dimopoulos MA
Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel J-M, Chollet Zondervan PE, see van der Sijp JRM
P, Misset J-L, Chouaki N, Marty M, Gamelin E, Zoubek A, see Bielack SS
Culine S, Dieras V, Mackenzie S, Spielmann M. Zuberbier T, see Meyer L
Phase II Study of Oxaliplatin and Fluorouracil in Zühlke H, see Dunst J
Taxane- and Anthracycline-Pretreated Breast Can- Zumaglini F, see Ravaioli A
cer Patients, 2551 Zwick DL, see Lones MA

Downloaded from on June 28, 2008 . For personal use only. No other uses without permission.
Copyright © 2002 by the American Society of Clinical Oncology. All rights reserved.